AU2002364291B2 - Triazoles as oxytocin antagonists - Google Patents

Triazoles as oxytocin antagonists Download PDF

Info

Publication number
AU2002364291B2
AU2002364291B2 AU2002364291A AU2002364291A AU2002364291B2 AU 2002364291 B2 AU2002364291 B2 AU 2002364291B2 AU 2002364291 A AU2002364291 A AU 2002364291A AU 2002364291 A AU2002364291 A AU 2002364291A AU 2002364291 B2 AU2002364291 B2 AU 2002364291B2
Authority
AU
Australia
Prior art keywords
triazol
sulfanyl
methoxybenzyl
propanamide
pentanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002364291A
Other versions
AU2002364291A1 (en
Inventor
Thomas Coulter
Anna Quattropani
Matthias Schwarz
Russell J Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of AU2002364291A1 publication Critical patent/AU2002364291A1/en
Application granted granted Critical
Publication of AU2002364291B2 publication Critical patent/AU2002364291B2/en
Assigned to LABORATOIRES SERONO SA reassignment LABORATOIRES SERONO SA Request for Assignment Assignors: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Assigned to MERCK SERONO SA reassignment MERCK SERONO SA Alteration of Name(s) in Register under S187 Assignors: LABORATOIRES SERONO SA
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to triazole derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such triazole derivatives. Said triazoles are useful in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to triazole derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and/or vasopressin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin and/or vasopressin. The present invention is furthermore related to novel triazole derivatives as well as to methods of their preparation.

Description

WO 03/053437 PCT/EP02/14594 Triazoles as oxytocin antagonists Field of the invention The present invention is directed to triazole derivatives, in particular for use as medicaments, as well as pharmaceutical formulations containing such triazole derivatives.
Said triazole derivatives are useful in the treatment and/or prevention ofpreterm labor, premature birth, dysmenorrhea, inappropriate secretion ofvasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension.
Preferably, the triazole derivatives display a modulatory, notably an antagonist activity of the oxytocin and/or vasopressin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin and/or vasopressin, including preterm labor, premature birth, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome, hypertension and dysmenorrhea.
Background of the invention Arginine vasopressin (AVP) and oxytocin (OT) are cyclic nonapeptides whose actions are mediated by activation of specific G protein-coupled receptors currently classified into V 1 vascular (V 1 V2-renal (V 2 R) and V 3 -pituitary (V 3 R) AVP receptors, as well as OT receptors (OT-R) Oxytocin (OT) causes the contraction of the uterus of mammals during labor. The corresponding oxytocin receptor belongs to the family of G-protein-coupled receptors and is similar to Vi and V 2 vasopressin receptors. OT receptors increase dramatically during the course of pregnancy. The concentration of OT receptors has been shown to correlate with spontaneous uterine activity OT-induced contractions of the uterus during labor result in the dilatation of the cervix and eventually in the movement of the foetus through the vaginal canal. In some cases, these contractions occur before the foetus is fully viable, WO 03/053437 PCT/EP02/14594 -2resulting in premature labor. Premature labor and premature birth are undesired as they are major causes of perinatal morbidity. Hence, the management of preterm labor represents a significant problem in the field of obstetrics.
Vasopressin, also called "antidiuretic hormone", is a cyclic nonapeptide hormone that exhibits a series of physiological effects including free water re-absorption, vasoconstriction, cellular proliferation and adrenocorticotrophic hormone (ACTH) secretion. In a healthy organism, vasopressin plays an important role in the homeostasis of fluid osmolality and volume status. However, in several diseases or conditions such as the syndrome of inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome, dysmenorrhea and ocular hypertension, vasopressin is assumed to play an important role In recent years, strong evidence has accumulated indicating that the hormone oxytocin plays a major role in initiating labor in mammals, in particular in humans. Thereby, it is assumed that oxytocin exerts said effect in a direct as well as an indirect way, by contracting the uterine myometrium and by enhancing the synthesis and release of contractile prostaglandins from the uterine endometrium/decidua. These prostaglandins may furthermore play a role in the cervical ripening process. This "up-regulation" of oxytocin receptors and increased uterine sensitivity seems to be due to trophic effects of rising plasma levels of estrogen towards term. By down-regulating oxytocin, it is expected that both the direct (contractile) and indirect (increased prostaglandin synthesis) effects of oxytocin on the uterus could be blocked. An oxytocin modulator, e.g. blocker or antagonist would likely be efficacious for treating preterm labor.
A further condition related to oxytocin is dysmenorrhea, which is characterised by pain or discomfort associated with menses. The pain is believed to result from uterine contractions and ischemia, probably mediated by the effect of prostaglandins produced in the secretory endometrium. By blocking both the indirect and direct effects of oxytocin on the uterus, an oxytocin antagonist would be a likely candidate for treating dysmenorrhea.
WO 03/053437 PCT/EP02/14594 -3- Some agents counteracting the action of oxytocin are currently used in clinical studies Such tocolytic agents uterine-relaxing agents) include beta-2-adrenergic agonists, magnesium sulfate and ethanol. The leading beta-2-adrenergic agonist is Ritodrine, which causes a number of cardiovascular and metabolic side effects, including tachycardia, increased renin secretion, hyperglycemia and reactive hypoglycemia in the infant. Further beta-2-adrenergic agonists, including terbutaline and albuterol have side effects similar to those ofritodrine. Magnesium sulfate at plasma concentrations above the therapeutic range of 4 to 8 mg/dL can cause inhibition of cardiac conduction and neuromuscular transmission, respiratory depression and cardiac arrest, thus making this agent unsuitable when renal function is impaired. Ethanol is as effective as ritodrine in preventing premature labor, but it does not produce a corresponding reduction in the incidence of fetal respiratory distress that administration ofritodrine does.
Atosiban, a peptide OT antagonist, suffers the problem of most peptides: low oral bioavailability resulting from intestinal degradation. Such compounds must be administered parenterally.
The development ofnon-peptide ligands for peptide hormone receptors is expected to overcome this problem. Small molecule selective oxytocin antagonists have been reported by Merck. In addition to cyclic hexapeptides, Merck suggested indanylpiperidines and tolyl-piperazines as orally deliverable OT antagonists In WO 96/22775 and US- 5,756,497, Merck reported benzoxazinylpiperidines or benzoxazinones as OT receptor antagonists.
Specific sulfonamides have been reported to antagonize ocytocin at the ocytocin receptor.
Elf Sanofi's EP-A-0469984 and EP-A-0526348 report N-sulfonyl indolines acting as antagonists of the vasopressin and the oxytocin receptors.
WO 03/053437 PCT/EP02/14594 -4- Summary of the invention It is an object of the present invention to provide substances which are suitable for the treatment of a variety of diseases, in particular preterm labor, premature birth, dysmenorrhea, inappropriate secretion ofvasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension.
It is notably an object of the present invention to provide chemical compounds which are able to down-regulate, including to antagonize, the function of OT and/or Via in disease states in animals, preferably mammals, especially in humans.
It is also an object of the present invention to provide small molecule chemical compounds for the modulation, preferably the down-regulation or antagonization of the oxytocin receptor.
Moreover, it is an object of the present invention to provide methods for preparing said small molecule chemical compounds. It is furthermore an object of the present invention to provide a new category of pharmaceutical formulations for the treatment ofpreterm labor and dysmenorrhea, and/or diseases mediated by the oxytocin receptor.
It is finally an object of the present invention to provide a method for the treatment and/or prevention of disorders mediated by the oxytocin receptor, like preterm labor, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome, dysmenorrhea and ocular hypertension with oxytocin and/or vasopressin antagonists, acting for example by antagonizing the binding of oxytocin and/or vasopressin to their receptor.
WO 03/053437 WO 03/53437PCT/EP02/14594 In a first aspect, the invention provides compounds of formula 1:
RR
N-N
wherein: RI and W 2 are independently selected from the group consisting of H, CI-C 6 -alkyl., aryl Ci-C6-alkyl, heteroarylC 1
-C
6 -alcyl, C 3
-C
6 -cycloalkyl CI-C 6 -alkyl and heterocycloalkyl.
CI-C
6 -alkyl; or R' and R 2 together with the nitrogen atom they are linked to, form a substituted or unsubstituted 5-8-membered saturated, partially unsaturated or aromatic ring containing optionally one or more additional heteroatoms selected from 0, N, S; A is selected from the group consisting of C(O) and SO 2
W
3 is selected from a the group consisting of H, CI-C 6 -alkYl, aryl CI-C 6 -alkYl, heteroaryl Cl-C6-alkyl, aryl, heteroaryl, C 3 -C6-cycloalkyl CI-C 6 -alkyl, heterocycloalkyl
G
1
-C
6 -alkyl, G 2
-G
6 -alkenyl; B is selected from the group consisting of S, 0 and NR 5 W. and Wi are independently selected from the group consisting of H, Cl-C 6 -alkyl, aryl
CI-C
6 -alkyl, heteroaryl CI-C 6 -alkyl, acyl, aryl acyl, heteroaryl acyl, C3-C6-cycloalcyl CI -C 6 -alkyl, heterocycloalkyl CI-C 6 -alkyl, C 2
-C
6 -alkenyl; and n is an integer from 2 to In a second aspect, the invention provides a compound according to formula I for the treatment of disease.
WO 03/053437 PCT/EP02/14594 -6- In a third aspect, the invention provides a compound of formula I, for the preparation of a pharmaceutical composition.
In a fourth aspect, the invention provides a compound according to formula I for the modulation of the function of OT and/or Via receptors.
In a fifth aspect, the invention provides a method of synthesis of a compound according to formula I.
Detailed description of the invention The following paragraphs provide definitions of the various chemical moieties that make up the compounds according to the invention and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader definition.
"Ci-C 6 -alkyl" refers to monovalent alkyl groups having 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tertbutyl, n-hexyl and the like.
"C
3
-C
6 -cycloalkyl" refers to saturated or partially unsaturated carbocyclic rings having 3 to 6 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl and the like.
"C
3 -C6 -heterocycloalkyl" refers to saturated or partially unsaturated rings having 3 to 6 atoms and containing at least one heterotom selected from N, S and 0. Examples include pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl and the like.
"C
3 -C6-cycloalkyl C 1
-C
6 -alkyl" refers to Ci-C 6 -alkyl groups having an C 3
-C
6 -cycloalkyl substituent, such as, for example methyl-cyclopropane, ethyl-cyclohexane and the like.
WO 03/053437 WO 03/53437PCT/EP02/14594 -7-
"C
3
-C
6 -heterocycloalkyl C 1
-C
6 -alkyl" refers to CI-C 6 -alkyl groups having an C 3
-C
6 heterocycloalkyl substituent, such as, for example methyl-pyrrolidine, methyl piperidine, ethyl-tetrahydro-furan and the like.
"Aryl" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring phenyl) or multiple condensed rings naphthyl). Examples of aryl include phenyl, naphthyl, phenanthrenyl and the like.
aryl CI-C 6 -alkyl" refers to CI-C 6 -alkyl groups having an aryl substituent, such as, for example, benzyl, phenethyl and the like.
"Heteroaryl" refers to a monocyclic heteromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group. Particular examples of heteroaromatic groups include optionally substituted pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, l,2,4-triazolyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5-oxadiazolyl, 1 ,3,4-oxadiazolyl,1I,3,4-triazinyl, 1 ,2,3-triazinyl, beuzofuryl, [2,3dihyclro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, iniidazo[l,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinolizinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnnolinyl, napthyridinyl, pyrido[3,4-blpyridyl, pyrido[3 ,2-blpyridyl, pyrido[4,3-blpyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl or benzoquinolyl and the like.
"heteroaryl Cl-C 6 -alkyl" refers to Cl-C 6 -alkyl groups having a heteroaryl substituent, such as, for example, 2-furylmethyl, 2-thienylmefflyl, 2-(lH-indol-3-yl)ethyl and the like.
"Alkenyl" refers to alkenyl groups preferably having from 2 to 6 carbon atoms and having one or more sites of alkenyl unsaturation. Example of alkenyl groups include ethenyl
CH=CH
2 n-2-propenyl (allyl, -CII 2
CH=CH
2 and the like.
WO 03/053437 WO 03/53437PCT/EP02/14594 "Alkynyl" refers to alkynyl groups preferably having from 2 to 6 carbon atoms and having one or more sites of alkynyl urisaturation. Examples of alkynyl groups include ethynyl prop argyl. (-CH 2 and the like.
"Acyl" refers to the group -C(O)R where R includes "C 1
-C
6 -alkYl", "aryl", "heteroaryl", "C i-C 6 -alkyl aryl" or "Ci-C 6 -alkyl heteroaryl".
"Acyloxy" refers to the group -OC(O)R where R includes "Ci-C 6 -alkyl", "aryl", "heteroaryl", "Cl-C 6 -alkyl aryl" or "Cl-C 6 -alkyl heteroaryl".
"Alkoxy" refers to the group -0-R where R includes "Ci-C 6 -alkyl" or "aryl" or "heteroaryl" or "C i-C 6 -alkyl aryl" or "C i-C 6 -alkyl heteroaryl". Examples of alkoxy groups include by way of example, methoxy, ethoxy, phenoxy and the like.
"Alkoxycarbonyl" refers to the group -C(O)OR where R includes "Cl-C 6 -alkyl" or "4aryl" or "heteroaryl" or "Ci-C 6 -alkyl aryl" or "Ci-C 6 -alkyl heteroaryl".
"Aminocarbonyl" refers to the group -C(O)NRR' where each R, R' includes independently hydrogen or CI-C 6 -alkyl or aryl or heteroaryl or "Ci-C 6 -alkyl aryl" or "Cl-C 6 -alkyl heteroaryl".
"Acylamino" refers to the group -NR(CO)R' where each R, R' is independently hydrogen or "CI-C 6 -alkyl" or "aryl" or "heteroaryl" or "CI-C 6 -alkyl aryl" or "Cl-C 6 -alkyl heteroaryl".
"Halogen" refers to fluoro, chloro, bromno and iodo atoms.
"Sulfonyl" refers to a group -S0 2 wherein R is selected from H, "Cl-C 6 -allcyl", "Cl-
C
6 -alkyl" optionally substituted with halogens, such as, for example, an -S0 2
-CF
3 group, "aryl", "heteroaryl", "Cl-C 6 -alkyl aryl" or "Ci-C 6 -alkyl heteroaryl".
WO 03/053437 PCT/EP02/14594 -9- "Sulfoxy" refers to a group wherein R is selected from H, "Ci-C 6 -alkyl", "C 1
C
6 -alkyl" optionally substituted with halogens, such as, for example, an -SO-CF 3 group, "aryl", "heteroaryl", "Ci-C 6 -alkyl aryl" or "Ci-C 6 -alkyl heteroaryl".
"Thioalkoxy" refers to groups -S-R where R includes "Ci-C 6 -alkyl" or "aryl" or "heteroaryl" or "Ci-C 6 -alkyl aryl" or "Ci-C 6 -alkyl heteroaryl". Examples of thioalkoxy groups include thiomethoxy, thioethoxy, and the like.
"Substituted or unsubstituted": Unless otherwise constrained by the definition of the individual substituent, the above set out groups, like "alkyl", "alkenyl", "alkynyl", "aryl" and "heteroaryl" etc. groups can optionally be substituted with from I to 5 substituents selected from the group consisting of "Ci-C 6 -alkyl", "C1-C 6 -alkyl aryl", "Ci-C-alkyl heteroaryl",
"C
2
-C
6 -alkenyl", "C 2
-C
6 -alkynyl", primary, secondary or tertiary amino groups or quarternary ammonium moieties, "acyl", "acyloxy",,"acylamino", "aminocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, alkoxy, thioalkoxy, trihalomethyl and the like. Within the framework of this invention, said "substitution" is meant to also comprise situations where neighboring substituents undergo ring closure, in particular when vicinal functional substituents are involved, thus forming e.g. lactams, lactones, cyclic anhydrides, but also acetals, thioacetals, aminals formed by ring closure for instance in an effort to obtain a protective group.
"Pharmaceutically acceptable salts or complexes" refers to salts or complexes of the identified compounds of Formula I that retain the desired biological activity and are not toxic. Examples of such salts include, but are not restricted to, acid addition salts formed with inorganic acids hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acid, naphthalene disul-fonic acid, and poly-galacturonic acid. Said compounds WO 03/053437 PCT/EP02/14594 can also be administered as pharmaceutically acceptable quaternary salts known by a person skilled in the art, which specifically include the quatemary ammonium salt of the Formula wherein R, R" is independently hydrogen, alkyl, or benzyl, and Z is a counterion, including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phos-phate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, fumarate, citrate, tartrate, ascorbate, cinnamoate, mandeloate, and diphenylacetate).
"Pharmaceutically active derivative" refers to any compound that upon administration to the recipient, is capable of providing directly or indirectly, the activity disclosed herein.
"Enantiomeric excess" (ee) refers to the products that are obtained by an asymmetric synthesis, i.e. a synthesis involving non-racemic starting materials and/or reagents or a synthesis comprising at least one enantioselective step, whereby a surplus of one enantiomer in the order of at least about 52% ee is yielded. In the absence of an asymmetric synthesis, racemic products are usually obtained that do however also have an activity as OT-R antagonists.
The term "preterm labor" or the term "premature labor" shall mean expulsion from the uterus of an infant before the normal end of gestation, or more particularly, onset of labor with effacement and dilation of the cervix before the 3 7 th week of gestation. It may or may not be associated with vaginal bleeding or rupture of the membranes.
The term "dysmenorrhea" shall mean painful menstruation.
The term "caesarean delivery" shall mean incision through the abdominal and uterine walls for delivery of a foetus.
The present invention also includes the geometrical isomers, the optical active forms, enantiomers, diastereomers of compounds according to formula I, mixtures of these, as well as their racemates and also pharmaceutically acceptable salts.
WO 03/053437 PCT/EP02/14594 -11- Preferred R' and R in compounds according to formula I are those that are independently selected from the group consisting of H, methyl, ethyl, propyl and butyl, optionally substituted by substituted or unsubstituted Ci-Cs-alkoxy, preferably methoxy, substituted or unsubstituted C2-C6-alkenyl, preferably ethenyl, substituted or unsubstituted aryl or heteroaryl, preferably mono- or poly- halogen substituted phenyl, methoxyphenyl, pyrrolidinone, furanyl, benzodioxolyl, substituted or unsubstituted C 3
-C
6 -cycloalkyl or 5-6membered heterocycle, preferably cyclopropyl, tetahydrofuryl and pyrrolidinone.
Preferred R 3 in compounds according to formula I are those that are independently selected from the group consisting of H, methyl, ethyl, propyl, butyl optionally substituted by substituted or unsubstituted C 1
-C
6 -alkoxy, preferably methoxy, substituted or unsubstituted
C
2
-C
6 -alkenyl, preferably ethenyl, substituted or unsubstituted aryl or heteroaryl, preferably mono- or poly- halogen substituted phenyl, methoxyphenyl, pyrrolidinone, furanyl, benzodioxolyl, substituted or unsubstituted C 3 -C6-cycloalkyl or 5-6-membered heterocycle, preferably cyclopropyl, tetahydrofuryl and pyrrolidinone and aryl, optionally substituted by substituted or unsubstituted C 1
-C
6 -allyl, preferably methyl, halogen, substituted or unsubstituted C 1
-C
6 -alkoxy, preferably methoxy.
Preferred R 4 and R 5 in compounds according to formula I are those that are independently selected from the group consisting of H, methyl, ethyl, propyl and butyl, optionally substituted by substituted or unsubstituted Ci-C 6 -alkoxy, preferably methoxyphenyl, substituted or unsubstituted C 2
-C
6 -alkenyl, preferably ethenyl, cthcnylphcnyl, substituted or unsubstituted acyl aryl, preferably, carbonyl aryl, substituted or unsubstituted aryl or heteroaryl, preferably mono- or poly- halogen substituted phenyl, cyanophenyl, methylphenyl, tri-halo-methylphenyl, substituted or unsubstituted C 3
-C
6 -cycloalkyl or 5-6membered heterocycle, preferably cyclohexyl.
A particularly preferred embodiment of the present invention is a triazole derivative according to formula I wherein A is B is S and n is 2, 3 or 4.
WO 03/053437 PCT/EP02/14594 -12- Compounds of formula I may be used for the treatment of a disease.
Specifically, the compounds of formula I are suitable for use in treating disorders such as preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome, ocular hypertension and for stopping labor prior to cesarean delivery. The compounds of the present invention are in particular useful for the treatment of preterm labor, premature birth and dysmenorrhea.
Preferably, the compounds according to Formula I alone or in a form of a pharmaceutical composition are suitable for the modulation of oxytocin and/or vasopressin (in particular Via) function(s), thus specifically allowing the treatment and/or prevention of disorders which are mediated by the oxytocin and/or vasopressin receptors. Such modulation preferably involves the inhibition of OT-R function(s), notably by the antagonization of the oxytocin receptor in mammals, and in particular in humans.
Abnormal activity or hyperactivity of the oxytocin and/or vasopressin receptors are frequently involved in various disorders including the above enumerated disorders and disease states. Hence, the compounds according to the invention may be used for the treatment of disorders by modulating OT-R function or pathways. The modulation of the OT-R function or pathways may involve the down-regulation and/or inhibition of the oxytocin receptor. The compounds of the invention may be employed alone or in combination with further pharmaceutical agents, e.g. with a further OT-R modulator.
When employed as pharmaceuticals, the triazole derivatives of the present invention are typically administered in the form of a pharmaceutical composition. Hence, pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier, diluent or excipient are also within the scope of the present invention. A person skilled in the art is aware of a whole variety of such carriers, diluents or excipients suitable to formulate a pharmaceutical composition.
WO 03/053437 PCT/EP02/14594 -13- The compounds of the invention, together with a conventionally employed adjuvant, car- Srier, diluent or excipient may be formulated as pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
When employed as pharmaceuticals, the triazole derivatives of this invention are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. Generally, the compounds of this invention are administered in a pharmaceutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
The pharmaceutical compositions of the invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. Depending on the intended route of delivery, the compounds are preferably Formula ted as either injectable or oral compositions. The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predeter- WO 03/053437 PCT/EP02/14594 -14mined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampoules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the triazole compound is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like.
Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatine; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art. As above mentioned, the triazole derivatives of Formula I in such compositions is typically a minor component, frequently ranging between 0.05 to 10% by weight with the remainder being the injectable carrier and the like.
The above described components for orally administered or injectable compositions are merely representative. Further materials as well as processing techniques and the like are set out in Part 8 of in The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can also be found in the incorporated materials in WO 03/053437 PCT/EP02/14594 Still a further object of the present invention is a process for preparing preparing [l,2,4]triazole derivatives according to Formula I.
The triazole derivatives exemplified in this invention may be prepared from readily available or previously described starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions reaction temperatures, time, moles of reagents, solvents, etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimisation procedures.
Synthesis of compounds of the invention: Generally, the [1,2,4]triazole derivatives according to the general Formula I may be obtained by several processes, using both solution-phase and solid-phase chemistry protocols. Depending on the nature of R 1
-R
4 A, B and n, certain processes will, in some instances, be preferred over others, and it is assumed that the choice of the most suitable process will be known to the practitioner skilled in the art.
Five examples of synthetic pathways for compounds of formula I will be described.
The following abbreviations refer respectively to the definitions below: ACN (Acetonitrile) AMEBA (Acid-sensitive Methoxy benzaldehyde) CDC13 (deuterated chloroform) cHex (Cyclohexanes) DCM (Dichloromethane) WO 03/053437 WO 03/53437PCT/EP02/14594 16- DECP (Diethylcyanophosphonate) DIG (Diisopropyl carbodiide) DMAP Dimethylainiinopyricline) DMF (Dimethylformn-amide) DMS0 (Dimethylsulfoxide) DMSO-d 6 (deuterated dimethylsul-foxide) EDC (1-(3-Dimethyl-amino-propyl)-3-ethylcarbodiimide) EtOAc (Ethyl acetate) Et 2 O (Diethyl ether) HOBt (1-Hydroxybenzotriazole)
K
2 C0 3 (potassium carbonate) NaH (Sodium hydride) NaHCO 3 (Sodium bicarbonate) nBuLi (n Butyllithium) TBTU (0-B enzotriazolyl-NNN',N'-tetramethyluronium-tetrafluoroborate) TEA (Triethyl aine) TFA (Trifluoro-acetic acid) THF (Tetrahydrofuran) WO 03/053437 PCT/EP02/14594 -17- MgSO 4 (Magnesium sulfate) PetEther (Petroleum ether) rt (room temperature).
Protocol I: A preferred pathway for preparing [1,2,4]triazole derivatives according to the general Formula I, wherein B is a sulphur moiety (Formula Ia), with R 2
R
3 and R 4 A and n being defined as above, consists in the alkylation of the corresponding mercaptotriazole precursor of formula II in presence of an appropriate alkylating agent RaX (formula III) in which R 4 is as defined above and X is a leaving group such as chloro, bromo, iodo, methanesulfonate or p-toluenesulfonate. This alkylation follows solution-phase chemistry protocols well known to those skilled in the art such as shown in Scheme I. The alkylation is conducted in any of a variety of solvents, including methanol, ethanol, 2methoxyethanol, tetrahydrofuran, N,N-dimethylformamide, dichloromethane and water, depending on the properties of the particular substituents, in the presence of a base, such as a trialkylamine, alkoxide or hydroxide. The alkylation reaction is generally run at a temperature comprised between 0°C and 125 0 C, depending on the reactivity of the alkylating agent.
Scheme I:
R
1 R R 4 X, R 1
R
3 I I [X=CI,Br,I,OMs,OTs] I R2 A- -N II R2 /N A N/ N Base NN R 4 II la WO 03/053437 PCT/EP02/14594 -18- Mercaptotriazole derivatives of Formula II, used for the preparation of triazoles derivatives of compounds of formula Ia according to scheme I can be prepared from an appropriate amine IV, using a variety of synthetic strategies, of which some selected examples are shown in Scheme 1I (9-14).
Scheme II: Carboxylic acid derivative e.g. R1
I
.CS, EtN S sH R l I N OMe 2. Mel .S HN-NH, N Ix OMe NHz R N Me R N NH, H IV 2 H H VI Heating
S
3 NH11
N
2. EtOCOCI IXI 6 N NaOH or NaOEt First, an amine of formula IV may be converted to a dithiocarbamate ester of formula V in a one-pot two-step sequence involving treatment with carbon disulfide in the presence of a base such as triethylamine followed by alkylation with methyl iodide. Treatment of a dithiocarbamate ester of formula V with hydrazine affords a 4-substituted thiosemicarbazide of formula VI (scheme II).
Then, reaction of a thiosemicarbazide of formula VI with the appropriate acid chloride of formula VII leads to an acylthiosemicarbazide of formula VIII (scheme II).
Finally, mercaptotriazoles of formula II may be obtained either by direct reaction of the thiosemicarbazide derivative of formula VI with an appropriate acid derivative of formula IX (for example reaction with a trimethyl orthoester at elevated temperature in a suitable WO 03/053437 PCT/EP02/14594 -19solvent, such as 2-methoxyethanol at reflux) or by cylization of an acylthiosemicarbazide of formula VIII in presence of hydroxide or alkoxide (scheme II).
An alternative way of obtaining an acylthiosemicarbazide of formula VIII is first reacting an amine of formula IV following standard reaction conditions widely described in the literature (9-14) to obtain an isothiocyanate of formula X which is then added to an acid hydrazide of formula XI to lead to an acylthiosemicarbazide of formula VIII (scheme II).
Acid hydrazides of formula XI can be readily obtained from the corresponding ester which is either commercial or can be prepared from available starting materials according to standard protocols well known to the practitioner skilled in the art.
Derivatives of mecaptotriazoles of formula II can be prepared using known modifications to the Scheme II reaction sequences.
Protocol H: An another preferred pathway for preparing [1,2,4]triazole derivatives according to the general Formula I wherein, wherein B can be S (formula Ia), NR 5 (formula Ib) or O (formula Ic), with R, R 4 and R s A and n being defined as above, consists in the displacement of a leaving group on the triazole, e.g. chlorotriazole of formula XII or methanesulfonyltriazole of formula XIII. The leaving group on the triazole can be displaced by an appropriate nucleophile of formula respectively XIV, XV or XVI under reaction conditions well known to the person skilled in the art and as described in Scheme III.
For example, S-substituted mercaptotriazoles of formula Ia (general Formula I, wherein B is a Sulphur moiety) can be prepared by addition of a thiol R 4 SH (formula XIV), wherein
R
4 is defined as above, on a chlorotriazole of formula XII or a methylsulfonyltriazole XIII in the presence of a base such as N,N-diisopropylethylamine, at elevated temperature (for example, in DMF at reflux).
WO 03/053437 WO 03/53437PCT/EP02/14594 20 Aniinotriazoles of formula lb (general Formula I, wherein B is NR 5 can be obtained by heating a chiorotriazole, of formula XII or- a methanesulfonyltri-azole of formula XIII with an amine of formula RWRNH where W. and R.
5 are defined as above.
,Alkoxy and aryloxytriazole of formula Ic (general Formula I, wherein B is Oxygen) can be prepared by heating a chiorotriazole XII or a methanesulfonyltriazole XIII with the appropriate alkoxyde or phenoxide anion R 4 0"(formula XVI), where P.
4 is defined as above.
Scheme III: R 3 XIV, XVor XVI R 1 R3 XFV, XVor XVI Rl I Heating IHeating
R.
N B NA N R R- A4 n Nl Xii N-N N-N RX111 e.g.
R
4 SH (XIV)
R
Base, Heating R21NA N N S la N-N R
R
4 RNH (XV) R R 3 Heating 2
R
XII orX11111 R A ~I -N lb N-N
R'
R
4 0 (XVI) R R F 3 HeatingI IN-N El 4
\R
The chiorotriazoles of formula XII used for the preparation of triazoles of formula Ia, lb or Ic according to scheme 111 may be prepared by treatment of a mercaptotriazole precursor of formula 11 with chlorine under anhydrous conditions in a solvent such as chloroformt or clichioromethane, as shown in Scheme IV.
The methyl~ulfonylthiotriazoles of formula XIII used for the preparation of triazoles of formula Ia, lb or Ic according to scheme III may be prepared by alkylation of the same mercaptotriazole precursor of formula II with methyl iodide to lead to a methyithiotriazole WO 03/053437 PCT/EP02/14594 -21of formula XVII which is then oxidized into the methylsulfunonyltriazole of formula XIII using hydrogen peroxide in acetic acid or similar methods known to the person skilled in the art and as described in Scheme IV.
Scheme IV: S R3
R
1 R3 R2'N'A- CH 2 R2'N' A N R2--N- N- II N~N XII N-N Base, Mel R R 3
H
2 0 2 AcOH R 1 R3 I or I M
R,
2 NA S MCPBA R2N\A N>M XVII NN Me Xll 0 Mercaptotriazole derivatives of Formula II, used for the preparation of chlorotriazoles of formula XII and methylsulfonylthiotriazoles of formula XIII according to scheme IV can be prepared from an appropriate amine IV, using a variety of synthetic strategies, of which some selected examples are previously shown in Scheme II (see protocol I).
Protocol III: An another preferred pathway for preparing [1,2,4]triazole derivatives according to the formula Id (formula I wherein, wherein B is NR s and R 5 H) can be prepared following the synthetic route described in Scheme V.
WO 03/053437 PCT/EP02/14594 -22- Scheme V: NR4 R 4 R2N A OH R1 R3 SHeating HN JR 3 X R
A
R3-NH 2 H2NN HSM e HN" N Heating IN H YH H N R4 IV XVIII XIX Id HaNNH,
NR
N SMe
H
XXI
An appropriate amine of formula IV is heated together with a S-methyl thiosemicarbyzide derivative of formula XVIII to give an aminoguanidine of formula XIX. Heating an aminoguanidine of formula XIX with an appropriate carboxylic acid of formula XX provides an aminotriazole of formula Id. Aminoguanidines of formula XIX can be also obtained by an hydrazine treatment of isothioureas of formula XXI.
Protocol IV: An another preferred pathway for the preparation of [1,2,4]triazole derivatives according to the formula Id (formula I wherein, wherein B is NR 5 and R 5 H) consists in the condensation of an aminotriazole of structure Ie (formula I wherein, wherein B is NR 5 and
R
4
R
5 H) with an aromatic aldehyde under suitable reaction conditions well known to the person skilled in the art. Reduction of the resulting Schiff base of formula XXII with a suitable agent such as sodium borohydride leads the [1,2,4]triazole derivatives according to the formula Id (Scheme VI).
WO 03/053437 PCT/EP02/14594 -23- Scheme VI: R RI 3 R 1 R3 R2N AA N ArCHO R2NN NaBH 4
FRNA-
N >-NH 2 AI N '4 le -N XXII NN -Ar I N.N R Aminotriazole of formula Ie used to prepare triazoles of formula Id according to the above scheme VI can be prepared by different synthetic routes, including the one described in Scheme V, starting with the suitable S-methyl thiosemicarbazide derivative XVIII with R 4
H.
[1,2,4]Triazole derivatives according to the general Formula I, whereby the substituents R
R
4 A, B and n are as above defined, can be prepared using modifications to Schemes I to VI reaction sequences or by other current methods or procedures according to published literature well known to the practitioner skilled in the art (9-14).
Protocol V: According to yet another preferred process, [1,2,4]triazole derivatives according to the general Formula I, whereby the substituents R 2
R
3
R
4 and R 5 A, B and n are as above defined, are prepared by solid-phase and/or mixed solid-/solution-phase synthesis protocols such as, those described in the Example I and shown in Scheme VII.
It will be appreciated by the practitioner skilled in the art that basically the same conditions, methods and reagents as above described in Schemes I to VI for the sollution-phase synthesis of compounds of Formula I can be applied to the solid-phase and/or mixed solid- /solution-phase synthesis of said compounds.
WO 03/053437 WO 03/53437PCT/EP02/14594 -24- Scheme VII: 0 R-NH cI, n 2 *1"NH XXVI XXIII X R e.g. Ameba
X
0 H H 1 H N~rN R
SX
R'-NCS
XXIX
0 *N.NA f
RXXVII
SN
2 NH 2 A A14 H 2 'I
H
R XXVIII R ~R 3 XXXII N-N R4
IKOH
RR
_SH
XXXI N-N
R
4
X,
IX=CI,Br,I,OMs,OTs]
III
Base
ITFA/DCM
R
1
R
3 RZ21NA N la Rl In the context of such a solid-phase and/or mixed solid-/solution-phase synthesis protocol (Protocol V, Scheme VII), the R' or R 2 -groups of compounds 11, VIL-IX, XI-X1I, XVII, XX and XXII shown in Schemes 1-VI, are found on a suitable resin comprising the appropriate cleavable linker. The circles within the Scheme VII illustrate the resin beads to which the corresponding compounds are linked during the solid phase synthesis. It is to be understood that further to the mentioned resin types, other suitable reagents, notably resins, known to a person skilled in the art, could be employed for the solid-phase synthesis of compounds of general Formula IL WO 03/053437 PCT/EP02/14594 Thus, in one preferred scenario, an amino-derivatised resin of formula XXV is obtained by coupling of an appropriate amine of formula XXIV with a suitable resin carrying an aldehyde moiety AMEBA II (15) or ArgoGel-CHO resin) of formula XXIII, using standard reductive amination conditions well known to the practitioner skilled in the art According to the methods outlined in Scheme VII and described hereinafter in the Examples I, this intermediate of formula XXV can then be reacted with an acyl or sulfonyl chloride of formula XXVI containing an ester moiety, in the presence of a base, Nethyldiisopropylamine) to lead to a compound of formula XXVII.
Then, addition of an excess of hydrazine to a compound of formula XXVII at 50 0 C leads to the corresponding acid hydrazide of formula XXVIII. This acid hydrazide of formula XXVIII is then converted into semicarbazide corresponding to a structure of formula XXX by addition of a isothiocyanate of formula XXIX at room temperature.
The semicarbazide of formula XXX is then cyclised into a triazole derivative of formula XXXI under basic conditions 0.3 M KOH), at elevated temperature, such as 65 0
C.
The resulting cyclized derivative of formula XXXI can be further functionalized in the presence of a base N-ethyldiisopropylamine) by an appropriate alkylating agent R 4
X
of formula IIII wherein R 4 is defined as above and is a leaving group such as chloro, bromo, iodo, methanesulfonate or p-toluenesulfonate. The resulting product of formula XXXII can be cleaved from the resin under acidic conditions in a TFA/DCM solution), affording the corresponding [1,2,4]triazole of formula Ia (formula I wherein B is a Sulphur moiety) as described hereinafter in the Example I.
Amines of formula XXIV used according to scheme VII are either commercial, 1-(3amino-propyl)-pyrrolidin-2-one, cyclopropyl-methylamine, phenethylamine, furan-2-ylmethylamine, 2-methoxy-ethylamine, butylamine, 3-methoxy-propylamine, benzo[1,3]dioxol-5-yl-methylamine, propylamine, 4-fluoro-benzylamine, (tetrahydro- WO 03/053437 WO 03/53437PCT/EP02/14594 -26furan-2-yl)-methylaniine, 2-methoxy-benzylamine, 4-methoxy-benzylarnine, benzylamine, isobutylamine, allylamine, or can be prepared from readily available starting material according published literature procedures and methods well known to the practioner skilled in the art.
Compounds of formula XXVI may also be either commercial, methyl 3- (clorofomiyl)-propionate, methyl 4-(cloroformyl)-butyrate, methyl pentanoate, or can be prepared from readily available starting material according published" literature procedures and current methods well known to the practioner skilled in the art.
Isotbiocyanates of formula XXIX are either commercial, l-isothiocyanato-3-methylbenzene, 1 -cbloro-4-isothiocyanato-benzene, l-isothiocyanato-4-methyl-benzenc, 2-.
isoihiocyanatomethyl-tetrahydro-furan, (2-isothiocyanato-ethyl)-benzene, 1 -isothiocyanato-, methyl-4-methyl-benzene, 3-isothiocyanato-propene, isotbiocyanato-methane, 1isothiocyanato-2-methyl-propanle, 1 -fluoro-4-isothiocyanato-benzene, isothio-cyanato-.
methyl-benzene, isothiiocyanato-benzene, 1 -cbloro-3-isothiocyanato-benzene, 1 -isothiocyanato-3 -methoxy-propane, 1 -isotbiocyanato-3-methoxy-benzene, or can be prepared from readily available starting material according published literature procedures and methods well known to the practioner skilled in the art.
Alkylating agent R 4 X of formula III are either commercial, benzylbromide, (3-bromopropenyl)-benzene, allylbromide, bromomethyl-cyclohexane, 1-bromomethyl-3 -methylbenzene, 1-bromomethyl-4-fluoro-benzene, l-bromomethyl-3,5-dimTethyl-benzene, 1bromomethyl-3-fluoro-beizene, 1 -bromomethyl-4-trifluoromethyl-benzene, (2-bromoethoxy)-benzene, bromoethane, 1 -bromo-2-methoxy-ethane, l-bromomethyl-4-methylbenzene, 2-bromomethyl-tetrahydro-pyran, 2-bromo-l1-phenyl-ethanone, bromno-acetic acid ethyl ester, 1 -bromomethyl-2,3,4,5,6-pentafluoro-benzene, (2-bromo-ethyl)-benzene, 1bromomethyl-2-methyl-benzene, l-bromomethyl-2-fluoro-beinzene, 1 -bromomethyl-3chloro-benzene, 1 -bromomethyl-2-cbloro-4-fluoro-benzene, 3-bromomethyl-benzonitrile, 1-bromo-butane, or can be prepared from readily available starting material according WO 03/053437 PCT/EP02/14594 -27published literature procedures and current methods well known to the practioner skilled in the art.
The reaction sequences outlined in the above Schemes (I to VII) provide enantiomerically pure compounds of general Formula I, if enantiomerically pure starting materials are used.
as well as enantiomers can be obtained depending upon whether or forms of commercially available starting materials are used.
According to a further general process, compounds of Formula I can be converted to alternative compounds of Formula I, employing suitable interconversion techniques.
If the above set out general synthetic methods are not applicable for obtaining,compounds according to Formula I and/or necessary intermediates for the synthesis of compounds of Formula I, suitable methods of preparation known by a person skilled on the art should be used. In general, the synthesis pathways for any individual compound of Formula I will depend on the specific substitutents of each molecule and upon the ready availability of intermediates necessary; again such factors being appreciated by those of ordinary skill in the art. For all the protection, de-protection methods, see (16) and (17).
Compounds of this invention can be isolated in association with solvent molecules by crystallization. The pharmaceutically acceptable acid addition salts of the compounds of Formula I, which contain a basic center, may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solu-tion of compound of Formula I with a suitable base. Both types of salt may be formed or interconverted using ion-exchange resin techniques.
WO 03/053437 PCT/EP02/14594 -28- Examples: The invention will be illustrated by means of the following examples which are not to be construed as limiting the scope of the invention.
The compounds of the present invention may be synthesized according to the different synthesis pathways provided above. The following examples illustrate preferred methods for synthesizing the compounds according to formula I and determining their activities.
Example I: 3-[5-[(3-chlorobenzvl)sulfanvl1-4-(3-methoxyphenvl)-4H-1,2,4-triazol-3-vll- N-(2-methoxvbenzvl)propanamide (compound of formula Ia). See Protocol V, Scheme
VII.
(1) Protocol V: Step 1: Reductive amination (compound of formula AWV): In a round bottomed flask, fitted with stirrer and nitrogen inlet, was suspended AMEBA II resin of formula XXIII (50 g, 0.048 mol, 0.96 mmol/g), in mixture 9:1 of THF/TMOF (500 mL). Primary amine (compound of formula XXIV), e.g. 2-methyoxy benzylamine (0.072 mol, 7.9 mL, 1.5 eq), followed by acetic acid (2.75 mL, 1.5 eq) were sequentially added. The resulting mixture was stirred for 1 hour (imine formation). Sodium triacetoxyborohydride (15.25 g, 0.072 mol, 1.5 eq) was added to the flask and the reaction stirred overnight at room temperature under nitrogen. The excess of hydride was neutralized with a 2 N NaOH solution (20 mL). The resin was recovered on a sintered funnel and was washed sequentially with DMF (250 mL), water (250 mL), DMF (250 mL), WO 03/053437 PCT/EP02/14594 -29water (250 mL), acetone (250 mL), methanol (250 mL), acetone (250 mL) and methanol (250 mL). The resin was first dried by flusing air for 1 hour, then in vacuo at 60 0
C.
Step 2: Reaction of the resin with an acylor sulfonyl chloride (compound of formula
XXTII:
The resulting Amino-derivatised AMEBA II resin of formula XXV obtained from Step 1 (0.75 mmol/g of resin), was suspended in dichloromethane (10 mL/g of resin) in a round bottomed flask. An acid chloride or sulfonyl chloride of formula XXVI (3 eq), e.g. methyl 3-(chloroformyl)-propionate, was added, followed by N-ethyldiisopropylamine (3 eq). The reaction mixture was shaken at room temperature for 18 hours. The resin was filtered and washed sequentially with DCM, DMF, DCM and MeOH before being dried in vacuo.
Step 3: Hydrazine addition (compound of formula XXVIII): Ester derivatised AMEBA II resin of formula XXVII obtained from Step 2 mmol/g), was put into a round bottomed flask with a magnetic stirrer. To the flask was added N,Ndimethylformamide (5 mL/g of resin), hydrazine hydrate (5 mL/g of resin). A water condenser was fitted and the reaction was stirred slowly at 50 0 C for 18 hours. The reaction was allowed to cool to room temperature, filtered and the resin washed five times with water and the waste disposed of-accordingly. The resin was then washed sequentially with DMF, DCM and MeOH before being dried in vacuo.
Step 4: Isocvanate addition (compound of formula XX2): The resin linked to the resulting acid hydrazide of formula XXVIII and recovered from above Step 3 (1.5 g, -0.7 mmol/g), was weighed into boiling tubes. Standard solutions of the isothiocyanates of formula XXIX, e.g. 1-isothiocyanate-3-methoxy-benzene, were made up (0.42 M in anhydrous THF). These standard solutions (25 mL, 10.5mmol, 10eq) were then added to the boiling tubes, which were sealed with a pressure releasing septum. The tubes were shaken at room temperature for 66 hours. The resin of each tube was filtered WO 03/053437 PCT/EP02/14594 and washed with 2 x DMF and the waste disposed of accordingly. The resin was then washed sequentially with DCM and MeOH before being dried in vacuo.
Step 5: Cyclization (compound of formula XXXI): The resins resulting from the previous Step 4 and of formula XXX, were transferred to a clean boiling tube and a 3:2 mixture of 1,4-dioxane and 0.3M KOH (20 mL) was added.
The tubes were heated to 65 C and shaken for 18 hours. The reactions were allowed to cool to room temperature. The resin was washed with 3 x water, 2 x MeOH, 2 x DCM and 2 x MeOH before being dried in vacuo.
Step 6: Alkllation (compound of formula XXII) The resin-bound compound of formula XXXI obtained from Step 5, was transferred into a 96-well filter-plate (approximatively 50mg of dry resin/well) and each well treated with Iml of alkyl bromide (formula III) solution (0.21 mmol/ml of 1,4-dioxane), e.g. 1- Bromomethyl-3-chloro-benzene. N-ethyldiisoprpylamine (50 tl) was added to each well, the plate sealed and shaken at room temperature for 18 hours. The resin was filtered and washed with 2 x DMF and the waste disposed of accordingly. The resin was then washed sequentially with DMF, DCM, MeOH and finally DCM before being dried in vacuo.
Step 7: Cleavageform the resin (compound of formula la): A standard solution of 60% TFA/DCM was prepared. This solution (3 x 0.5ml) was dripped through each well of the filter plate containing the resin-bound compound of formula XXXII obtained from Step 6, collecting in a 2ml plate. The solvents were evaporated. This procedure was repeated once (3 x 0.5ml of 60% TFA/DCM solution) and the solvents were removed in vacuo. Dry THF (0.5 mL) and MeOH (0.5 mL) were finally dripped through and the solvent removed in vacuo. The final compound (formula Ia) obtained after purification by two successive flash chromatography processes (first column using 100% ethyl acetate progressing to 5% methanol/ethyl acetate as eluent; second WO 03/053437 WO 03/53437PCT/EP02/14594 -31column performed with a mixture 50% hexane/ethyl acetate progressing to 100% ethyl -acetate over 1 hour as eluent) is 3-[5-[(3-cllorobenzyl)sulfanyl]-4-(3-methoxyphenyl)-4H- 1 ,2,4-triazol-3-yl] -N-(2-methoxybenzyl)propanamide (111 NMR (400 MHz, CDCl 3 (in, 2H), 2.6 (mn, 2H), 3.6 3H), 3.7 311), 4.1-4.3 (mn, 4H), 5.3 (mn, 1H), 5.4 (in, 2H), 5.7 (in, 2H), 5.8 (mn, 111), 6.9-7.1 (in, 6H), 7.2 (in, 111). M+(ESn~: 523).
The below listed compounds in Table 2 (designated by example numbers) were prepared in a similar way by following the general method as outlined in Example 1 and using the corresponding starting arnines (Table 1).
Table 1 WO 03/053437 WO 03/53437PCT/EP02/14594 Chemical Structure FMWT
NH
2 97.12 0
H
2 N ,CH 3 75.11
H-
3 C" NH- 2 73.14
NH
2 89.14 itc-O o N N 2 151.17
H
3 N H 2 59.11 WO 03/053437 WO 03/53437PCT/EP02/14594 -33- Chemical Structure FMWT FONH 2 125.15 0 101.15 0, 0
CH
3 137.18 I 137.18 'N
NH
2 107.16
NH
2 1- 3 C
CH
3 731 WO 03/053437 WO 03/53437PCT/EP02/14594 Chemical Structure FMWT H 2 N- CH 2 57.10 Table 2 Example Chemical Structure M.W. IUPAC-Name M"(ESI+) No. 3-{4-benzyl-5-[(3- 2 507.0 chlorobenzyl)sulfanyl]-4H-1,2,4- triazol-3-yI}-N-(2b l- N-Nmethoxybenzyl)propanamide
CI
N 3-{4-(3-chlorophenyl)-5-[(3- N 0/ 507.06 methylbenzyl)sulfanyl]-4H-1,2,4- 507 3 triazol-3-yl}-N-(2methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M-(ESI~) No.
3-[5-[(3-chlorobenzyl)sulfanyl]-4- 48.0 (3-methoxypropyl)-4H-1,2,4- 48 4 N-N 89.04 riazol-3-yi]-N-(2-48 methoxybenzyl)propanamide 3-[5-[(3-fluorobenzyI)sulfanyI]-4- 0 0 N 490.60 (4-methylphenyl)-4H-i 2,4- 49 f N triazol-3-yl]-N-(2-49 N F methoxybenzyl)propanamide N-(2-methoxybenzyl)-3-{4-(4- 6 N0.6 methylbenzyl)-5-[(3- 501 N N50.6 methylbenzyl)sulfanyfl-4H-1,2,4triazol-3-yl~propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -36- Example Chemical Structure M.W. IUPAC-Name M'(ESI') 0/N> 465 3-{5-[(3-fluorobenzyl)sulfanyl]-4- 7 456.58isobutyl-4H-1,2,4-triazol-3-yl}-N- 457 N-N F (2-methoxybenzyl)propanamide
CI
0 9 3-[5-[(3-chlorobenzyl)sulfanylJ-4- "N57.0 (3-methylphenyl)-4H-1,24 8 ~~riazol-3-yl]-N-(2- ,2450 0- methoxybenzyl)propanarnide 3-L5-(benzylsulfanyi)-4-(4- 0 N 472.61 methylphenyl)-4H-1 ,2,4-triazol- 47 N 3-yI]-N-(2- N-N methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M-(ESI-) No.
0 N0 3-[5-(benzylsulfanyl)-4-isobutyl- N -N 438.59 4H-I ,2,4-triazol-3-y]-N-(2- 439 N-N methoxybenzyl)propanamide 0 3-{4-(3-chlorophenyl)-5-[(4- 0 NS -1rF 511.02 fuorobenzyl)sulfanyl]-4H-1,2,4- 51 N" N-N tdazol-3-yl}-N-(2-51 methoxybenzyl)propanamide 0 3-[5-(benzylsulfanyl)-4-(3- 430chlorophenyl)-4H-1,2,4-triazol-3- 49 N N-N f methoxybenzyl)propananiide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name
M+(ESI+)
No.
\3-{4-isobutyl-5-[(3- 13N /526 methylbenzyl)sulfanyl]-4H-i,2,4o- r riazol-3-yi}-N-(2methoxybenzyl)propananiide N 40.63N-(2-methoxybenzyI)-3-[5-[(3- 14 0 N 480.63 methylbenzyl)sulfanyl]-4-48 (tetrahydrc-2-furanylmethyl)-4H- 48 tI 1,2,4-triazol-3-yI]propanamide
CI
NCI N-butyl-3-[5-[(3- 0 N 463.43 chi orob enzyl)su lfanyl]-4-(3- 46 N/ chlorophenyl)-4H-1 ,2,4-triazol-3- 46 NN ylipropanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M-(ESI-) No.
0 N-(2-methoxybenzyl)-3-{4-(3methoxyphenyl)-5-[(3- 16 0 "1502.6450 -N M-N /methylbenzyl)sulfanyl]-4H-1 triazol-3-yI~propanamide
CI
0 N3{-(-hooezlslayJ4 N S /[3-hooeny~ufay]4 17 N 430.96 methyl-4H-i ,2,4-triazol-3-yl}-N- 431 (2-methoxybenzyl)propanamide 0 N3-[5-[(3-fluorobenzyl)sulfanyl]-4- 18 N 48459(tetrahydro-2-furanylmethyl)-4H- 48 NN F I 2,4-triazoI-3-yl]-N-(2methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name No.
0 3-{4-allyl-5-[(3- 19 N 436.5 methylbenzyl)sulfanyl]-4H-1,2,4- 43 N N-N triazol-3-yi)-N-(2a methoxybenzyl)propanamide N. 3-[5-[(3-fluorobenzyl)sufanyl]-4- 2 0 N rs 50.0(3-methoxyphenyl)-4H-1 N F triazol-3-yI]-N-(2-50 methoxybenzyl)propanamide 0 N0 3[5-(butylsulfanyl)A4(3- 21 N 420.5 methoxypropyl)-4H-1 ,2,4-triazol- 42 mnethoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -41- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
1 0 'IraN-benzyl-3-{4-(3- 22 Il -N 4459 mehoxypropyl)-5-[(2-45 N N 0phenoxyethyl)sulfanyl]-4H-1 ,2,4triazol-3-yI)propanamide NF 3-{4-benzyI-5-[(2- 23 0 40.60 fuorobenzyl)sulfanyl]-4H-1,2,4- 49 N triazol-3-yI)-N-(2-49 N-N methoxybenzyl)propanamide I CI 3-[5-[(3-chlorobenzyl)sulfanyl]-4- 24 0 N 511.02(4-fluorophenyl)-4H-1 ,2,4-51 N riazol-3-yI]-N-(2-51 NN methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -42- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
3-11-(benzylsulfanyl)-4-(4- G/ N 476.57 furpey)H-,2,4-triazol-3- 47 uorophN l)-4-47 N-N methoxybenzyl)propanamide rA 3-[5-[(3-chlorobenzyl)sulfanyl]-4- 26 N614 (3-clilorophenyl)-4H-1,2,4-46 N 6*triazol-3-yi]-N-46 N-N (cyclopropylmethyl)propanamide 0
C
0 -[5-[(3-cyanobenzyl)sulfanyl]-4- 27 0/ 513.62 (3-methoxyphenyl)-4H-1,2,4- 514 N N-Nriazol-3-yi]-N-(2methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -43 Example Chemical Structure M.W. IUPAC-Name M-(ESI-) No.
o N -E5-(benzylsulfanyl)-4- 28N0/ 466 (tetrahydro-2-furanylmethyl)-4H- 46 N-N 1,2,4-triazoI-3-yII-N-(2methoxybenzyl)propanamide 0 29 N 46.2methoxypropyl)-5-[(3- N N46862methyl benzyl)su lfanyl]-4H-1 469 triazoi-3-yllpropanamide N 3-[4-ally1-5benzylsulfanyl)-4H- Nl 422.55 1 ,2,4-triazol-3-yI]-N-(2-42 N N -42 C methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 44- Example Chemical Structure M.W. IUPAC-Name M'(ESl 4 No.
S 0 N -3-[5(3fluorobenzyl)sulfanyl]-4- 31 0 472.58 (3-methoxypropyl)-4H-1,2,4- 47 31N-N F triazol-3-yiI-N-(2methoxybenzyl)propanamide 3-{4-(4-fluorophenyl)-5-E(3- 32 0 N S,490.60 methylbenzyl)sulfanyl]-AH,2,4- 9 N triazol-3-yi)-N-(2-49 c N-N methoxybenzyl)propanamide 0 0 N 3 [5-(benzylsulfanyl)-4-(3- N ~methoxypropyl)-4H-1 ,2,4-triazol- 33 N-N 45.93-yl]-N-(2-45 tc methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
F
3-[5-[(3-fluorobenzyl)sulfanyll-4- 34 N.4. (4-fluorophenyl)-4H-1 ,2,4-49 triazol-3-yi]-N-(2- NNF methoxybenzyl)propanamide 0 3-(4-allyI-5-[3fl 405 uorobenzyl)sulfanyl]-4H-1,2,4- N-N triazol-3-yI}-N-(2-
CC
3-{4-(3-chlorophenyl)-5-[(3,5- 36 N/510 dimethylbenzyl)sulfanyl]-4H- 521 N 12.8 ,2,4-triazol-3-yl}-N-(2methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -46- Example Chemical Structure M.W. IUPAC-Name M'(ESI')
CI
3-[4-(3-chlorophenyl)-5-[(3- 37 44.9 fuorobenzyl)sulfanyl]-4H-1 44 44.8riazol-3-yl)-N- N-N F isobutylpropanamide 0 N dimethylbenzyl)sulfanyl]-4-(3- N38 516.66 methoxyphenyl)-4H-1,2,4- 517 N triazol-3-yl]-N-(2methoxybenzyl)propanamide N 3-{5-[(2-chloro-4- N 470.95 uorobenzyl)sulfanyl]-4-phenyl- 47 39 N-N 409 H-I ,2,4-triazol-3-yI}-N-(2-47 furylmethyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -47- Example Chemical Structure M.W. IUPAC-Namne M'(ESI-) No.
50.3-[65-3-fluorobenzyl)sulfany]-4- N04.6 (4-rnethybenzylt-4H-l NNF methoxybenzyl)propanamide I 3-[4-(3-chlorophenyl)-5-[(3- 41 m ethylbenzyl)sulfanyl]-4H-1 42 42.9 riazol-3-yl)-N- N N-N propylpropanamide
CI
CI 3-[5-[(3-chlorobenzyl)sulfanyl]-4- 42 P (3-chlorophenyl)-4H-1 ,2,4-46 42 465.40 triazol-3-yI]-N-(2-46 0 methoxyethyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -48- Example Chemical Structure M.W. IUPAC-Name M'(ESl-) No.
1: N -[5-(allylsulfanyl)-4-(4- 43 0 N 436.58 methylbenzyl)-4H-1 ,2,4-triazol- 43 N" 3-yl]-N-(2t c N-Nmethoxybenzyl)propanamide
CI
CI 3-[5-(3-chlorobenzyl)sulfanyl]4- 44 0 N 479.43 (3-chlorophenyl)-4H-i ,2,4-47 triazol-3-yl]-N-(3- -0 N-Nmethoxypropyl)propanamide
CI
N 3-{4-(3-chlorophenyl)-5-[(3- 450 N 4.1methylbenzyl)sulfanyl]-4H-1,2,4- 43 -N 430 riazol-3-yI}-N-43 N-N isobutyipropanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -49- Example Chemical Structure M.W. IUPAC-Name MW(ESI") No.
N-(2-methoxybenzy)-3-[5-[(3- N6466 methylbenzyl)sulfanyl]-4-(4- 487 46 J\ 866 methylphenyl)-4H-1 ,2,4-triazol- N-N 3-yl]propanamide 0 F Y13-[5-(2-fluorobenzyl)sulfanyl]-4- 47 N N 506.60 (3-methoxyphenyl)-4H-1,2,4- 507 I N~ methoxybenzyI)propanamide N 3-[5-(benzylsulfanyl)-4-(4- 48 0/ N 48.4methylbenzyl)-4H-1,2,4-triazol- 487 N I 46.64-yl]-N-(2- L-N methoxybenzy)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
4 metNhy/43664 zyl~sufanyl]-AH124 48 49 48.6 azol-3-yi}-N-(2-48 methoxybenzyl)propanamide
CI
N-allyl-3-{4-(3-chlorophenyl)-5- 0 N 441.00 [(3,5-dimethylbenzyl)sulfanyl]- 441 4H-I ,2,4-triazol-3- N-M yl~propanamide 0 3-[5-[2-fiuorobenzyl)sulfanyl]-4- S" 49.0(-methylphenyl)-4H-1,24 51 N' s 490.0 491 N-14 riazol-3-yi]-N-(2- N-N methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -51- Example Chemical Structure M.W. IUPAC-Namne M'(ESI") No.
D F 3-{5-[(4-fluorobenzyl)sulfanyl]-4- 52 N NN 456.58 isobutyl-4H-1 ,2,4-triazol-3-yl}-N- 457 N N-N(2-metho'xybenzyl)propanamide -,0 N 45.6 dimethylbenzyl)sulfanyl]-4-(3- 53 N 45.2methoxyphenyl)-4H-1 453 N N-N triazol-3-yi]-Nisobutylpropanamide
CI
3-[4-(3-chlorophenyl)-5-[(4- 04 F 44.8fuorobenzyl)sulfanyl]-4H-1 47 N 446.98riazol-3-yll-N- N-N sobutyipropanamide WO 03/053437 WO 03/53437PCT/EP02/14594 52- Example Chemical Structure M.W. IUPAC-Name M-(ESI 4 No.
CI N-butyl-3-[5-[(3- -463.43 chlorobenzyl)sulfanyl]-4-(4- 463 N chlorophenyl)-4H-1 ,2,4-triazol-3y l/ Ipropanamide
N
CI -[5-(3-chlorobenzyl)sulfanyI-4- 56 511.47 (4-chlorophenyl)-4H-1 ,2,4-51 N tri2ZOl-3-yl]-N-(2-51 phenylethyl)propanamide /F 3[5[(2-fluorobenzyl)sulfanyl]-4- 0 N425(3-methoxypropyl)-4H-1 .2,4riazol-3-yiI-N-(2- 0 methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -53- Example Chemical Structure M.W. IUPAC-Name M'(ESI') No.
0 3-{4-(3-chlorophenyl)-5-[(3- N8NS 410 methylbenzyl)sulfanyl]-4H-1,2,4- 47 N" riazol-3-yi}-N-(tetrahydro-2- 47 Cf. M14 franylmethyl)propanamide aI 3-{4-(4-chlorophenyl)-5-[(3- 59 0491.06 melhylbenzyl)sulfanyl]-4H-1 491 N s riazol-3-yI}-N-(2- N_ phenylethyl)propanamide
CI
N
0 3 -{4-(3-chlorophenyl)-5-[(3- N 502.04 cyanobenzyl)sulfanyl]-4H-1 502 N-14 riazol-3-yI}-N-(2phenylethyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -54- Example Chemical Structure M.W. IUPAC-Name
M+(ESI+)
No.
F F N-(4-fluorobenzyl)-3-[5- [(,,456 61 F 564.55 pentafluorobenzyl)sulfanyl]-4-(2- 565 /11 NF phenylethyl)-4H-1,2,4-tiazo-3- F yl]propanamide 0 N-{4-ally-5-[(4- 62 N rs440.54 Iluorobenzyl)sulfanylJ-4H-1 441 C- C N-N triazol-3-y}-N-(2- I methoxybenzyl)propanamide
CI
3-[5-[(3-chlorobenzyl)sulfanyl]-4- 630 '4 00 (3-methylphenyl)-4H-1 41 N -s/triazcl-3-yi]-N-41 N-N (cyclopropylmethyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M"(ESI") No.
C
N -[5-[(3-chlorobenzyl)sulfanyl]-4- 64 N) 48.0 (tetrahydro-2-furanylmethyl)-4H- 48 54 NN450 ,2,4-triazol-3-y]-N-(2-48 phenylethyl)propanamide 0 3-[5-(benzyisulfanyl)-4-(3- N5 0N s 488.61 methoxyphenyl)-4H-1,2,4-48 0/ N riazol-3-yi]-N-(2-49 11-N methoxybenzyl)propanamide 3-{4-aIlyI-5-[(3- 66 N N s Imethylbenzyl)sulfanyfl-4H-1,2,4- 66 40.5 0N-N 40.5riazol-3-yl-N-(tetrahydro-2- furanylmethyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M4*(ESI4) No.
0' 670 3-[5-(allylsulfanyl)-4-(3- 67 0 438.55 methoxyphenyl)-4H-1 ,2,4-43 triazol-3-yI]-N-(2- N- N methoxybenzyl)propanamide
CI
N N-butyl-3-[5-[(3- 68 44.0 chlorobenzyl)sulfanyl]-4-(3- 43 68 N_ 43.01methylphenyl)-4H-1 .2,4-triazol- 43 N 3-yl]propanamide
CI
3-{4-(4-chlorophenyl)-5-[(4- 69 0444.99 methylbenzyl)sulfanyl]-4H-1 N tdazol-3-yI}-N-(2- N-N_ methoxyethyi)propanamide Example343 WO 03/53437PCT/EP02/14594 -57- No.
Chemical Structure 7M.W.
IUPAC-Name M~(ESl~) "N s
N
N- N 388.53 3-[5-(allylsulfanyl)-4-isobutyl-4H- I ,2,4-triazol-3-yI]-N-(2methoxybenzyl)propanamide 0 0 9-
PI
506.60 3-[5-[(4-fluorobenzyl)sulfanylj-4- (3-methoxyphenyl)-4H-i .2,4triazol-3-yl]-N-(2methoxybenzyl)propanamide r 4 0 C)
N-
491.06 3-[4-(3-chlorophenyl)-5-[(2methylbenzyl)sulfanylj-4H-1 .2,4triazol-3-yi}-N-(2phenylethyl)propanamide 491 I I WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M-(ESI'-) No.
0 3..14.benzyl..5.(butylsulfanyl).4H- 73 43.6 N 1PO~,2,4-triazol-3-yI]-N-(2- 439 N N-N methoxybenzyl)propanamide 0 ]3-[5-[(3-fluorobenzyl)sufanyl]-4- 74 N 442.56(3-methoxyphenyl)-4H-1 43 N sl -Q riazol-3-yi]-N- N-N F isobutyipropanamide N N 466.6 dimethylbenzyl)sulfanyl]-4- /-N466.65isobutyl-4H-i ,2,4-triazol-3-yl}-N- 46 (2-methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 59-- Example Chemical Structure M.W. IUIPAC-Name M'(ESI-) No.
0 F -[5-[(4-fluorobenzyl)sulfanylJ-4- 0(tetrahydro-2-furanylrnethyl)-4H-48 76 N- N _18.9~,2,4-triazol-3-yI]-N-(2methoxybenzyl)propenamide CI N-butyl-3-{5-[(3- 0 N489chlorobenzyl)sulfanyl]-4-phenyl 2 N Ir H-I ,2,4-triazol-3- N-N yIlpropanamide CI 3-[5-[(3-chlorobenzyl)sulfanyl]-4- 78 N4590 (3-methylphenyl)-4H-I ,2,4triazol-3-yI]-N-(3-45 -01 N-Nmethoxypropyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M-(ESI-') No.
3-14-(3-chlorophenyl)-5-[(3,5- N dimethylbenzyl)sulfanyl]-4H- 79 457.04 1,2,4-triazol-3-yi}-N-45 N-N isobutylipropanamide N N-butyl-3-[5-[(3- N 2.9 thy] benzyl)su lfanyl]-4-(3- 42 80 methylphenyl)-4H-1,2,4-triazol- N M-N3-yI]propanamide 0-a 81 0 N s436.58 dimethylbenzyl)sulfanyl]-4-(3- 437 S/ methoxyphenyl)-4H-1 ,2,4- N-N triazol-3-yI]propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -61- Example Chemical Structure M.W. IUPAC-Name M*(ESI 4 No.
CI
0 3-{4-(3-chlorophenyl)-5-[(3,5- 82N 48.5dimethylbenzyl)sulfanyl]-4H- 48 I/ ,2,4-triazol-3-yI}-N-(tetrahydro- 48 00 -furanylmethyl)propananhide 0/C 3-[5-(allylsulfanyl)-4-(3- 83 0 N 442.97 chlorophenyl)-4H-1 ,2,4-triazol-3- 44 yN]- -N methoxybenzyl)propanamide o 3-[5-[(3-cyanobenzyl)sulfanyl]-4- 84 N/ 497.62 (3-methylphenyl)-4H-1 498 -N triazol-3-yl]-N-(2methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -62- Example Chemical Structure M.W. IUPAC-Name M-(ESI 4 No.
N N 1 472,61 4H-I ,2,4-triazol-3-yI]-N-(2- 473 NN methoxybenzyl)propanamide I 3-{4-(4-chlorophenyl)-5-[(3,5- 86 505.08 dimethylbenzyl)sulfanyl]-4H- 0 0 N I ,2,4-triazol-3-y}-N-(2-50 N \phenylethyl)propanamide
N-
F
F 3-[5-[(2-fluorobenzyl)sulfanyl]-4- 870 N \r (4-fluorophenyl)-4H-1 .2,4- N" riazol-3-yI]-N-(2- N-N methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 63- Example Chemical Structure M.W. IUPAC-Name M'(ESI") No.
-01 3-[5-[(4-fluorobenzyl)sulfanyl]-4- 88 N s Ir 442.56 (3-methoxyphenyl)-4H-1 43 N- I riazol-3-yi]-N- N N-N isobutyipropanamide NCI -[-(-horobenzyl)sulfanyl]-4 0 (3-methylphenyl)-4H-1,2,4- -44 89 N 4.1riazol-3-yi]-N-43 N-N isobutylpropanamide o 3-[5-[(3-methylbenzyl)sulfanyl]- 4-(4-methylphenyl)-4H-1 47 N-1 t 7.4riazol-3-yI]-N-(2phenylethyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -64- Example Chemical Structure M.W. IUPAC-Name M"(ESI+) No.
0 1' N-(2-mothoxybenzy)-3-{4-(3- 91~ N 426 methoxypropyl)-5-[(2-oxo-2- 48 N-N phenylethyl)sulfanyl]-4H-1 ,2,4riazol-3-yIlpropanamide
CI
3-{4-(4-chlorophenyl)-5-[(3,5- 92 473.04 dirnethylbenzyl)sulfanyl]-4H- 473 I ,2,4-triazol-3-y}-N-(3- N- methoxypropyl)propanamide -,0 'N -[5-[(3-fluorobenzyl)sulfanyl]-4- 93 0 N 42.3(3-methoxyphenyl)-4H-1 429 0- 428.5 riazol-3-yl]-N- N N-N F propyipropanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M-(ESI-) No.
F
3-[5-[(4-fluorobenzyl)sulfanyl]-4- 94 N F 494.57 (4-fluorophenyl)-4H-1 ,2,4-49 94 0 0 N Friazol-3-yi]-N-(2- N N-N methoxybenzyl)propanamide 00 'I 0 -[5-[(3-chlorobenzyl)sulfanyl]-4- 95N)-1 511.47 (3-chlorophenyl)-4H-1 511 N- N triazol-3-yl]-N-(2phenylethyl)propanamide
CI
3-[5-(benzylsulfanyl)-4-(3- 96 0 N s414.96 chlorophenyl)-4H-1,2,4-triazol-3- 415 I ]-N-propylpropanamide
N-N
WO 03/053437 WO 03/53437PCT/EP02/14594 -66- Example Chemical Structure M.W. IUPAC-Name M+(ESI+) No.
CI
47.3N-benzyl-3-{4-(3-chlorophenyl)- 97)- 470 5-[(3-methylbenzyl)sulfanyl]-4H- 477 c/f N ,2,4-triazol-3-yl~propanamide 0 F -[5-[(2-chloro-4- Nr s fluorobenzyl)sulfanyl]--3 98 N N 529.46 chlorophenyl)-4H-1 ,2,4-triazol-3- 529 phenylethyl)propanamide N -{4-(3-chlorophenyl)-5-[(4- 99 N N N 512.08ethylbenzyl)sulfanyl]-4H-1 ,2,4-51 99 N-N 12.08 riazoI-3-yl}-N-[3-(2-oxo-l- 51 pyrrolidinyl)propyl]propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 67- Exapl Chemical Structure MW IUPAC-Name M'(ESl-)
CI
3-14-(4-chlorophenyI)-5-[(3,5- 100 0 459. 01 dimethylbenzyl)sulfanyl]-4H- 459 N~ 1,2,4-triazol-3-yl}-N-(2methoxyethyl)propanamide N N-Isobutyl-3-[5-[(3- 101 N 422.59 methylbenzyl)sulfanyl]-4-(4- 423 s I methylphenyl)-4H-1,2,4-trazol- N 3__-yI]proponamide 0 N-butyl-3-{4-(3-chlorophenyl)-5- 102 N446.98 [(3-fluorobenzyl)sulfanylj-4H- 447 N 1'/I,2,4-triazol-3-yl~propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name
M'(ESI-)
No.
CI
3-{4-(3-chlorophenyl)-5-[(3- 103 N s /410methylbenzyl)sulfanyl]-4H-1,2,4- 4 N s'I' 410triazol-3-yI}-N-41 N-N Ccyclopropylmethyl)propanamide N F1S 3-15-[(4-fluorobenzyi)sulfany]-4- F0 472.5 (3-methoxypropyl)-4H-1,2,4- 43 14 /N-N triazol-3-yi]-N-(2-47 methoxybenzyl)propanamide 3-{4-(4-chlorophenyl)-5-[(3- 459.01 methylbenzyl)sulfanyl]-4H-1,2,4- triazoI-3-yI}-N-(3-45 N N-Nmethoxypropyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -69- Example Chemical Structure M.W. IUPAC-Name
M
4
(ESI+)
No.
0 -5[35 N s dimethylbenzyl)sulfanyll-4-(4- 106 .1 484.67 methylphenyl)-4H-1,2,4-triazol- 485 N" NN 3-yl]-N-(2phenylethyl)propanamide 0 3-[5-[(3-fluorobenzyl)sulfanyl]-4- 107 \i s 474.60 (4-methylphenyl)-4H-1,2,4- 475 N N-N F triazol-3-yi]-N-(2rol henylethyl)propanamide 0 N-5[35 108 N N-N 40.65imethylbenzyl)sulfanyl]-4- 108 -N 40.65isobutyl-4H-1 ,2,4-triazo-3-yl}-N- 451 (2-phenylethyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure
M.W.
No. IUPAC-Name
M*"(ESI")
505.08 I (4.(3-chkoropheny)-5{(3,5- 1 ,2,4-triazol-3-yl)-N-(2phenylethyl)propanamide
N-N
507.06 3-{4-(3-chlorophenyl)-5-f (3methylbenzyl)sulfanyl]p4H-1,2,4triazol-3-yI}-N-(4methoxybenzyl)propanamide 507 0 N s 406.55 3-{4-aliyI-5-[(3methylbenzyl)sulfanyl].4H-1 .2,4trlazol-3-yI}-N- 407 benzylpropanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M'(ESl 4 No.
0 N-(4-methoxybenzyl)-3-{4-(3- N Imethoxyphenyl)-5-[(3- 112 N 502.6450 N1-N methylbenzyl)sulfanyl]-4H-1,2,4- _0 triazol-3-yi~propanamide 0~~ 0
N
0 N" r3{5(2-fluorobenzyI)sulfanyI]-4 113 414.50 methyl-4H-1,2,4-triazol-3-y}-N- 415 (2-methoxybenzyl)propanamide N 3-14-(3-chlorophenyl)-5-[(2- 11 S /uOrobenzyl)sulfanyl]-4H-1,2,4- 11-N~ 495.02 triazol-3-yl)-N-(2-49 phenylethyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 72- Example Chemical Structure M.W. IUPAC-Name M'(ESl") No.
CI
F 3-{4-(4-chlaropheny)-5-[(3- 115 0 N9.0 fuorobenzyl)sulfanyl]-4H-1,2,4- 495 N 49.2riazol-3-yi-N-(2- N r\ phenylethyl)propanamide 3-(4-(4-chlorophenyi)-5-[(3- 0 020 cyanobenzyl)sulfanyl]-4H-1 502 116 N I 50.4riazol-3-yI}-N-(2- N-N "Nphenylethyl)propanamide
N
C 3-[5-[(3-cyanobenzyl)sulfanyl]-4- 117 0/ N 501.58 (4-fiuorophenyl)-4H-I ,2,4-50 N riazol-3-ylI-N-(2-50 NN methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 73 Example Chemical Structure M.W. IUPAC-Name M-(ESI-) No.
CI
118 0 -0 426.97 chlorobenzyl)sulfanyl]-4-(3- 427 methylphenyl)-4H-1,2,4-triazol- I /3-yl]propanamide 3-{4-(4-chlorophenyl)-5-[(4- 119 0 459.01 methylbenzyl)sulfanyl]-4H-1 ,2,4triazol-3-yl}-N-(3-45 N-N methoxypropyl)propanamide f N-aIly-3-[4-(3-methoxyphenyl)- 120 0 N 422.55 5-[(3-methylbenzyl)sulfanyl]-4H- 423 r,2,4-triazol-3-yl~propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 74- Example Chemical Structure M.W. IUPAC-Name MW(ESI-) No. F 3-(4-(3-chlorophenyl)-5-{[4- N2 49.9 (trifluoromethyl)benzyl]sulfanyl}- 49 F 46.98H-I ,2,4-triazol-3-yI)-N- N-N isobutyipropanamide
N
N2 480.63 methoxyphenyl)-4H-i,2,4- 481 N-N triazol-3-yI]-N-(tetrahydro-2furanylmethyl)propanamide 0 N3-[5-(butylsulfanyl)-4-(3- 123 N s 45.9methoxyphenyl)-4H-1 ,2,4-45 N N- Nriazol-3-yi]-N-(2- N-N methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M-(ESI-) No.
N-butyl-3-{4-(4-chlorophenyl)-5- 124 0443.01 [(4-methylbenzylsulfanyl]-4H- 443 N N-N I,2,4-triazol-3-yIlpropanamide
NN
N-aIlyI-3-[5-[(3- 125 0 N 426.51 fuorobenzyl)sulfanyl]-4-(3- 427 N methoxyphenyl)-4H-1 .2,4- N-N triazol-3-yI]propanamide 3-{4-(4-chlorophenyl)-5-[(4- 12651.0 methylbenzyl)sulfanyl]-4H-1 512 N triazol-3-yi)-N-[3-(2-oxo-1 KNlL pyrrolidinyl)propyl]propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M(ESI-) No.
0 Nr~ F 3-{5-[(2-chloro-4- 127 N N-N 448.95 nuorobenzyl)sulfanyl]-4-methyl- 49 4H-I ,2,4-triazol-3-yl}-N-(2methoxybenzyl)propanamide 0 128 N N- 6.5dimethylbenzyl)sulfanyl]-4-(3- 128 -N 46.65methoxypropyl)-4H-1 ,2,4-triazol- 467 3-yi]-N-(2pllenylethyl)propanamide 0 F -{4-(3-chlorophenyl)-5-[(4- 129 r 51.0 iuorobenzyl)sulfanyl]-4H-1 51 N-N triazoi-3-yi}-N-(4methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -77- Example Chemical Structure M.W. IUPAC-Name M+(ESI") No.
CI
0F N-butyl-3-{4-(3-chlorophenyl)-5- 130 N 446.98 [(2-fluorobenzyl)sulfanylJ-4H- 447 I,2,4-triazol-3-yI~propanamide
N-N
3-15-[(3-methylbenzyl)sulfanyl]- 131 0 408.57 4-(4-methylphenyl)-4H-1,24 triazol-3-yi]-N- N /propyipropanamide
N-N
CI
3-{4-(3-chloropheiyl)-5-[(3- 132 0 N 432.95 fuorobenzyl)sulfanyl]-4H-1 43 triazol-3-yI}-N- N N-N Fpropyipropanamide WO 03/053437 WO 03/53437PCT/EP02/14594 78- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
0 3-{4-(3-chlcropheny)-5-[(3,5- 133 N N 521.08 dimethylbenzyl)sulfanyl]-4H- 521 N-N 141,2,4-triazol-3-yi}-N-(4methoxybenzyl)propanamide dimethylbenzyl)sulfanyl]-4- 134 N NN 494.66 (tetrahydro-2-furanylmethyl)-4H- 495 I ,2,4-triazol-3-yl]-N-(4methoxybenzyl)propanamide 3-{4-(4-chlorophenyl)-5-[(2- 135 0 rb 491,06 methylbenzyl)sulfanyl]-4H-1 491 N rieazol-3-yl}--N-(2- N phenylethyl)propanamide
N-N
WO 03/053437 WO 03/53437PCT/EP02/14594 -79- Example Chemical Structure M.W. IUPAC-Name M'(ESI') N o.
I-
N-isobutyl-3-{4-(3- 136 0 N s 438.59 methoxyphenyl)-5-[(3-43 N methylbenzyl)sulfanyl]-4H-1 ,2,4- N-N triazol-3-yI~propanamide
N
c) r, 4-{5-[(3-chlorobenzyl)sulfanyl]-4- 131/ 507.06 phenyl-4H-1 ,2,4-triazol-3-yl-N- 507 N s (2-methoxybenzyl)butanamide
N-N
C1 -[5-[(3-chlorobenzyl)sulfanyll-4- 138 N N s -515 (3-chlorophenyl)-4H-1 ,2,4-54 I 541.50riazol-3-yl]-N-(2- 0 N-Nmethoxybenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name
M'(ESI-)
No.
4-[5-[(3-chlorobenzyl)sulfanyl]-4- 139 N N 57.08(3-methoxyphenyl)-4H-1 ,2,4rs triazol-3-yI]-N-(2- 0 0 Nmethoxybenzyl)butanamide
CI
N-benzyl-4-[5-[(3- 140 N 511.47chlorobenzyl)sulfanylJ-4-(3- 51 140 N 11.47chlorophenyl)-4 H-I ,2,4-triazol-3-51 NN yl]butanamide N-(2-methoxybenzy)-4-{4-(3- 141 N methoxyphenyl)-5-[(3methylbenzyl)sulfanyl-4H-1 51 N-N riazol-3-yl}butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -81- Exapl Chemical Structure M.W. IUPAC-Name M (ESI') 0 I 4-[5-[(3-chlorobenzyl)sulfanyl]-4- 142 N 503.07 (3-methoxypropyl)-4H-1,2,4- 503 triazol-3-yl]-N-(2- S N-N methoxybenzyl)butanamide 0 CI 4-[6-[(3-chlorobenzyl)sulfanyll-4- 143 487.0 (3-methoxypropyl)-4H-1 487 triazol-3-ylJ-N-(2- No phenylethyl)butoanide 4-[5-[(3-chlorobenzyl)sulfanyl]-4- 144 P3-methoxyphenyl)-4H-1 ,2,4- 144- 52505riazol-3-yi]-N-(4- 525 fuorobenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name MW(ESI") No.
4-[5-1(3,5- N dimethylbenzyl)sulfanyl]-4-(3- 145 N 530.69 methoxyphenyl)-4H-1 531 N-N rao3ylN-2 /0 methoxybenzyl)butanarnide N-(4-fluorobenzyl)-4-{4-(3- 14 504.63 methoxyphenyl)-5-[4-50 146 F N Nmethylbenzyl)sulfanylJ-4H-1,2,4- 0 N-N triazol-3-yI~butanamide 0 F N 4-[5-[(3-fluorobenzyl)sulfanyl]-4- 147 N (3-methoxyphenyl)-4H-1 52 520.63 ral-3-yl]-N-(2-52 o 0 N-N methoxybenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 83- Example Chemical Structure M.W. IUPAC-Name M'(ESI-') No.
N 4-{4-(3-methoxyphenyl)-5-[(3- 148 N 00.66 mehylbenzyl)sulfanyl]-4H-1 ,2,4-50 triazol-3-yi}-N-(2o phenylethyl)butanamide rl- 14 586 -(4-(3-methoxypropyl)-5-{[(2E)- 509 N 508.64-phenyl-2-propenyl]sulfanyl}- 14 4H--,2,4-triazol-3-yI)butanamide
CI
-{4-(3-chlorophenyl)-5-[(2- 70furbny~ufnl-H124 Nl 4- 5.0 riazol-3-yI}-N-(2-52 01 methoxybenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 84- Example Chemical Structure M.W. IULPAC-Name M-(ESl-) No.
151 \N-benzyl-4-{4-(3- 486.64methoxyphenyl)-5-[(2- 0 1N N Smethylbenzyl)sulfanyll-4H-1 48 0 N-N triazoI-3-yI}butanamide 0 ci N-benZyl-4-[5-[(3- 152 507.06 chlorobenzyl)sulfanyl]-(3 507 N methoxyphenyl)-4H-1 ,2,4- Ny iao-3-yllbutanamide 0 N-(4-fluorobenzyl)-4-{4-(3- 153 1504.63 methoxyphenyl)-5-[(2- 0 methylbenzyl)sulfanyl]-4H-1 50 triazol-3-yi~butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
4-[5-[(3-chlorobenzyl)sulfanyl]-4- 154 N 473.04 (3-methoxyphenyl)-4H-1 47 N N raoS3y]N I isobutylbutanamide 0 N-N I F N-(4-fluorobenzyl)-4-{4-(3- 155 FF F 80.5 methoxyphenyl)-5-L(2,3,4,5,6- 58 N pentafluorobenzyl)sulfanyl]-4H- N I ,2,4-triazol-3-yI~butanarnide 4-{4-(3-chlorophenyl)-5-[(2- 156 N 521.08 methylbenzyl)sulfanyl]-4H-1,2,4- 52 9 0 N- N -riazol-3-yI}-N-(2-52 "0 methoxybenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 86- Example Chemical Structure M.W. IUPAC-Name M-(ESI-) No.
4-[5-[(3-chlorobenzyl)sulfanyl]-4- 157 459.01 (3-methoxyphenyl)-4H-1,2,4- 459 N N triazol-3-yII-N-propylbutanamide 0
N-N
N -[5-[(4-fluorobenzyl)sulfanyl]-4- 158 I (3-methoxyphenyl)-4H-1 52 52.3riazol-3-yI]-N-(2methoxybenzyl)butanamide N -[5-[(3-chlorobenzyl)sulfanyl]-4- /j(3-chlorophenyl)-4H-1 52 159 N y-IN)- -6 529.46 triazol-3-yI]-N-(4-52 0 N-N fuorobenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 87- Example Chemical Structure M.W. IUPAC-Name M"(ESI'*) 160 P, 537.08 (3-methoxyphenyl)-4H-l 53 N riazol-3-yi]-N-(4- N-Nmethoxybenzyl)butanamide
CIC
4-[5-[(3-chlorobenzyl)sulfanyl]-4- 16 fN- 054 (3-chlorophenyl)-4H-1 ,2,4-50 16 N r6 554 riazol-3-yi]-N-(tetrahydro-2- 0 N--N uranylmethyl)butanamide I 9 N-benzyl-4-{4-(3-chlorophenyl)- 162 N N 505.08 5-[(3,5-dimethylbenzyl)sulfanyl]- 505 V 4H-I ,2,4-triazol-3-yIlbutanamide y WO 03/053437 WO 03/53437PCT/EP02/14594 -88- Example Chemical Structure M.W. IUPAC-Name M'(ESI'-) No.
N 4-[5-[(3-fluorobenzyl)sulfanyl]-4- 163 N 04.63(3-methoxyphenyl)-4H-1 0 163Y-"I Nr N>t 0.3riazol-3-yi]-N-(2- 0 N-N phenylethyl)butanamide 4-{4-(3-chlorophenyl)-5-[(3- 164 532.07cyanobenzyl)sulfanyl]-4H-1,2,4- 53 N-N riazol-3-yl)-N-(2- /0 N methoxybenzyl)butanamicle N I -[5-[(3-chlorobenzyl)sulfanyl]-4- 16 r 415 (3-chlorophenyl)-4H-1 ,2,4-54 00 _N 541.50riazol-3-yl]-N-(4-54 0 NNmethoxybenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 89- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
I
4-15-f (3-cyanobenzyl)sulfanyl]-4- 166 (3-methoxyphenyl)-4H-1 52 52.5riazol-3-yI]-N-(2-52 "0N methoxybenzyl)butanarnide N-isobutyl-4-{4-(3- 167 N452.62 methoxyphenyl)-5-[3-45 methylbenzyl)sulfanyl-4H-1 ,2,4- N-N riazol-3-yl~butanamide N-(4-methoxybenzyl)-4-{4-(3- 168 Nmethoxyphenyl)-5-[(4-51 516.66 methylbenzyl)sulfanyll-4H-1,2,4- 51 N-N riazol-3-yl~butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M*(ESI+) No.
169 54.69dimethylbenzyl)sulfanyl]-4-(3- 16 146 methoxyphenyl)-4H-1 515 N-N riazol-3-yl]-N-(2- N-N phenylethyl)butanamide N-benzyl-4-{4-(3-chlorophenyl)- 170 N491.06 5-[(3-methylbenzyl)sulfanyl]-4H- 491 N-N 1 ,2,4-triazol-3-yI~butanamide 4-[5-[(2-chloro-4- N luorobenzyl)sulfanyl]-4-(3- 171 55.4 Nc Fhlorophenyl)-4H-1 ,2,4-triazol-3- 559 y-N-2 a methoxybenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -91- Example Chemical Structure M.W. IUPAC-Namne M'(ESI-) No.
N-allyl-4-[6-E(3- 172 N 461.41chlorobenzyl)sulfanyl]-4-(3- 46 172 461.41chlorophenyl)-4H-l ,2,4-triazol-3- 46 0 N-N I]butanamide
CI
NCI -[5-[(3-chlorobenzyl)sulfanyl]-4- 173 N 47.4 (3-Ghlorophenyl)-4H-1 ,2,4-47 N 47.6riazol-3-yl]-N- IN-N 6 isobutylbutanamide, dimethylbenzyl)sulfanyl]-4-(3- 174 F N N518.66 methoxyphenyl)-4H-1,2,4- 519 triazol-3-yI]-N-(4- N-N Iuorobenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 92- Example Chemical Structure M.W. IUPAC-Name M'(ESI") No.
CI
\1 N-benzyl-4-(4-(3-chlorophenyl)- 175 NN 495.02 5-[(3-fluorobenzyl)sulfanyl]-4H- 495 -01,N Y rg1,2,4-triazol-3-yllbutanamide 0
N-N
CI
1 176 N N~ 477.03 4-(3-chlorophenyl)-4H-1 477 riazo-3-yl]butanamide 0 N-N 4-{4-(3-chlorophenyl)-5-[(2- 177 N 521.08 phenylethylsulfany]-4H-1 521 0 methoxybenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 93 Example Chemical Structure M.W. IUPAC-Name M"(ESI') No.
0 178 dimethylbenzyl)sulfanyll-4-(3- 18N N 480.67 methoxypropyl)-4H-1,2,4-triazol- 481 0 N- N 3-yl]-N-(2- I 0 phenylethyl)butanamide N-benzyl-4-{4-(3- 179 /N466methoxyphenyl)-5-[3- N ~methylbenzyl)sulfanyl]-4H-1 8 N-N riazol-3-yllbutanamide
CI
CII
N-N
0 463.43 4-[5-[(3-chlorobenzyl)sulfanyl]- '3-chlorophenyl)A4H-1 ,2,4riazo-3-yl]-N-propylbutanamide WO 03/053437 WO 03/53437PCT/EP02/14594 94- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No. 4-14-(3-chlorophenyl)-5-[(2- 11N 509.05 methylbenzyl)sulfanyl]-4H-1,2,4- 509 0 N-N fuorobenzyl)butanamide 182 N 452.62 dimethylbenzyl)sulfanyl]-4-(3- 453 N smethoxyphenyl)-4H-1 ,2,4- 0 triazol-3-yI]-N-propylbutanamide 0
C
[(cyclohexylmethyl)sulfany]-4- 183 <I N508.69 (3-methoxyphenyl)-4H-1 509 triazol-3-yi]-N-(2- 0 methoxybenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. lUPAC-Name M'(ESI-) No.
a 0 5-[5-j(3-chlorobenzyl)sulfanyl]-4- 184 N- 555.53 (3-chlorophenyl)-4H-1,2,4- 555 N-N triazol-3-yl]-N-(2a methoxybenzyl)pentanamide C1 2 s b5-{5-[(3-chlorobenzyl)sulfanyll-4- 185 N JN 521.08 phenyl-4H-1 ,2,4-triazol-3-yl}-N- 521 0 (2-methoxybenzyl)pentanamide N-(2-methoxybenzyl)-5-{4-(3- 186 N 49.6 ethoxypropyl)-5-[(3- N N-9 methylbenzyl)sulfanylj-4H-1,2,4- 0 riazol-3-yl~pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -96- Example Chemical Structure M.W. IUPAC-Name M'(ESl 4 No.
CI
CI 5-[5-[(3-chlorobenzyl)sulfanyl]-4- 187 N 491.48 (3-chlorophenyl)-4H-1 491 N >S Iriazol-3-yII-N- M-11 isobutylpentanamide 5-{4-allyI-5-[(3- 18 N 464.63 methylbenzyl)sulfanyl]-4H-1 465 Nmethoxybenzyl)pentanamide C \9 N-(2-methoxybenzyl)-5-[5-[(3- 189 52N8.72 methylbenzyl)sulfanyl]-4-(2- 529 N 52.7 phenylethyl)-4H-1 ,2,4-triazol-3- \F D N /l]pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 97- Example Chemical Structure M.W. IUPAC-Name M+(ESI+) No.
C N-(2-methoxybenzyl)-5-{5-[(3- 190 N N500.66 methylbenzyl)sulfanyl]-4-phenyl- 501 0" H-I ,2,4-triazol-3- N' N ilpentanamide 191\ N /luorobenzyl)sulfanylF-4H-1,2,4- 539.0 riazol-3-yl}-N-(2methoxybenzyl)pentanamide 5-[5-[(3-fluorobenzyl)sulfanyl]-4- 192 500.64 (3-rnethoxypropyl)-4H-1 501 N-N ta -2 methoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Namne M'(ESI-) No. I 5.{5-[(3-chorobenzyl)sulfanyl]J4- 193 razol-3-yi]-N-(4fuorobenzyl)pentanamide 194 478.7 dimethylbenzyl)sulfanyl]-4-(2- 479 /N-benzyl-5-{5-L(3- 1951.0N chlorobenzyl)sulfanyl]-4-phenyl- 491 19 0 49.6H-1,2,4-triazol-3- \N Ilpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -99 Example Chemical Structure M.W. IUPAC-Name M'(ESl-) No.
q 196- F 046 5-{5-[(3-fluorobenzyl)sulfanyl]-4- 09 546 phenyl-4H-1 ,2,4-triazol-3-yl}-N- 505 0 NN (2-methoxybenzyl)pentanamide 0 5-[5-(benzylsulfanyl)-4-(3- 170 N< s 482.65 methoxypropyl)-4H-1 ,2,4-triazol- 483 N9 N-N 3-yI]-N-(2methoxybenzyl)pentanamide 198 N N-benzyl-5-{4-(3-chlorophenyl)- 198' /N 505.08 5-[(4-methylbenzyl)sulfanyl]-4H- 505 I ,2,4-triazol-3-yllpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -100- Example Chemical Structure M.W. IUPAC-Name M 4
(ESI-)
No.
0 5-[4-alIyI-5-[(3,5- 199 N486 imethylbenzyl)sulfanyl]-4H- 479 N NJ 47.61,2,4-triazol-3-yl-N-(2- 0 5-{4-aIlyI-5-f (3- 200 Nr 450 hlorobenzyl)sulfanyl]-4H-1 485 N S 45.05riazol-3-yl-N-(2- N A methoxybenzyl)pentanamide
N
WO 03/053437 WO 03/53437PCT/EP02/14594 101 Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
5-[4-allyl-5-(benzylsulfanyl)-4H- 202 N N450.61 1,2,4-triazol-3-yIF-N-(2- 451 \14 Nmethoxybenzyi)pentanamide dimethylbenzyl)sulfanyl]-4-(2- 203 N526.75 phenylethyl)-4H--1,2,4-triazol-3- 527 0 N lN-2 _j V phenylethyl)pentanamide 5-[5-[(3-chlorobenzyl)sulfanyl]-4- 204 s-549.14 (2-phenylethyl)-4H-1 ,2,4-triazol- 54 N N- 3-yl]-N-(2- \N N methoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -102- Example Chemical Structure M.W. IUPAC-Name M+(ESI*) No.
0 N-benzyl-5-{4-(3-chlorophefl)- 205 N505.08 5-[(2-methylbenzyl)sulfaflyl]-4H- 0 I ,2,4-triazol-3-yl~pentanamide 206 N N468.60 fuorobenzyl)sulfanyl-4H--1 469 N Frazo3yl;#j(2methoxybenzyl)pentanamide /0 207 /N-(1,3benzodioxol5ylethyl)s_ 542.70 4-(2-phenylethyl)-4H-i 54 0 triazol-3-yllpentanamide
N
WO 03/053437 WO 03/53437PCT/EP02/14594 -103- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
dimethylbenzyl)sulfanyl]-4-(2- 208 6 42.75 phenylethyl)-4H-1 ,2,4-triazol-3- 543 o yiJ-N-(2- N Amethoxybenzyl)pentanamide \o 5-{5-[(2-flucrobenzyl)sulfanyl]-4- 209 N N 504.63 phenyl-4H-1 ,2,4-triazol-3-y}-N- 505 o (2-methoxybenzyl)pentanamide 21 1/ 3-c lorobenzy sl f anyII4- 21 N 537.10 3 N 3-I--4 NIN fuorobenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -104- Example Chemical Structure M.W. IUPAC-Name M 4
(ESI-)
No.
N FF N-benzyl-5-{4-(3-chlorophenyl)- 21- 581.01 5-[(2,3,4,5,6-58 N N-N Fpentafluorobenzyl)sulfanyl]-H 58 F~ 1,2,4-triazol-3-yI~pentanamide \05-5[3- A dimethylbenzyl)sulfanyl]-4-(3- 212 N (510.70 methoxypropyl)-4H-1 ,2,4-triazol- 511 -o -N methoxybenzyl)pentanamide
Q
5-{4-(3-chlorophenyl)-5-[(4- 213 methylbenzyl)sulfanyl]-4H-1 ,2,4- 0 N N-N 49.8riazol-3-yI}-N-(tetrahydro-2furanylmethyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -105- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
-1 N-benzyl-5-[5-[(3- 21 N chlorobenzyl)sulfanylJ-4-(3- 52 N-N 55.50chlorophenyl)-4H-1 ,2,4-triazol-3- I]pentanamide 5-{5-[(3-chlorobenzyl)sulfanyl]-4- 215 N N S- 509.05 phenyl-4H-1 ,2,4-triazol-3-y}-N- 509 0 (4-fluorobenzyl)pentanamide ~N
N
0 a
N-N
546.09 5-{4-(3-chloropheny)-5-[(3cyanobenzyl)sulfanyl]-4H-1 .2,4triazol-3-yI)-N-(2-.
methoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -106- Example Chemical Structure M.W. IUPAC-Name
M
4 (ESl-) No.
CI
N 5-4-(3-chlorophenyl)-5-[(2- 217 99.0 methylbenzyl)sulfanyl]-4H-1 ,2,4- NN riazol-3-yll-N-(tetrahydro-2- N furanylmethyl)pentanamide N 5-[5-(benzylsulfanyl)-4-(3- 218~~ N51.0 chlorophenyl)-4H-1,2,4-triazol-3- 52 N-N lN-2 o methoxybenzyl)pentanamide 0 N 219 N N s 42.62dimethylbenzyl)sulfanyl]-4- 210 J426 phenyl-4H-1 ,2,4-triazo-3-y}-N- \N (2-meth oxyethyl )pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -107- No.pl Chemical Structure M.W. IUPAC-Name M-(ESI') 5-[5-[(3-methylbenzyl)sulfanyl]- 220 1 NJ 512.72 4-(2-phenylethyl)-4H-1,2,4- 513 N triazol-3-yl]-N-(2phenylethyi)pentanamide CI N-aIlyl-5-[5-[(3- 221 a N 47544chlorobenzyl)sulfanyl]-4-(3- 45 22 454 hlorophenyl)-4H-1 ,2,4-triazol-3- %VN -N lpentanamide 5-[5-[(2-chloro-4- 22 N 50.4 fluorobenzyl)sulfany]-4-(3- 22\ 594 chlorophenyl)-4H-1 ,2,4-triazoI-3- 509 CI l]-N-isobutylpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 108- Example Chemical Structure M.W. IUPAC-Name M'(ESI') No.
/N-butyl-5-[5-[(3,5- 223 NI N5.6 imethylbenzyl)sulfanyI]-4 451 45.5phenyl-4H-1 ,2,4-triazol-3- Ilpentanamide 5-{4-(3-chlorophenyl)-5- 224 N" 611.04 pentafluorobenzyl)sulfanyl]-4H- 611 F F 1,2,4-triazo-3-y}-N-(2methoxybenzyl)pefltaflamide 225 519.71 phenyl~5-(-43,-i 24tizl3y} 2 0 dimethylbenzyl)sulfanyl]-4- [3-(2-oxo-1pyrrolidinyl)propyl]pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -109- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
0 226 N N514.69 dimethylbenzyl)sulfanyl]-4- 51 o phenyl-4H-1 ,2,4-razol-3-y}-N- 51 N'N (2-methoxybenzyl)pentanamide o 0 dimethylbenzyl)sulfanyl]-4-(3- 227 N498.67 methoxypropyl)-4H-1 ,2,4-triazol- 499 N N.3-yiJ-N-(4- F Iluorobenzyl)pentanamide
CI
5-[5-[(3-chlorobenzyl)sulfanyl]-4- 228 NN471.07 (2-phenylethyl)-4H-1 ,2,4-triazol- 471 o 3-yl]-N-propylpentanamide
N
WO 03/053437 WO 03/53437PCT/EP02/14594 -110- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
5-{4-(3-chlorophenyl)-5-[(3- N ~fuobenzy)sulfany]-4H--1 .2,4- 229 N- /590 riazol-3-yl-N-(2-53 methoxybenzyl)pentanamide 5-f 4-allyl-514- 230 N s464.63 methylbenzyl)sulfanyl]-4H-1 465 o riazol-3-yl}-N-(2- N- N methoxybenzyl)pentanamide 0 U N N methoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 III Example Chemical Structure M.W. IUPAC-Name M+(ESl+) No.
N-(4-fluorobenzyl)-5-{4-(3- 232 0 N 484.64methoxypropyl)-5-[(3-48 r N methylbenzyl)sulfanyll-4H-1 .2,4-48 triazol-3-yI~pentanamide F0 7 5-{4-(3-chlorophenyl)-5-[(2- 233 N 527.04uorobenzyl)sulfanyl]-4H-1 52 fuorobenzyl)pentanamide 5-[4-(3-chlorophenyl)-5-[(4- N methylbenzyl)sulfafyl]-4H-1,24 234 535.11 riazol-3-yi}-N-(4- 24 methoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 112- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
0 I /N-(4-methoxybenzyl)-5-{5-[(4- 235 500.66 methylbenzyl)sulfanyl]-4-phenyl- 501 N H-I,2,4-triazol-3- 0 lpentanamide
N
5-[5-[(3-chlorobenzyl)sulfanyl]-4- 236 N 513.10 (tetrahydro-2-furanylmethyl)-4H- 513 N I ,2.4-triazol-3-yi]-N-(2phenylethyl)pentanamide 5-{4-(3-chlorophenyl)-5-[(4- 237 0 N methylbenzyl)sulfanyl]-4H-1,2,4-47 237 0 471.07 triazol-3-yl)-N-47 N N-N isobutylpentanamide, WO 03/053437 WO 03/53437PCT/EP02/14594 -113- Example Chemical Structure M.W. IUPAC-Name M+(ESI+) No.
5-{4-(3-methoxyphenyl)-5-I(3- 238 9N methylbenzyl)sulfanyl]-4H-1 51 514.69 triazol-3-yi}-N-(2-51 N N-N -phenylethyl)pentanamide 5-[5-K2-chloro-4- N F uorobenzyl)sulfanyl]-4-(3- 239 N 537.48 chlorophenyl)-4H-1 ,2,4-triazol-3- 537 IJ]-N-(tetrahydro-2- CI furanylmethyl)pentanamide /N-benzyl-5-{5-L(3- 240 N N methylbenzyl)sulfanyl]-4-phenyl- 47 24S 470.64 4H-I ,2,4-triazol-3-47 I N yIlpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -114- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
N N-banzyl-5-15-L(2-chloro-4- N Fuorobenzyl)sulfanyl]-4-(3- 54 241 F 534 4 -N chlorophenyl)-4H-1 ,2,4-triazol-3- CC C I]pentanamide
F
N-(4-fluorobenzyl)-5-[5-[(2- 242 N 56.68melhylbenzyl)sulfanyl]4(2 51 24 N 51,11 phenylethyl)-4H-1 ,2,4-triazol-3- 51 N Vl]pentanamide
CI
b 5-[5-[(3-chlorobenzyl)sulfaiyl]-4- 243 N N- j 485.09 (2-phenylethyl)-4H-1 ,2,4-triazol- 485 0 3-y]-N-isobutylpentanamide
N
WO 03/053437 WO 03/53437PCT/EP02/14594 -115- Example Chemical Structure M.W. IUPAC-Name M'(ESI') No.
244 N /N.(cyclopropylmethyi)-5-{5-[(3- 434H-I ,2,4-triazol-3- .N llpentanamide 5-{4-(3-mefiioxypheny)-5-[(4- 245 45.6 methylbenzyl)sulfanyl]-4H-I 452.62 iazol-3-yl}-Npropylpentanamide 0 246 s466.65 dimethylbenzyl)sulfanyl]-4- 46 N N phenyl-4H-I ,2,4-triazol-3-yl}-N- 46 0 (3-methoxypropyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 116- Example Chemical Structure M.W. IUPAC-Name M'(ESl-) No.
/N-benzyl-5-[5-[(3,5- 247 N N sdimethylbenzyl)sulfanyl]-4-(2- 51 247 ~512.72 phenylethyl)-4H-1 ,2,4-triazol-3- 51 N> I]pentanamide -0 S 5-{5-[(3-methylbenzyl)sulfanyl]- 248 N N484.67 4-phenyl-4H-1 ,2,4-triazol-3-y}- 485 N N-(2-phenylethyl)pentanamide /N-(4-fluorobenzyl)-5-{5-[(3- 2498.6N methylbenzyl)sulfanyl]-4-phenyl- 489 04 S- 48.3H-I ,2,4-triazol-3- I N yl~pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 117 Example No.
250 Chemical Structure 448.63 IUPAC-Name
M'(ESI-)
N-(cyclopropylmethyl)-5-{5-[(3,5 dimethyibenzyl)sulfanyl]-4phenyl-4H-1 ,2,4-triazol-3-49 yI~pentanamideI 436.62 dimethylbenzyl)sulfanylj-4phenyl-4H-1 ,2,4-triazol-3-yl}-Npropylpentanamide 0 7
N
N N
N-N
528.72 5-[5[35 dimethylbenzy)sulfanyl]4-(3methoxyphenyl)-4H-1 ,2,4triazol-3-yI]-N-(2phenylethyl)pentanamide I I J Exampl5343 WO 03/53437PCT/EP02/14594 118 No.
253 Chemical Structure M.W.
IUPAC-Name
M'(ESI-)
N
r s~ I
N-
505.08 \J-benzyl-5-{4-(3-chlorophenyl)- 5-[(3-methyibenzyl)sulfanyl]-4H- I 2 4 -triazol-3-yllpentanamide 505 470.64 N-benzyl-5-t5-[(4methylbenzyl)sufanyl]-4-phenyl.
4H-1 ,2,4-triazol-3yilpentanamide
N
-N
535.11 5-[4-(3-chlorophenyl)-5-[(2methylbenzyl)sulfanyl]IAH-1,2,4triazol-3-yi}-N-(4methoxybenzy!)pentanamide L I WO 03/053437 WO 03/53437PCT/EP02/14594 119- Example Chemical Structure M.W. IUPAC-Name M-(ESI 4 No.
N 5-(4-(3-chlorophenyl)-5-[(3,5- 256 N 533.14 dimethylbenzyl)sulfanyl]-4H- 53 ,2,4-triazol-y}N(2 N N-Nphenylethyl)pentanamide -I 5-{4-(3-chlorophenyl)-5-[(3,5dimethylbenzyl)sulfanyl]-4H- 257 N- 541 ,2,4-triazol-3-yI}-N-[3-(2-oxo-1 pyrrolidinyl)propyl]pentanamide 5-{4-(3-chlorophenyl)-5-[(3methylbenzyI)sulfanyl]-4H-1 51 28N519.11 triazol-3-yI}-N-(2-51 N-N phenylethyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -120- Example Chemical Structure M.W. IUPAC-Namne M"(ESI') No.
259 F5-[5-[(3-fluorobenzyl)sulfanyl]-4- 259 532.68(2-phenylethyl)-4H-1 ,2,4-triazol- 53 N N 53.83-ylI-N-(2- N Nmethoxybenzyl)pentanamide 0 N 5-(4-(3-chlorophenyl)-5-[(2- 260 3.1methylbenzyl)sulfanyl]-4H-1 ,2,4- N N-N 35.11 riazol-3-yi}-N-(2-53 -o methoxybenzyl)pentanamide 5-{4-aIlyl-5-[(3- 261 8J/ N methylbenzyl)sulfanyl]-4H-1 ,2,4- 26 452.60 triazol-3-y)--N-(4-45 S Nfuorobenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 121 Example Chemical Structure M.W. IUPAC-Name M'(ESI 4 No.
N-benzyl-5-{4-(3-chlorophenyl)- 0 N 5-[(2-oxo-2- 262 phenylethyl)sulfanyl]-4H-1,2,4- 51 triazol-3-y~pentanamide
CI
'9 5-{4-(3-chlorophenyl)-5-[(3- 263 N methylbenzyl)sulfanyl]-4H-1 ,2,4-54 263540.13 riazol-3-yI}-N-[3-(2-oxo-1 pyrrolidinyl)propyl]pentanamide N-(cyclopropylmethyl)-5-{4-(3- 264 N 464.63 methoxyphenyl)-5-E(2-46 methylbenzyl)sulfanyl]-4H-1,2,4- N-N triazol-3-yI~pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -122- Example Chemical Structure M.W. IUPAC-Name M+(ESI-) No.
5-{5-[(3-methylbenzyl)sulfanyl]- 26 N 558-phenyl-4H-1 ,2,4-triazol-3-yI}- 56 50.6 N-[3-(2-oxo-1-50 ,N pyrrolidinyl)propyl]pentanamide N-aIlyI-5-{4-(3-chlorophenyl)-5- 266 0 N /455.02 [(4-methylbenzyl)sulfenyl]-4H- 455 N -NI1,2,4-triazol-3-yIlpentanamide
CI
N-allyI-5-[5-[(2-chloro-4- 26 N fl 933uorobenzyl)sulfanyl]-4-(3- 493 26 49.4 chlorophenyl)-4H-I ,2,4-triazol-3- SN-N yl]pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -123- Example Chemical Structure M.W. IUPAC-Name M-(ESI-) No.
5-{4-(3-chlorophenyl)-5-[(2- 268 methylbenzyl)sulfanyl]-4H-I,2,4- 47 268 471.07 triazoI-3-yI}-N-47 N-N isobutylpentanamide
F
/N-(4-fluorobenzyl)-5-{5-[(4- 269 /N 488.63 methylbenzyl)sulfanyl]-4-phenyl- 489 269 N H-I ,2,4-triazol-3- N N yIpentanamide 5-[5-[(3-chlorobenzyl)sulfanyll-4- N7 50.0 (3-methoxypropyl)-4H-1 270 51.09riazol-3-yI]-N-(2- N N-N henylethyl)pentanamide WO 03/053437 PTEO/49 PCT/EP02/14594 124- Example Chemical Structure M.W. IUPAC-Name
M'(ESI')
No.
5-[5-[(2-chloro-4- 271 N N489.06 fuorobenzyl)sulfanyl]-4-(2- 489 o phenylethyl)-4H-1 ,2,4-triazol-3- N I]-N-propylpentanamide 0 N-benzyl-5-(4-(3-chlorophenyl)- 272 N 516.07 5-[(3-cyanobenzyl)sulfanyl]-4H- 516 N-N I ,2,4-triazol-3-yIlpentanamide 5-[5-[(3-chlorobenzyl)sulfanyl]-4- 273 477.46(3-chloroplienyl)-4H-1,2,4- 47 273 N<477.46riazol-3yl]N 47 N-N /propylpentanamicle WO 03/053437 WO 03/53437PCT/EP02/14594 -125- Example No.
274 F 1* Chemical Structure M.W. IUPAC-Name M '(ESI-) I- I 438.59 N-(2-methoxyethyl)-5-{5-[(3methylbenzyl)sulfanyl]-4-phenyl- 4H-1 ,2,4-triazol-3yl}pentanamide 439 t i -I I 559.66 N-[3-(2-oxo-i pyrrolidinylpropyl]-5-(4-phenyl- (trifluoromethyl)benzylqsulfanyl) 4H-1 ,2,4-triazol-3yl)pentanamide I 4
S
II
0
N
N
498.69 dimethylbenzyl)sulfanyll-4phenyl-4H-1 ,2,4-triazol-3-y)-N- (2-phenylethyl)pentenamide L I L WO 03/053437 WO 03/53437PCT/EP02/14594 126- Example Chemical Structure M.W. IUPAC-Name M(S~ No.
N-benzyl-5-(5-[(3,5- 277 N 48.6 dimethylbenzyl)sulfanyl]-4- 485 \'44.6 phenyl-4H-1 ,2,4-triazol-3- N lpentanamide /N-(4-fluorobenzyl)-5{[5-[(4- 278N 516.68 *ehlezlslay]-(2- 51 278 phenylethyl)-4H-1 ,2,4-triazol-3- N IN l]pentanamide 5-{4-(3-chlorophenyl)-5-[(2-oxo- 279 59.09-phenylethyl)sulfanyl]-4H-1 .2,4triazol-3-yl)-N-(4methoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -127- Example Chemical Structure M.W. IUIPAC-Name
M
4 (ESl-) No.
Q N-(cyclopropylmethyl)-5-[5-[(3,5- 280 0 N 478.66 dimethylbenzyl)sulfanyl]-4-(3- 479 N methoxyphenyl)-4H-1 ,2,4- N-N riazol-3-yI]pentanamide N-butyl-5-{5-[(3- 281 N N s 46.62methylbenzyl)sulfanyl]-4-phenyl- 281 N N- 46.62 i,2,4-triazol-3-43 N I~pentanamide 5-{4-(3-methoxyphenyl)-5-[(4- 282 N 535.71methylbenzyluIfnyI.4H-1,2,4- 53 N triazol-3-yl}-N-[3-(2-oxo-1 -53 pyrrolidinyl)propyi]pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 128- Example Chemical Structure M.W. IUPAC-Name M"(ESI-) No.
F
283 44.60 -[5-(benzylsulfanyl)-4-phenyl- 28 44604H-I ,2,4-triazol-3-yl]-N-(4- 475 0 fluorobenzyl)pentanamide 5-[5-[(3-chlorobenzyl)sulfanyl]-4- 284 9-0 535.11 (3-methoxyphenyl)-4H-I 53 N triaZOl-3-yI]-N-(2- N 0 N-N r6phenylethyl)pentanamide 5-[5-[(4-fluorobenzyl)sulfanyl]-4- 285 sO 532.68 (2-phenylethyl)-4H-1 ,2,4-triazol- 53 0 3-yI]-N-(2- O methoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 129- Example Chemical Structure M.W. IUPAC-Name
M
4
(ESI')
No.
I /N-aIlyI-5-{5-[(3,5- 286 N 434.61dimethyibenzyl)sulfanyl]-4- 43 26 N 0 /NJ4 .6 phenyl-4H-1 ,2,4-triazol-3-43 N Illpentanamide /N-(2-methoxybenzyl)-5-{5-[(4- 287 N N s500.66 methylbenzyl)sulfanyl]-4-phenyl- 0 4H-I ,2,4-triazol-3- N I}pentanamide N-butyl-5-[5-[(3- 288 N491.48 chlorobenzyl)sulfanyl]-4-(3- 491 Nr chlorophenyl)-4H-i ,2,4-triazol-3- N-N i]pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -130- Example Chemical Structure M.W. IUPAC-Name M'(ESl-) No.
CI
Ct 5-[5-[(3-chlorobenzyl)sulfanyl]-4- 28 0N 8947(3-chlorophenyl)-4H-1,2,4- 489 289 0N 48947 razol-3-ylJ-N- N N-N(cyclopropylmethyl)pentanamide 290 51.68N-(4-fluorobenzyl)-5-5-[(3- 0 /N phenylethyl)-4H-1 ,2,4-triazol-3- N Q~pentanamide
FF
N-(cyclopropylmethyl)-5-(4phenyl-5-{[4- 291 N N488.58 (trifluoromethyl)benzyl]sulfanyl}- 489 H-I ,2,4-triazol-3- N II)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 131 Example Chemical Structure M.W. IUPAC-Name
M'(ESI-)
No.
5-{4-alli-5-[(3,5- 292 s N 6 466.62 dimethylbenzyl)sulfanyl]-4H- 46 0 1,2,4-triazol-3-yl}-N-(4-46 N fuorobenzyl)pentanamide N-isobutyl-5-[5-[(2- 293 N N464.68methylbenzyl)sulfanyl]-4-(2- 46 o phenylethyi)-4H-1,2,4-triazol-3- ~N lpentanamide 0 dimethylbenzyl)sulfany]-4-(3- 294 N 549.74 methoxyphenyl)-4H-1 550 trIazol-3-yI]-N-[3-(2-oxo-1 pyrrolidinyi)propyljpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -132- Example Chemical Structure M.W. IUIPAC-Name M'(ESI-) No.
5-[5-[(2-chloro-4- F fuorobenzyl)sulfanyl]-4-(3- 295 N573.52 chlorophenyl)-4H-1 ,2,4-triazol-3- 574 al- -2 methoxybenzyl)pentanamide s 5-{5-[(3-methylbenzyl)sulfanyl]- 290 422.59 4-phenyl-4H-1,2,4-triazol-3-y}- 423 \N N-propylpentanamide 5-[5-[(3-chlorobenzyl)sulfanyl]-4- 297 0N \6 450 (3-methoxyphenyl)-4H-1 485 N- triazol-3-yII-N- N-N (cyclopropylmethyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -133- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
CI
5-.(4-(3-chlorophenyl)-5-[(4- 298 523.07 fuorobenzyl)sulfanyl]-4H-1,2,4- 52 298 riazol-3-yil-N-(2- N-N phenylethyl)pentanamide A N-(2-methoxyethyl)-5-{4-(3- 299 46.6 methoxyphenyl)-513methylbenzyl)sulfanyl]-4H-,24 46 0O 7N N- N triazol-3-yI~pentanamide 5-{4-(3-chlorophenyl)-5-[(3- 3004.0N- cyanobenzyl)sulfanyl]-4H-1 53 N00 N t 3.6riazol-3-yI}-N-(4- 'N luorobenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -134- Example Chemical Structure M.W. IUIPAC-Name, M'(ESI-) No.
CI
s- 5-{5-[(3-chlorobeflzyl)sulfanyU-4- 301 N N457.04 phenyl-4H-1 ,2,4-triazol-3-y}-N- 457 ~N isobutylpentanamide
N
CI 5-[5-(bnzylsulfnyl)-4-(3- 302 505.08 'hlorophenyl)-4H-1,2,4-triazol-3- N IJyl-N-(2-50 N-N phenylethyl)pentanamide N F N-allyI-5-{4-(3-chlorophenyl)-5pentafluorobenzyl)sulfanyl]-4H- 53 F N24tiao---petnmd
F
WO 03/053437 WO 03/53437PCT/EP02/14594 -135- Example Chemical Structure M.W. IUPAC-Name
M-(ESI-)
N-(2-methoxybenzyl)-5-[5-[(2- 304 N 528.72methylbenzyl)sulfanyl]-4-(2- 52 J6,/587 phenylethyl)-4H-i ,2,4-triazol-3- 52 \N Il]pentanamide
F
dimethylbenzyl)sufanyl]-4-(2- 305 N N530.71 phenylethyl)-4H-1,2,4-triazol-3- 531 Iuorobenzyl)pentanamide 306 N -N-isobutyl-5-{5-[(4- N 436.62 methylbenzyl)sulfanyl]-4-phenyl- 43 -0 462 H-I ,2,4-triazol-3-43 ,N Ipentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -136- Example Chemical Structure M.W IUPAC-Name M'(ESI-) No.
307 4 6.6 N-isobuty 4H-I ,2,4-triazol-3- A Ilpentanamide 5-{4benzyl-5-[(3- 308 N N519.71methylbenzyl)sulfanyl]-4H-I 52 308 N 0 59.71rtazol-3-yI}-N-[3-(2-oxo-I -52 N IN pyrroildinyl)propyl~pentanamide 0 N-benzyl-5-{4-(3- 309 466.65 methoxypmopyl)-5-[(3-46 methylbenzyl)sulfanyl]-4H-I,2,4- 46 N riazol-3-yllpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -137- Example Chemical Structure M.W. IUPAC-Name M+(ESIF) No.
'1F 5-{4-(3-chlorophenyl)-5- F 310 F 546.99 peritafluorobenzyl)sulfanyl]-4H- 547 N N-N F ,2,4-triazol-3-yl}-N- F isobutylpentanamide, 0F FN-(4-methoxybenzyl)-5-[5- /F 60.4[2,3,4,5,6- 311 60.4pentafluorobenzyl)sulfanyl]-4-(2- 605 N 0 F phenylethyl)-4H-1 ,2,4-tnazol-3- IN ylpentanamide o 312\ 491.06 4-(3-chlorophenyl)-4H-1 491 N-N triazol-3-yi]pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 138- Example Chemical Structure M.W IUPAC-Name M'(ESI') No.
0NC 5-[5-(butylsulfanyl)-4-(3- 31 423.02 chlorophenyl)-4H-1 ,2,4-triazol-3- 423 -NN-N yi]-N-isobutylpentanamide 0 /NN-(cyclopropylmethyl)-5-{4-(3- 314 N 464.63 methoxyphenyl)-5-[3-45 N- methylbenzyl)sulfanyl]-4H-1 ,2,4-46 triazol-3-yl~pentanamide 5-{4-allyl-5-[(3,5- 315 N462.66 dimethylbenzyl)sulfanyl]-4H- 463 I ,2,4-triazol-3-yl}-N-(2phenylethyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M(ESI') No.
5-[5[35 /dimethylbenzyl)sulfanylU-4-(2- 316 542.75 phenylethyl)-4H-1,2,4-triazol-3- 543 -N yl-N-(4- N methoxybenzyl)pentanamide 317/ f N-benzyl-5-{4-(3-chlorophenyl)- 31N 509.05 5-f (2-fluorobenzyl)sulfanyl]-4H- 509 NI N i,2,4-triazol-3-yllpentanamide Cc N I 5-15-[(3-chlorobenzyl)sulfanyl]-4- 315 N ~(3-chlorophenyl)-4H-1,2,4- 318 N 493.46 triazol-3-yl]-N-(2-49 N-N methoxyethyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 140- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
0 /N-(cyclopropylrnethyl)-5-{4-(3- 319 SJ 464.63methoxyphenyl)-5-[4-46 N methylbenzyl)sulfanyl-4H-1,2,4triazol-3-yllpentanamide
N'
5-{4-(3-chlorophenyl)-5-[(2- 523.07 methylbenzyl)sulfanyl]-4H-1,2,4- 52 32 r riazol-3-yI}-N-(4-52 Iluorobenzyl)pentaia mid e
CI
0 ~'//5-[5-[(3-chlorobenzyl)sulfanyl]-4- 321 N N513.10(2-phenylethyl)-4H-1 .2,4-triazol- 51 31N 0 3-yi]-N-(tetrahydro-2- ~N furanylmethyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 141 Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
5-{4-(3-chlorophenyi)-5- F 322 611.04 pentafluorobenzyl)sulfanyl]-4H- 61'1 N NN F F 1 ,2,4-triazol-3-yl}-N-(4methoxybenzyl)pentanamide
CI
5-[5-(butylsulfanyI)-4-(3- 0 chlorophenyl)-4H-1,2,4-triazol-3- 323N 449 lI-N-(2-42 N-N methoxyethyl)pentanamide N 324 N 456.61 4-phenyl-4H-1 ,2,4-triazol-3- 457 \r N Illpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -142- Example Chemical Structure M.W. IUPAC-Name M-'(ESI') No.
/(3,5 325 N- N 450.65 dimethylbenzyl)sufanyl]-4-45 phenyl-4H-1,2,4-triazol-3-yl}-Nisobutylpentanamide /5-{5-[(4-fluorobenzyl)sulfanyl]-4- 326 N N504.63 phenyl-4H-1 ,2,4-triazol-3-y}-N- 505 N (2-methoxybenzyl)pentanamide 327 /5-{4-benzyl-5-[(3,5- 0 cimethylbenzyI)sulfanyl]-4H- 37N 53.7 ,2,4-triazol-3-yl)-N-[3-(2-oxo-1 53 WO 03/053437 WO 03/53437PCT/EP02/14594 143- Example No.
Chemical Structure M.W. IUPAC-Name
M
4 (E SlI 483 0 -rN
N-N
483.08 5-(4-(3-chlorophenyl)-5-{[(2E)-3- Phenyl-2-propenylsulfanyl}-4H- I ,2,4-triazol-3-yl)-Nisobutylpentanamide N 4 a
I'
A
N N
N-N
523.07 5-(4-(3-chlorophony)-5-[(3fluorobenzyl)sulfanyl]-4H-1 ,2,4triazol-3-yl}-N-(2phenylethyl)pentanamide I t i 450.65 5-[5-[(2-methylbenzyl)sulfanyl]- 4-(2-phenylethyl)-4 H-I ,2,4triazol-3-y]-Npropylpentanamide I WO 03/053437 WO 03/53437PCT/EP02/14594 -144- Example No.
Chemical Structure
M.W.
IUPAC-Name
M-(ESI')
N r
N-N
455.02 N-allyl-5-{4-(3-chlorophenyl)-5- [(2-methyibenzy)sulfany]-4H- 1 ,2,4-triazol-3-yl}pentanamide
I
490.59 N-buty!-5-(4-phenyl-5-[4- (trifluoromethyl)benzyl]sulfanyl)} 4H-1 ,2,4-triazol-3- /I)pentanamide 1 1 1 4 485.05 5-{5-[(3-chlorobenzyl)sulfanyl]-4- Dhenyl-4H-i ,2,4-triazol-3-y}-N- Itetrahydro-2ruranylmethyl)pentanamide 485 I L WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M'(ESI 4 No.
I
5-[5-[(4-fluorobenzyl)sulfanyl]-4- 334 N-0 500.64 (3-methoxypropyl)-4H-1 501 N-N riazol-3-yl]-N-(2- N-N methoxybenzyl)pentanamide /N-(3-methoxypropyl)-5-{5-[(3- 335 452.62 methylbenzyl)sulfanyl]-4-phenyl- 453 N 4H-I,2,4-triazol-3o I~pentanamide
N
N
478.66 N-isobutyl-5-[5-[(2-oxo-2phenylethyl)sulfanyl]-4-(2phenylethyl)-4H-1 ,2,4-triazol-3yl]pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M'(ESI 4 No.
N' NJ 5-{5-[(3-fluorobenzyl)sulfanyl]-4- 33 0488.63 phenyl-4H-1 ,2,4-triazol-3-y}-N- 489 (2-phenylethyl)pentanamide
FF
F
0 N-(2-methoxyethyl)-5-(4-phenyl- 338 NS492.57 (trifluoromethyl)benzyl~sulfanyl}- 493 N N H-I ,2,4-triazol-3- N yl)pentanamide 0 /5-{5-[(4-methylbenzyl)sulfanyl]- 339 N N4-phenyl-4H-1 ,2,4-triazol-3-yI)- 46 39N 0 /N 464.63 N-(tetrahydro-2-46 U INI N uranylmethyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 147- Example Chemical Structure M.W. IUPAC-Name M'(ESl-') No.
a 5-{4-(3-chlorophenyl)-5-[(3,5- 34 471.0 dimethylberizyi)sulfanyl]-4H- 471 3471.0 1,2,4-triazol-3-yI}-N- N-N propylpentanamide
CI
N-butyl-5-{4-(3-chlorophenyl)-5- 341 471.07 [(4-methylbenzyl)sulfanylJ-4H- 471 N N-NI1,2,4-triazol-3-yI}pentanamide CI i r_6r-5-[5-[(3-chlorobenzyl)sulfanyl]-4- 342 0 N 507.48 (3-chlorophenyl)-4H-1 507 N-N methoxypropyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 148 Example Chemical Structure M.W. IUPAC-Name
M
4
(ESI-)
No.
A
N 5-{4-(3-chlorophenyl)-5-[(2-oxo- 51.0 -phenylethyi)suifanyl]-4H-i,2,4- O N N triazol-3-yI)-N-(tetrahydro-2- 51 uranylmethyl)pentanamide 344 -dimethylbenzyl)sulfany]-4- 34N N 478.66 phenyl-4H-1 ,2,4-triazol-3-yl}-N- 479 C) (tetrahydro-2- 'v furanylmethyl)pentanamide 0F N-(3-methoxypropyl)-5-(4- 506.59 trirmthyl)benzyI IfanI}- 507 N N- 4H-I,2,4-triazol-3- \N IN Il)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 149- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
5-{4-(3-chlorophenyl)-5-[(4- 34 53.0 fuorobenzyl)sulfanyl]-4H-1 53 346~N- t 3.7riazol-3-yl}-N-(2methoxybenzyl)pentanamide N F 5-(4-(3-chlorophenyl)-5-{[4- F (trifluoromethyl)benzyl]sulfanyl}- 347N -N594.10 4H-i,2,4-triazol-3-yI)-N-[3-(2- 594 347 Noxo-1pyrrolidinyl)propyl]pentanamide
F
F N-(4-fluorobenzyl)-5-L5-[(2- 348~~ N 2.6luorobenzyl)sulfanyl]-4-(2-52 348 N- 520.65phenylethy)-4H-1 ,2,4-triazol-3- 52 N I]pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -150- Example Chemical Structure M.W. IUPAC-Name
M-'(ESI
4 No.
0
F
C1115-[5-[(2-chloro-4- 34 C luorobenzyl)sulfanyl]-4-(2- N\ N s567.13 phenylethyl)-4H-1 ,2,4-triazol-3- 567 -2 (J I N methoxybenzyl)pentanamide /N-benzyl-5-[5-[(3- 350 48.69methylbenzyl)sulfanyl]-4-(2o phenylethyl)-4H-1 ,2,4-triazol-3- N IN l]pentanamide 0 9 5-{4-(3-chlorophenyl)-5-[(3- 351 N546.09 cyanobenzyl)sulfanyl]-4H-1,2,4- 546 N-N triazol-3-y}-N-(4- -0 mothoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 151 Example Chemical Structure M.W. IUPAC-Name M-(ESI-) No.
C
5-(4-(3-chlorophenyl)-5-[(2-oxo- 3520 48.5-phenylethyl)sulfanyl]-4H-1 ,2,4- -450 riazol-3-yI}-N- 485 U\1, isobutylpentanamide 0 5-(4-benzyl-5-[(3- 353 M NP526 methylbenzyl)sulfanyl]-4H-1,2,4- o5.6 trazol-3-yl}-N-(2-45 \NN methoxyethiyl)pentanamide 0
CI
N-(1 3543.1 5-[5-[(3-chlorobenzyl)sulfanyll-4- 563 N; s-56.1 (2-phenylethyl)-4H-1,2,4-triazol- 0 3-yI]pentanamide
\N
WO 03/053437 WO 03/53437PCT/EP02/14594 152 Example Chemical Structure M.W. IUPAC-Name M 4 '(ESl+) No.
aa 5-[5-[(3-chlorobenzyl)sulfanyl]-4- 519.4 (3-chlorophenyl)-4H-1,2,4-51 triazol-3-yl]-N-(tetrahydro-2- N-N furanylmethyl)pentanamide 0 I /N-(4-mnethoxybenzyl)-5-[5-[(2- 356 528.72methylbenzyl)sulfanyl]-4-(2- 52 N N s phenylethyl)-4H-1 ,2,4-triezol-3o Ipentanamide
N
CI 5-{4-(3-chlorophenyl)-5-[(2- 0 475.03 fuorobenzyl)sulfanyl]-4H-1 47 N- isobutylpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 153- Example No.
Chemical Structure M.W. IUPAC-Name FM'(ESIr) 1 I- 4 476.57 15-(4-phenyl-5-{[4- (trifluoromethyl)benzyl]sulfanyl)- 4H-1 ,2,4-triazol-3-yI)-Npropylpentanamide 477 i I- 468.60 5-{4-allyI-5-[(4quorobenzyl)sulfanyl]-4H-1 ,2,4triazol-3-yI}-N-(2- 'nethoxybenzyl)pentanamide I 0
N
N
514.69 5-[5-(benzylsulfanyl)-4-(2phenylethyl)-4H-1 ,2,4-triazoi-3yl]-N-(2methoxybenzyl)pentanamide 515 I WO 03/053437 WO 03/53437PCT/EP02/14594 -154- Example No.
361 Chemical Structure
N-N
M-W.
IUPAC-Name -benzyl-5-{4-(3-chlorophenyl)y 5 -[(3-fluorobenzyl)sulfanyl]4H- 1 2 4 -triazol-3-yllpentanamide M'(ESl-) 509 509.05 540.73 N-(2-methoxybenzyI)-5-(4-(2 phenylethyl)-5-{[(2E)-3-phenyl- 2-propenyi]sulfanyi}-4H-1,2,4triazol-3-yl)pentanamide 457.04 5-{4-(3-chiorophenyl)-5-[(3rn ethyl benzyl)s u fanyl].4 H-1, 2,4triazol-3-yl}-N- WO 03/053437 WO 03/53437PCT/EP02/14594 -155- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
N 5-{4-(3-chlorophenyI)-5-[(4- 364 N 487.07ethylbenzyl)sulfanylj-4H-I 2,4-48 364 47.07riazol3yl}N-(3 48 N-N methoxypropyl)pentanamide N-butyl-5-{4-(3-chlorophenyl)-5- 365 485.09 [(3,5-dimethylbenzyl)sulfanyl]- 485 N 4H-I ,2,4-triazol-3- N-N yl~pentanamide /N-benzyl-5-{5-[(2- 36N470.64 methylbenzyl)sulfanyl]-4-phenyl- 471 36 N 4H-I ,2,4-triazol-3- N ylpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -156- Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
o 5-15-[(3,5- N dimethylbenzyl)sulfanyl]-4-(3- 367 0 482.65 methoxyphenyl)-4H-1 483 triazol-3-yi]-N-(2- N-N methoxyethyl)pentanamide N 5-{4-(3-chlorophenyl)-5-[(3,5- 368 N 485.09dimethylbenzyl)sulfanyl]-4H- 48 36 48.0 1 ,2,4-triazol-3-yi}-N-48 N-N isobutylpentanamide lfnl--3
N
369 N N~ 487.07chlorophenyl)-4H-1 ,2,4-triazol-3-48 N-N lN-2 'so methoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
5-{4-allyI-5-[(3- 370 F 145.2chlorobenzyl)sulfanyl]-4H-1 S N S 5.2riazol-3-yl-N- N\ benzylpentanamide
N
0N /5-{5-[(3-cyanobenzyl)sulfanyfl-4- 371 s511.65 phenyl-4H-1 ,2,4-triazol-3-yl}-N- 512 N N (2-methoxybenzyi)pentanamide
NN
5-[4-aIlyl-5-[(3- 372 43.6 methylbenzyl)sulfanyl]-4H-1 43 0/ 434.61riazol-3-yl}-Nbenzylpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -158- Example Chemical Structure M.W. IUPAC-Name M' (ESl-') No.
0 F N-(1 373 t 546.67 5-[5-[(2-fluorobenzyl)sulfaiyl]-4- 54 (2-phenylethyl)-4H-1 ,2,4-triazol- 54 N N 5-{4-allyl-5-[(3- 374 49.0 chlorobenzyl)sulfanyl]-4H-1 ,2,4- 0 N 49.0 Nriazol-3-yI)-N-(1 ,3-benzodioxol- 49 o N' 5-[5-[(3-methylbenzyl)sulfanyl]- -(2-phenylethyl)-4H-1 ,2,4- 375 N N--S 450.65 tizIy]. 451 propylpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 159- Example Chemical Structure M.W. IUPAC-Name
M'(ESI-)
No.
0 376 51[5-(2-fluorobenzyl)sulfanyli4- 37 464.60 (tetra hydro-2-fu ranyl methyi)-4H- 465 N 0 N I,2,4-triazol-3-yl]-N-(3methoxypropyl)pentanamide
\N
/N-(2-methoxybenzyl)-5-[5-[(4- 377 S528.72 methylbenzyl)sulfanyl]-4-(2- 529 NJ phenylethy)-4H-1 ,2,4-triazol-3- N lilpentanamide 0
F
GI 5-[5-[(2-chloro-4- 78 1> 56.1luorobenzy)sulfanyl-4-(2- 37856713phenylethyl)-4H-1 ,2,4-triazol-3- 567 N\ C N lN-4 \fNN methoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 Example Chemical Structure M.W. IUPAC-Name M'(ESI-) No.
CI
5-{5-[(3-chlorobenzyl)sulfanyl]-4- 379 /N N S443.01 phenyl-4H-1 ,2,4-trIazol-3-yl.-N- 443 'I propylpentanamide 0 //5-[5-[(4-methylbenzyl)sulfanyl]- 380 N N492.69-(2-phenylethyl)-4H-1 ,2 4- 38 N426 riazol-3-yI]-N-(tetrahydro-2- 49 N uranylmethyl)pentanamide 0 5-{4(3-chlorophenyl)-5-[(2- 381 N 55.11phenylethyl)sulfanyll-4H-1 ,2,4- N-55.1 riazol-3-ylj-N-(2-53 381 N-N -methoxybenzyi)pentanamide WO 03/053437 PCT/EP02/14594 -161- Example No. Chemical Structure M.W. IUPAC-Name M+(ESI)
CI
o 5-[5-[(2-chloro-4- 382. fluorobenzyl)sulfanyl]-4-(3- 382 N 507.46 chlorophenyl)-4H-1,2,4-triazol-3- 507 a yl]-N- (cyclopropylmethyl)pentanamide
F
Example 383: Preparation of a pharmaceutical Formula tion The following Formulation examples illustrate representative pharmaceutical compositions according to the present invention being.
Formulation 1 Tablets A triazole compound of Formula I is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ration. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (80-90 mg of active triazole compound per tablet) in a tablet press.
Formulation 2 Capsules A triazole compound of Formula I is admixed as a dry powder with a starch diluent in an approximate 1:1 weight ratio. The mixture is filled into 250 mg capsules (125 mg of active triazole compound per capsule).
Formulation 3 Liquid A triazole compound of Formula I (1250 mg), sucrose (1.75 g) and xanthan gum (4 mg) are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously WO 03/053437 PCT/EP02/14594 -162prepared solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, mg) in water. Sodium benzoate (10 mg), flavor, and color are diluted with water and added with stirring. Sufficient water is then added to produce a total volume of 5 mL.
Formulation 4 Tablets A triazole compound of Formula I is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active triazole compound) in a tablet press.
Formulation 5 Injection A triazole compound of Formula I is dissolved in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/ml.
Example 384: Biological assays The compounds according to Formula I may be subjected to the following assays: a) In vitro competition binding assay on hOT receptor with Scintillation Proximity Assay (18).
This assay allows to determine the affinity of the test compounds for the human Oxytocin (hOT) receptor. Membranes from HEK293EBNA (cells expressing the hOT receptor) were suspended in buffer containing 50 mM Tris-HC1, pH 7.4, 5 mM MgC12 and 0.1 BSA The membranes (2-4 pg) were mixed with 0.1 mg SPA bead coated with wheat-germ aglutinin (WGA-PVT-Polyethylene Imine beads from Amersham) and 0.2 nM of the radiolabelled [125I]-OVTA (OVTA being Omithin Vasoactive, an analogue of OT for competitive binding experiments). Non-specific binding was determined in the presence of 1 [tM Oxytocin. The total assay volume was 100 jl. The plates (Corning NBS plate) were incubated at room temperature for 30 min and counted on a Mibrobeta® plate WO 03/053437 WO 03/53437PCT/EP02/14594 163 scintillation counter. Competitive binding was performed in presence of compounds of formula at the following concentrations: 30 jiM, 10 jiM, 1 gM, 390 nM, 100 nM, 19 nM, 1 nM, 100 pM, 10 pM. The competitive binding data were analysed using the iterative, nonlinear, curve-fitting program, "Prism" (GrapbPad Software, Ic).
The ability of triazole derivatives of formula to inhibit the binding of 2 5 1-OVTA to thle OT-receptor was assessed using the above described in vitro biological assay.
Representative values for some examiple compounds are given in Table 3 where the binding affinity of the compounds is expressed by the inhibition constant (Ki; jiM). From these values, it can be derived that said test compounds according to formula I do show a significant binding to the oxytocin receptor.
Table 3 ExampleBinding Affinity Exapl IUPAC-Name hOT-R No. (Ki [4iM]) 3-[5-[(3-chlorobenzyl)sulfanyl]-4-(3- 1 methoxyphenyl)-4H-1 ,2,4-triazol-3-yI]-N-(2- 0.045 methoxybenzyl)propanamide 3-[5-[(3-fluorobenzyl)sulfanyl]-4-(4methylphenyl)-4H-1 ,2,4-triazol-3-yI]-N-(2- 0.127 methoxybenzyl)propanamide 3-{4-(3-chlorophenyl)-5-[(3- 3 methylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3- 0.134 Il)-N-(2-methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -164- ExampleBinding Affini No.pl IUIPAC-Namne hOT-R N (Ki N-(2-methoxybenzyl)-3-{4-(3- 16 methoxyphenyl)-5-[(3-0.9 methylbenzyl)sulfany]-4H-1 ,2,4-triazol-3- 0.9 ylpropanamide 3-[5-(benzylsulfanyl)-4-(4-methylphenyl)- 9 4H-I,2,4-triazol-3-yI]-N-(2- 0.205 methoxybenzyl)propanarnide 3-[5-[(3-chlorobenzyl)sulfany]-4-(3- 8 methylphenyl)-4H-1 ,2,4-triazoI-3-yI]-N-(2- 0.229 methoxybenzyl)propenamide N-butyl-3-[5-[(3-chlorobenzyl)sulfanyl]-4-(3chlorophenyl)-4H-1 ,2,4-triazol-3- 0.245 ylipropanamide N-(2-methoxybenzyl)-3-{4-(4- 6 methylbenzyl)-5-[(3-methylbenzyl)sulfanyl]- 0.246 4H-i ,2,4-triazol-3-yllpropanamide 3-[5-[(3-chlorobenzyl)sulfanyl]-4-(3- 4 methoxypropyl)-4H-1 ,2,4-triazol-3-yI]-N-(2- 0.326 methoxybenzyl)propananmide WO 03/053437 WO 03/53437PCT/EP02/14594 ExampleBinding Affinity Exapl IUPAC-Name hOT-R No. (Ki [ttM]) 3-{4-(3-chlorophenyl)-5-[(4- 11 fluorobenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl}- 0.329 N-(2-methoxybenzyl)propanamide 3-[5-(benzylsulfanyl)-4-(3-chlorophenyl)- 12 4H-I ,2,4-triazol-3-yU]-N-(2- 0.439 methoxybenzyl)propanamide 5-[5-[(3-chlorobenzyl)sulfanyl]-4-(3- 184 chlorophenyl)-4H-1 ,2,4-triazol-3-yI]-N-(2- 0.481 methoxybenzyl)pentanamide N-(2-methoxybenzyl)-5-L5-[(3- 189 methylbenzyl)sulfanyU-4-(2-phenylethyl)- 0.615 4H-i ,2,4-triazol-3-yl~pentanamide 5-{5-[(3-chlorobenzyl)sulfanyl]-4-phenyl- 1 85 4H-I ,2,4-triazoi-3-yl)-N-(2- 0.603 methoxybenzyl)pentanamide 4-{5-[(3-chlorobenzyl)sulfanyl]-4-phenyl- 137 4H-I ,2,4-triazo-3-yI}-N-(2- 2.550 methoxybenzyl)butanamide WO 03/053437 PCT/EP02/14594 -166b) In vitro competition binding assay on h Via receptor with Scintillation Proximity Assay (18).
This assay allows the determination of the affinity of the test compounds for the Via receptor. Membranes from CHO cells expressing the hVla receptor are suspended in buffer containing 50 mM Tris-HC1, pH 7.4, 5 mM MgC12 and 0.1 BSA The membranes (5-10 pg) are mixed with 0.2 mg SPA bead coated with wheat-germ aglutinin (WGA beads from Amersham) and 0.03 nM of the radiolabelled [125I]-LVA (LVA being Linear Vasopressin Antagonist and is an analogue of AVP for competitive binding experiments).
Non-specific binding is determined in the presence of 1 pM AVP. The total assay volume is100 The plates (Coming NBS plate) are incubated at room temperature for 2 hours and counted on a Mibrobeta plate scintillation counter. Competitive binding can be performed in presence of test compounds at the following concentrations: 30 PtM, 10 itM, 1 iM, 300 nM, 100 nM, 10 nM, 1 nM, 100 pM, 10 pM. The competitive binding data can then be analysed using the iterative, nonlinear, curve-fitting program, "Prism" (GraphPad Software, Inc).
The binding affinities to the Via receptor of the triazole derivatives claimed in the formula I can be measured using the above described in vitro biological assay.
c) Functional assay No. 1: Inhibition of oxytocin mediated Ca 2 +-mobilization by FLIPR® (Fluorimetric Imaging Plate Reader) The action of OT on the OT-receptor triggers a complex cascade of events in the cell which leads to an increase in the intra-cytoplasmic Ca 2 concentration. This increase in Ca 2 concentration results from both calcium release from the sarcoplasmic reticulum (calcium stores) into the cytoplasm and from calcium influx from the extracellular space through WO 03/053437 PCT/EP02/14594 -167- Ca 2 channels. This Ca 2 +mobilization into the cytoplasm triggers the contractile machinery of the myometrial cells which leads to uterine contractions (4 and 19).
This assay allows the measurement of the inhibition of OT/OT-R mediated calcium mobilization by test compounds of formula FLIPR is a fluorimetric imaging device using a laser (Argon-ion laser) for simultaneous illumination and reading (cooled CCD camera) of each well of a 96-well-plate, thus enabling rapid measurements on a large number of samples.
Preparing the plates: FLIPR-plates were pre-coated with PLL (Poly-L-Lysine) 10g/ml 0.1% gelatine to attach HEK293EBNA cells (Human Embryonic Kidney cells expressing the hOT receptor) and incubated for 30min up to 2 days at 37 The cells were plated out into 96-well-plates (60000 cells/well).
Labelling with fluo-4: 50[ig of fluo-4 (Ca2+ sensitive fluorescent dye) were dissolved in pluronic acid (20% in DMSO). The dissolved fluo-4 was then diluted in 10ml DMEM (Dubecco's Minimal Essential Medium)-F12 culture medium. The plates were washed one time with DMEM-F12 medium. 100l of the fluo-4 containing-DMEM-F12 medium were added to the HEK-cells which were incubated for 1.5-2h in this fluorescent medium. Fluo-4 is taken up by the cytoplasm of the cells.
Buffer: 145mM NaC1, 5mM KC1, 1mM MgC1 2 10mM Hepes, 10mM Glucose, EGTA (Ethylene-bis oxyethylene nitrilo tetraacetic acid). The pH was adjusted to 7.4.
Performance of the assay: A minimum of 80pl/well of compounds of formula (5x) in the above buffer (lx) were prepared (96-well-plates). The compounds of formula were added to the 96-well-plates at different concentrations (30 pM, 10 pM, 1 gM, 300 nM, 100 nM, 10 nM, 1 nM, 100 pM, 10 pM). OT was added at a concentration of 40 nM.
WO 03/053437 WO 03/53437PCT/EP02/14594 168- The relative fluorescence of Fluo-4 (Xex= 488i Xem= 590 n) is then measured by the FLIPR in presence or absence of compounds of formula -The fluorescence of the marker being sensitive to the amount of Ca 2 the Ca 2 oeet can be detected. Then, it can be determined the ability of compounds of formnula to antagonize the oxytocin-induced intracellular Ca2 -mobilization mediated by the oxytocin receptor.
The activities of the triazole derivatives according to formula I were assessed using the above described in vitro biological assay. Representative values for some example compounds are given in Table 4. The values refer to the concentration of the test compounds according to formula I necessary to antagonize by 50% the OT/OTR intracellular Ca 2 +-mobilization. From the values, it can be derived that said example compounds according to formula I do exhibit a significant activity as oxytocin receptor antagonists.
Table 4 Inhibition of Ca2+ Chemical Structure IUPAC-Name mobilisation; hOT-R 1C50 1 iM] 3-[5-[(3-chlorobenzyl)sulfanyI]-4-(3- I methoxyphenyl)-4H-1 ,2,4-triazol-3-yI]- 0.026 N-(2-methoxybenzyl)propanamide 5-{5-[(3-chlorobenzyl)sulfanyl]-4- 185 phenyl-4H-1 ,2,4-triazol-3-yl}-N-(2- 0.058 methoxybenzyl)pentanamide 4-{5-[(3-chlorobenzyl)sulfanyl]-4- 137 phenyl-4H-1 ,2,4-triazol-3-yI}-N-(2- 0.486 methoxybenzyl)butanamide WO 03/053437 PCT/EP02/14594 -169d) Functional assay No. 1: Inhibition of vasopressin-mediated Ca 2 -mobilization by FLIPR® (Fluorimetric Imaging Plate Reader) The action of AVP on the Vi-receptor triggers a complex cascade of events in the cell which leads to an increase in the intra-cytoplasmic Ca 2 concentration. This increase in Ca2 concentration results from both calcium release from the sarcoplasmic reticulum (calcium stores) into the cytoplasm and from calcium influx from the extracellular space through Ca 2 channels. This Ca2+mobilization into the cytoplasm triggers the contractile machinery of the myometrial cells which leads to uterine contractions (4 and 19).
This assay can be used to measure the inhibition ofAVP Via-R mediated calcium mobilization by test compounds of formula FLIPR® is a fluorimetric imaging device using a laser (Argon-ion laser) for simultaneous illumination and reading (cooled CCD camera) of each well of a 96-well-plate, thus enabling rapid measurements on a large number of samples.
Preparing the plates: FLIPR-plates are pre-coated with PLL (Poly-L-Lysine) 10pgg/ml 0.1% gelatine to attach the CHO cells (expessing hVia) and incubated for 30min up to 2 days at 37 The cells are plated out into 96-well plates (60000 cells/well).
Labelling with fluo-4: 50pg fluo-4 (fluorescent marker) is dissolved in 201 pluronic acid in DMSO). The dissolved fluo-4 is then diluted in 10ml DMEM (Dubecco's Minimal Essential Medium-F12 medium. The medium is removed from the plates, followed by one wash with DMEM-F12 medium. 1001p of the DMEM-F12 medium containing fluo-4 are added and the cells incubated for 1-1.5h (CHO-cells).
Buffer: 145mM NaCI, 5mM KC1, 1mM MgC12, 10mM Hepes, 10mM Glucose, EGTA (Ethylene-bis oxyethylene nitrilo tetraacetic acid). Adjust to pH 7.4.
WO 03/053437 PCT/EP02/14594 -170- Performance of the assay: A minimum of 80l/well of antagonists (5x) in the above buffer (lx) is prepared (96-well plates). The antagonists can be added to the well-plates at different concentrations (30 AM, 10 pM, 1 pM, 300 nM, 100 nM, 10 nM, 1 nM, 100 pM, pM). AVP is added at a concentration of 40 nM.
The relative fluorescence of Fluo-4 (Xex= 488nm, em= 590 nm) can then be measured by the FLIPR in presence or absence of compounds of formula The fluorescence of the marker being sensitive to the amount of Ca 2 the Ca 2 movements can be detected.
In the same way as for the FLIPR assay with OT receptor expressing cells, the capacity of the triazole derivatives according to formula I, to effectively antagonize AVP-induced intracellular Ca+-mobilization mediated by the action of AVP at the Via-receptor, can be assessed using the above described in vitro biological assay.
e) Functional assay No. 2: Inhibition of P3 (Inositol Tri-Phosphate)-Synthesis in HEK/EBNA-OTR cells The interaction of OT on the OT-receptor leads to the IP3 synthesis, second messenger for Ca 2 release from sarcoplasmic reticulum, involved in the uterine contraction triggering process This assay can be used to show the inhibition of the OT OT-R mediated IP3 synthesis by using test compounds of formula Stimulation of the cells: HEK/EBNA OTR (rat or human) cells are plated out into costar 12-well plates, and equilibrated for 15-24h with 4 pCi/ml radiolabelled 3 Inositol with 1% FCS (0.5ml/well) and without inositol supplement. The medium containing the label is aspirated. DMEM medium (without FCS, inositol), 20mM Hepes (4-(2-hydroxyethyl)-lpiperazine-ethane-sulphonic acid), Img/ml BSA containing 10mM LiC1 (freshly prepared), are added and incubated for 10-15min at 370C. The agonist oxytocin used at a concentration of 10 nM) and the antagonists the tests compounds of formula can be WO 03/053437 PCT/EP02/14594 -171used in a concentration of 10 rM, 1pM, 300 nM, 100 nM, 10 nM, 1 nM, 100 pM, 10 pM, 3 pM) can be added at the required time (15-45min), followed by aspiration of the medium.
In the presence of OT, the radiolabelled inositol is converted to radiolabelled IP3.
Antagonizing OT at the OT-receptor inhibits the IP3 formation.
The amount of the radiolabelled IP3 may be determined through the ensuing work-up. The reaction is stopped with lml STOP-solution 0.4 M perchloric acid), and let sit for at Room Temperature. Then, 0.8ml are transferred into tubes containing 0.4ml of neutralizing solution (0.72 M KOH/0.6M KHC0 3 and the tubes vortexed and kept in the cold at least for 2h.
Separation of IP's: The samples are spun in a table top centrifuge at 3000-4000 rpm for lml of the supernatant is transferred to new tubes containing 2.5ml H 2 0. Packed resin (Dowex AG1X8) is equilibrated with 20ml H20, and the whole samples are poured onto the chromatography columns, thus separating the mixture. To remove free inositol, two washes with 10ml H20 are carried out.
Elution of total IP's: Elution is achieved using 3ml 1M ammonium formate/0.1M formic acid. The eluant is collected in scintillation counting tubes, after the addition of 7ml of scintillation liquid. The amount of 3 H]-IP3 is determined by a scintillating counter.
The ability of compounds of formula(I) to effectively antagonize oxytocin-induced IP3synthesis mediated by the oxytocin receptor, can be assessed using the above described in vitro biological assay.
J) In vivo model for inhibtion of uterine contractions The assay evaluates the biological effect of tested compounds in an in vivo model of preterm labor, premature birth.
WO 03/053437 PCT/EP02/14594 172- Non-pregnant Charles River CD (SD) BR female rats (9-10 weeks old, 200-250g) were treated at 18 and 24 hours before the experiment with 250 [ig/kg, i.p. diethylstilbestrol (DES). For the assay, the animal was anaesthetised with urethane (1.75 g/kg, and placed on a homeothermic operating table. The trachea was isolated and cannulated with a suitable polyethylene (PE) tubing. A midline incision at the hypogastrium level was made and one uterine horn exposed, its cephalic end cannulated with a PE240 tubing and, after filling the internal cavity with 0.2 ml of sterile physiological saline, connected to a "Gemini" amplifying/recording system via a P23ID Gould Statham pressure transducer.
One jugular vein was isolated, cannulated with a PE60 tubing and connected to a butterfly needle to provide an i.v. route of administration of the test compounds via a dispensing syringe.
in the case of intraduodenal administration of the test compounds, the duodenum can be isolated and similarly cannulated through a small incision in its wall.
One carotid artery was also isolated and cannulated with PE60 catheter and connected to a suitable syringe for blood sample collection.
After a stabilization period and throughout the experiment, the same dose of oxytocin was repeatedly injected intravenously at 30-min intervals. When reproducible contractile responses of the uterus to the same OT stimulus (selected dose of oxytocin) were obtained, the dose of the test or of the reference (vehicle) was administered. Further injection cycles of the same dose of oxytocin, were continued (OT injections at 30-min intervals) for a suitable time after treatment to assess the inhibitory effects and the reversibility of these effects.
The contractile response of the uterus to oxytocin was quantified by measuring the intrauterine pressure and the number of contractions. The effect of the reference and test compounds was evaluated by comparing pre- and post-treatment pressure values. In addition, at 2, 30, 90 and 210 minutes after test compound administration, a 0.5-ml blood 173sample was withdrawn from the cannulated carotid artery of each experimental animal.
Plasma was obtained by standard laboratory procedure and the resulting samples were stored at -20 0
C.
The activities of the triazole derivatives claimed in the Formula I can be assessed using s the above described in vivo biological assay. Representative values for one example compound are given in Table 5. The values refer to the capacity of the example compound according to Formula I to effectively antagonize oxytocin-induced uterine contractions in the rat. From the values shown in Table 5 it can be derived that said example test compound according to Formula I does exhibit a significant activity as tocolytic, i.e. uterine-relaxing, agent.
Table Chemical Structure IUPAC-Name %Reduction of Doses [m/1 Uterine Contraction 3-[5-[(3-chlorobenzyl)sulfanyl]-4-(3- 1 methoxyphenyl)-4H-1,2,4-triazol-3-yl]- 16.9 5.1 N-(2-methoxybenzyl)propanamide In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.
N'.Melboume\CasPatent\53000-53999p53301 AU\SpecisT5330I AU Specificati 2007-6-29 doc 29/06/07 WO 03/053437 WO 03/53437PCT/EP02/14594 -174- References: 1. Thibonnier, M. et al. Adv. Rev. Pharmnacol Toxicol. 2001, 41, 175-202.
2. Brinbauer, M. TEM2000, 11, 406-410.
3. Maggi, M. et al. J. Cliii. Endocrinol. Metabol. 1990, 70,1142-1154.
4. Mitchell, B. F. and Schmid, B. J. Soc. Gynecol. Invest. 2001, 8,122-33.
Thibonnier et al. Adv. Exp. M'ed. Biolog. 1998, 449, 251-203.
6. Thorton, S. et al., Experimental Physiooy 200[; 86, 297-302.
7. Evans B. E. et al. .JMed. Chem. 1992, 35, 3919-3927.
8. Gennaro, A. R. et al., Remington's Pharmaceutical Sciences. 18Sth ed. Easton: The Mack Publishing Company, 1995.
9. Moustafa, 0. S. Heterocyci. Commun. 2000, 6, 465-471.
Ashiton, W. T. et al. Med. Chem. 1993, 36, 591-609.
11. Ashton, W. T. at al. (1992) EP 505 111.
12. Carey, Let al. (1982) EP 48555.
13. Bertin, J. et al. (2000) WO 0046220.
14. Ashton, W. T. et al. (1991) EP 409332.
Fritch, Paul C. et al. Solid-Phase Org. Synth. 2001, 1, 105-112 16. Philip J. Kocienski, in "Protecting Groups", Georg Thieme Verlag Stuttgart, New York, 1994.
17. Theodora W. Greene et al. in "Protective Groups in Organic Synthesis", Wileyhiterscience, 1991.
18. Cook, N.D. et al. Pharmaceutical Manufacturing International 1992; p.
49 53 19. Gimpi G. and Fahrenholz, F. Physiological Reviews 2001, 81, 629-683

Claims (11)

175- 1. A triazole derivative of Formula I: R3 RR N A CH2 4' N-N its geometrical isomers, its optically active forms as enantiomers, diastereomers, mixtures of these and its racemate forms, as well as salts thereof, wherein: R' and R 2 are independently selected from the group consisting of H, C 1 -C 6 alkyl, aryl Ci-C 6 -alkyl, heteroarylCI-C 6 -alkyl, C 3 -C 6 -cycloalkyl Ci-C 6 -alkyl and C 3 -C 6 -heterocycloalkyl C -C 6 -alkyl; R' and R2, together with the nitrogen atom they are linked to, form a substituted or unsubstituted 5-8-membered saturated, partially unsaturated or aromatic ring containing optionally one or more additional heteroatoms selected from O, N or S; A is selected from the group consisting of C(O) and SO 2 R is selected from a the group consisting of H, Ci-C 6 -alkyl, aryl Ci-C 6 -alkyl, heteroaryl Ci-C 6 -alkyl, aryl, heteroaryl, C3-C6-cycloalkyl CI-C 6 -alkyl, C 3 -Cs 6 heterocycloalkyl C 1 -C 6 -alkyl and C 2 -C 6 -alkenyl; B is selected from the group consisting of S, O and NR 5 R 4 and R 5 are selected from the group consisting of H, CI-C 6 -alkyl, aryl C,-C 6 alkyl, heteroaryl Ci-C 6 -alkyl, acyl, aryl acyl, heteroaryl acyl, C 3 -C 6 -cycloalkyl Ci-C 6 -alkyl, C 3 -C 6 -heterocycloalkyl Ci-C 6 -alkyl and C 2 -C 6 -alkenyl; n is an integer from 2 to 2. A triazole derivative according to claim I wherein A is carbonyl. 3. A triazole derivative according to claim 1 or 2, wherein B is sulphur. H:\Simeona\Kecp\SMC stds'2002364291.doc 9/0306
176- 4. A triazole derivative according to any one of the preceding claims wherein n is an integer from 2, 3 or 4. A triazole derivative according to claim 1 wherein A is carbonyl, B is sulfur and n is an integer from 2, 3 or 4. 6. A triazole derivative according to any one of the preceding claims selected from the following group: 3- {4-benzyl-5 -I(3-chlorobenzyl)sulfanyl] -4H- 1,2,4-triazol-3-yl methoxybenzyl)propanamide 3- {4-(3-chlorophenyl)-5-[(3-methylbenzyl)sulfanyl] -4H- 1,2,4-triazol-3-yl (2-methoxybenzyl)propanamide 3-[5-[(3-chlorobenzyl)sulfanyl]-4-(3-methoxypropyl)-4H- 1,2,4-triazol-3-yl]-N- (2-methoxybenzyl)propanamide 3- [5-[(3-chlorobenzyl)sulfanyl]-4-(3-methoxyphenyl)-4--1,2,4-triazol-3-yl]-N- (2-methoxybenzyl)propanamide 3- [5-[(3-fluorobenzyl)sulfanyl] -4-(4-methylphenyl)-4H- 1,2,4-triazol-3-yl] methoxybenzyl)propanamide N-(2-methoxybenzyl)-3- {4-(4-methylbenzyl)-5-[(3-methylbenzyl)sulfanyl]-4H- 1 ,2,4-triazol-3-yl~propanamide H:%.Simeorm\Kccp\SMC stds\2002364291 .doc 9/03(06 WO 03/053437 WO 03/53437PCT/EP02/14594
177- 3- {5-[(3-fluorobenzyl)sulfanyl]-4-isobutyl-4H-1,2,4-triazol-3-yl} methoxybenzyl)propanamide 3 -[5-[(3-chlorobenzy1)sulfany]-4-(3-methylpheny)Aw-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3-[5-(benzylsulfanyl)-4-(4-methylphenyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3-[5-(benzylsulfanyl)-4-isobutyl-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3- {4-(3-cblorophenyl)-5-[(4-fluorobenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl}-N-(2- methoxybenzyl)propanamide 3-[5-(benzylsulfanyl)-4-(3-chlorophenyl)-4H-1,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3- {4-isobutyl-5-[(3-methylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)propanamide N-(2-methoxybenzyl)-3 -[5-[(3-methylbenzyl)sulfanyl]-4-Qtetrahydro-2-furanylmethyl)- 4H-1 ,2,4-triazol-3-yl]propanamide N-butyl-3-[5-[(3-chlorobenzy)sulfany]-4-(3-chlorophenyl)-4-14,2,4-triazol-3- yl]propananiide N-(2-methoxybenzyl)-3- {4-(3-methoxyphenyl)-5-[(3-rnethylbenzyl)sulfanyl]y4H- 1,2,4-triazol-3-yllpropanamide 3- {5-[(3-chlorobenzyl)sulfanyl]-4-methyl-4H-1 ,2,4-triazol-3-yl}-N-(2- rnethoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/1159-l -178- 3-r5-r(3-fluorobenzyl)sulfanyl]-4-(tetrahydro-2-furanylmethyl)-4H- 1,2,4-triazol-3-yl]- N-(2-methoxybenzyl)propananiide 3- {4-allyl-5-[(3 -rethylbenzyl)sulfanyl]-4H- 1,2,4-triazol-3-yl}-7N-(2- rnethoxybenzyl)propananiide 3-[5-[(3-fluorobenzyl)sulfanyl]-4-(3-methoxypheny1)-4H-1,2,4-triazo-3-y1I-N-(2- methoxybenzyl)propanamide 3-[5-(butylsulfanyl)-4-(3-methoxypropyl)-4H-1 ,2,4-triazol-3-yl]-N-(4- methoxybenzyl)propanainide N-benzyl-3- {4-(3-methoxypropyl)-5-[(2-phenoxyethiyl)sulfanyl]-41-1 ,2,4-triazol-3- yllpropanarnide 3- {4-benzyl-5-[(2-fluorobenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)propanamide 3-[5-[(3-clilorobenzyl)sulfanyl]-4-(4-fluorophenyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanarmide 3-[5-(benzylsulfanyl)-4-(4-fluorophenyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- rnethoxybenzyl)propanamide 3-[5-[(3-chlorobenzyl)sulfanyl]-4-(3-cblorophenyl)-4H-1,2,4-triazol-3-yl]-N- (cyclopropylmethyl)propananiide 3-[5-[(3-cyanobenzyl)sulfanylj-4-(3-methoxyphenyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3-[5-(benzylsulfanyl)-4-(tetrahydro-2-furanylmethyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propananiide WO 03/053437 WO 03/53437PCT/EP02/14594 -179- N-(2-methoxybenzyl)-3-{4-(3-methoxypropyl)-5-[(3-methylbenzyl)sulfanyl]-4H-1 ,2,4- triazol-3-yllpropananiide 3-[4-allyl-5-(benzylsulfanyl)-4H-1 ,2,4-triazol-3-yl]-N-(2-medhoxybenzyl)propanamide 3-[5-[(3-fluorobenzy~sulfany1]-4-(3-methoxypropyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3- {4-(4-fluorophenyl)-5-[(3-methylbenzyl)sulfanyl]-411-1,2,4-triazol-3-yl) methoxybenzyl)propananiide 3-[5-(benzylsulfanyl)-4-(3-methoxypropyl)-4H-1,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3-[5-I(3-fluorobenzyl)sulfanyl]-4-(4-fluorophenyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propananiide 3- {4-allyl-5-[(3-fluorobenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)propanamide 3- {4-(3-chlorophenyl,)-5-[(3,5-dirnethylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)propanamide 3- {4-(3-chlorophenyl)-5-[(3-fluorobenzyl)sulfanyl]-4H-I ,2,4-triazol-3-yl} -N- isobutyipropanamnide 3-[5-[(3,5-dimethylbenzyl)sulfanyl]-4-(3-methoxyphenyl)-4H-1 ,2,4-tria-zol-3-yl]-N-(2- methoxybenzyl)propanamide 3-{5-[(2-chloro-4-fluorobenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3-yl} furylmcthyl)propananiide WO 03/053437 WO 03/53437PCT/EP02/14594
180- 3-[5-[(3-fluOrObenzY1)sulfanY1]-4-(4-methylbenlZY)-4H-l ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3-4(-hoohnl--(-mtyb y~ufnl-H1 ,2,4-triazol-3-yl} -N- propylpropananiide 3-[5-[(3-chlorobenzyl)sulfany1]-4-(3-chloropheflyl)- 4 H-I ,2,4-triazol-3-yl]-N-(2- mothoxyethyl)propanamide methoxybenzyl)propanamide 3-[5-[(3-chlorobenzy1)sulfafl]-4-(3-cb1orOPheflyl)- 4 H-l ,2,4-triazol-3-yl]-N-(3- methoxypropyl)propanamide 3-{4-(3-chlorophenyl)-5-[(3-methybenlZY)sulfaflYW 4 H-1,2,4-triazol-3-yl}-N- isobutyipropanamide N-2mtoyezl--5[3mtybnzlslay]4 -ehlhnl-H1,2,4- triazol-3-yl]propanamide 3-5[2furbny~ufnl--3mthxpey)4-,,-rao--l--2 methoxybenzyl)propanamide methoxybenzyl)propanamide 3- {4-benzyl-5-[(3 -methylbenzyl)sulfanyl]-4H-l ,2,4-triazol-3-yl} methoxybenzyl)propanamide N-allyl-3- {4-(3-chloropheny)-5-[(3,5-dimethybel)sufal-4H-1 ,2,4-triazol-3- yl}propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 181 3-[5-[(2-fluorobenzy1)sulfany1I-4-(3-methylpheflyl)- 4 H-l ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3-{5-II(4-fluorobenzy)sulfafl-4-isobutyl-4H-l ,2,4-triazol-3-yl} methoxybenzyl)propananiide 3-[5-[(3,5-dimethylbenzy)sufanyI-4-(3-methoxyphelyl)- 4 H-k1 ,2,4-triazol-3-yl]-N- isobutyipropanamide 3- {4-(3-chloropheny1)-5-[(4-fluorobelzy)sulfafl1-4H-l ,2,4-triazol-3-yl} -N- isobutylpropanamide N-uy--5[3clrbny~ufnl-4(-hoohnl-H124tizl3 yl]propanamide 3-[5-[(3-chlorobenzy1)sulfany]-4-(4-chorophefl)-4H-l ,2,4-triazol-3-yl]-N-(2- phenylethyl)propanamide 3-[5-[(2-fluorobenzy1)sulfany1]-4-(3-methoxypropy1)- 4 H-l ,2,4-triazol-3-yl]-N-(2- rnethoxybenzyl)propanamide 3-4(-hoohny)5[3mtybnzlslay]4-,2,4-triazol-3-yl}-N- (tetrahydro-2-fiiranyhmethyl)propalalide 3- {4-(4-chloropheny1)-5-[(3-nethybel)sulfafl]-4H-1,2,4-triazol-3-yl} phenylethyl)propanamiide 3- {4-(3-cblorophenyl)-5-[(3-cyanobel)sulfall- 4 H 4 ,2,4-triazol-3-yl} phenylethyl)prcopananiidc N-4furbny)3[-(,,,,-etfurbny~ufnl--2peyehl-H 1,2,4-triazol-3-yllpropanalnide WO 03/053437 WO 03/53437PCT/EP02/14594
182- 3- {4-allyl-5-[(4-fluorobenzyl)sulfariyl]-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)propananiide 3-[5-[(3-clilorobenzyl)sulfanyl]-4-(3-methylphdflyl)-4H- 1,2,4-triazo1-3-y]-N-, (cyclopropylmethyl)propananiide 3-[5-[(3-cblorobenzy1)sulfanyl]-4-(tetrahydro-2-furaflyflmethyl)- 4 H-l ,2,4-triazol-3-yl]- N-(2-phenylethyl)propanamide 3-[5-(benzylsulfanyl)-4-(3-methoxyphelyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanainide 3-{4-allyl-5-[(3-methylbenzyl)sulfanyl]-4H-1,2,4-triazol- 3 -yl} -N-(tetrahydro-2- ffiranylmethyl)propananiide 3-[5-(allylsulfanyl)-4-(3-methoxyphenyl)-4H-1,2,4-trazol- 3 2 methoxybenzyl)propanarnide N-buty1-3-[5-[(3-chlorobenzy1)sulfanyl]-4-(3-methyphel)-4H-1 ,2,4-triazol-3- yl]propanamide 3- {4-(4-chlorophenyl)-5-[(4-methylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl}-N-(2- methoxyethyl)propananiide 3-[5-(allylsulfanyl)-4-isobutyl-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3-[5-[(4-fluorobenzy1)sulfany]-4-(3-methoxypheflyl)-4H-l ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3- {4-(3-chiloropheny1)-5-[(2-methylbenzy)sulfal-4H-1 ,2,4-triazol-3-yl} phenylethyl)propanamnide WO 03/053437 WO 03/53437PCT/EP02/14594
183- _methoxybenzyl)propanamide 3-[5-[(3-fluorobenzy1)sulfany1]-4-(3-methoxypheflyl)- 4 H-1,2,4-triazol-3-yl]-N- isobutyipropananide 3-{5-[(3,5-dimethylbenzy)sulfany]-4-isobutyl- 4 H- 1,2,4-triazol-3-yl}-N-(2- methoxybenzyl)propanamnide 3-[5-[(4-fluorobenzy)sufal14-(tetrahydro-2-f11ralml2ethyl)- 4 H-l ,2,4-triazol-3-ylI- N-(2-methoxybenzyl)propanamide N-butyl-3 -{5-[(3-chlorobenzy1)sulfany1-4-phely1-4H-1 ,2,4-triazol-3-yllpropanaiide 3-5[3clrbny~ufnl--3mtypey)4-,,-rao--l--3 rnethoxypropyl)propanamnide 3-{4(-hoohnl-5[35dmtybnzlslay]4-,2,4-triazol-3-yl} -N- isobutyipropanamide N-uy--5[3mtylezlslay]4(3mtypey)4-,2,4-triazol-3- yl]propananude N-ly--5[35dmtybny~slay]4(- hxpey)4-,2,4-triazol-3- yl]propanamide 3- {4-(3-cbloropheny1)-5-[(3,5-dimethybel)sulfafl]-4H-1,2,4-triazol-3-yl}-N- (tetrahydro-2-ftiranylmethyl)propananhide 3-[5-(allylsulfanyl)-4-(3-cloropheflyl)-4H-l ,2,4-triazol-3-yl]-N-( 2 methoxybenzyl)propananiide WO 03/053437 WO 03/53437PCT/EP02/14594 -184- 3-[5-[(3-cyanobenzy)sulfany]-4-(3-mfethy1phefl)- 4 H-1,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3-[4-benzyl-5-(benzylsulfanyl)-41l,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propa-namide 3-{4-(4-chloropheny)-5-[(3,5-dimethybenzy)sulfafl1- 4 H-l ,2,4-triazo1-3-y1l-N-(2- plienylethyl)propananiide 3-[5-[(2-fluorobenzy)sulfany]-4-(4-fluorophel)-4H- 1,2,4-triazol-3-yl]-N-(2- mothoxybenzyl)propanamide 3-[5-[(4-fluorobenzy1)sulfany1]-4-(3-mfethoxyphiefyl)-4IIA ,2,4-triazol-3-yl]-N- isobutylpropananiide 3-[5-[(3-chlorobenzy1)sulfany1]-4-(3-methy1pheflyl)- 4 H 1 ,2,4-triazol-3-yl]-N- isobutylpropanamnide 3-[5-[(3-methylbenzy1)sulfanyl]-4-(4-mfethy1pheflyl)-4H-l ,2,4-triazol-3-yl]-N-(2- phenylethyl)propanamide N-(2-methoxybenzyl)-3-{4(-ehxpoy)5[2oo--hnlty~ufnl-H 1 ,2,4-triazol-3-yllpropananiide 3- {4-(4-chloropheny1)-5-[(3,5-dimethybel)sulfall- 4 H-l ,2,4-triazol-3-yl} methoxypropyl)propanamide 3-[5-[(3-fluorobenzy)sulfany1]-4-(3-methoxyphel)-4H-1 ,2,4-triazol-3-yl] -N- propylpropananiide 3-5[4furbny~ufnl--4furpey)4-,,-rao--l--2 methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594
185- 3-[I5-[(3-cblorobenzy)sulfany]-4-(3-c111orophefl)-4H-1 ,2,4-triazol-3-yl]-N-(2- phenylethyl)propanamide 3-[5-(benzylsulfanyl)-4-(3-chlorophenyl)-4H-l ,2,4-triazol-3-yl]-N-propylpropanamide N-benzyl-3- {4-(3-chlorophenyl)-5-[R3-methylbel)sulfafl]l-4H-l ,2,4-triazol-3- yl}propanamide 3-[5-[(2-chloro-4-fluorobenzy)sufany]-4-(3-cI31orophefl)- 4 H-l ,2,4-triazol-3-ylI-N- (2-phenylethyl)propanamide 3- {4-(3-choropheny)5[(4-methybenzy)sufafly11H-1,2,4razol3yl}N-[ 3 2 oxo-l-pyrroliclinyl)propyl]propanamide 3-14(-hoohnl-S[35dmtyb zlslay]4-,2,4-triazol-3-yl} methoxyethyl)propanamnide N-sbtl3[-(-ehlezlsuf l--4mtypey)4-,2,4-triazol-3- yl]propananfide N-butyl-3- {4-(3-chloropheny)-5-[(3-fluorobenzy)sufal-4H-1 ,2,4-triazol-3- yllpropanami~de 3-{4-(3-chlorophenyl)-5-(3-methylbelzyl)sulfafl]l- 4 H-l ,2,4-triazol-3-yl} -N- (cyclopropylmethyl)propanamide 3-[5-[(4-fluorobenzy)sfany]-4-(3-methxyprpy1)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)propanamide 3- {4-(4-cblorophenyl)-5-[(3-methylbenzyl)sulfanyl]- 4 H-l ,2,4-triazol-3-ylI mothoxypropyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594 186 phenylethyl)propanamide 3-[5-[(3-fluorobenzyl)sulfanyl]-4-(4-methylphenyl)- 4 II-l,2,4-triazol-3-yl]-N-(2- phenylethyl)propanamicle 3-f{5-[(3,5-dimethylbenzyl)sulfanyl]-4-isobutyl-4H- 1 ,2,4-triazol-3-yl}-N-(2- phenylethyl)propanamide 3-{4-(3-cbloropheny1)-5-[(3,5-dmethybel)sulfal]-4H-1 ,2,4-triazol-3-yl} phenylethyl)propanamide 3- 4(-hoohnl--(-mtybny~ufnl-H-,,-rao--l--4 methoxybenzyl)propananiide 3- f{4-allyl-5-[(3-methylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} -N-benzylpropanamide N-4mtoyezl--4(-ehxpey)5[3mtybny~ufnl-H 1 ,2,4-triazol-3-yl}propanamide 3- {5-[(2-fluorobenzyl)sulfanyl]-4-methyl-4H-l ,2,4-triazol-3-yl} niethoxybenzyl)propanainide 3- {4-(3-chlorophenyl)-5-[(2-fluorobenzyl)sulfalyl]-4H-l ,2,4-triazol-3-yl} phenyletliyl)propanainide 3- {4-(4-chloropheny1)-5-I[(3-fluorobenzy)sulfafl1- 4 H-l ,2,4-triazol-3-yl} phenylethyl)propanamnide 3- {4-(4-chloropheny1)-5-[(3-cyanobenzyl)sulfany1]-4H-1 ,2,4-triazol-3-yl} phenyletliyl)propananiide WO 03/053437 WO 03/53437PCT/EP02/14594 -187- 3-[5-[(3-cyanobenzyl)sulfanyl]4-(4-fluorophenlY)-4H-1,2,4-fdazol3ylN-( 2 _methoxybenzyl)propananmide N-ly--5[3clroezlslay]4(3mtypey)4--,2,4-triazol-3- yl]propananiide 3- {4-(4-chlorophenyl)-5-[(4-methylbenzyl) sulfanyl]-411-1,2 ,4-triazo 1-3 -yl} methoxypropyl)propanamide N-allyl-3- {4-(3-methoxypheny)-5-[(3-methybenzy)sulfal]-4H-l ,2,4-triazol-3-' yllpropananmide 3-(4-(3-chlorophenyl)-5- {[4-(trifluoromethyl)benzyl]sulfany} -4H-1 ,2,4-triazol-3-yl)- N-isobutylpropanamide 3-[5-[(3,5-dimethylbenzy1)sulfany1]-4-(3-methoxyphefl)-4H-l ,2,4-triazol-3-yl]-N- (tetrahydro-2-ftuanylmethyl)propanamide 3-5(uyslanl--3mtoxpey 4-,2,4-tiazol-3-yl]-N-(2- methoxybenzyl)propananmide N-uy--4(-boopey)5[4mtybezlslay]4-,2,4-triazol-3- yl~propananiide N-ly--5[3furbny~ulay 4(-ehxpey)4-,2,4-triazol-3- yl]propanamide 3- {4-(4-chlorophenyl)-5-[(4-methylbenzyl)sulfalyl]- 4 H-l ,2,4-triazol-3-yl} oxo-1 -pyrrolidinyl)propyl]propanarnide 3- {5-[(2-chloro-4-fluorobenzyl)sulfanyl]-4-methyl-4H-1 ,2,4-triazol-3-yl}-N-(2- methoxybenzyl)propanamide WO 03/053437 WO 03/53437PCT/EP02/14594
188- 3-[5-[(3,5-dimethylbenzyl)sulfanyl]-4-(3-rnetioxypropyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- phenylethyl)propanamide 3- {4-(3-chlorophenyl)-5-[(4-fluorobenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)propanamide N-butyl-3- {4-(3-cblorophenyl)-5-I(2-fluorobenzyl)sulfanyl]-4{-1 ,2,4-triazol-3- yl}propananiide 3-[5-[(3-methylbenzyl)sulfanyl]-4-(4-methylphenyl)-4H-1 ,2,4-triazol-3-yl]-N- propyipropanamide 3- {4-(3-chlorophenyl)-5-[(3-fluorobenzyl)sulfanyl]-4H-1,2,4-triazol-3-yl} -N- propyipropananide 3- {4-(3-cblorophenyl)-5-[(3,5-dimnethylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl}-X-(4- methoxybenzyl)propanamide 3-[5-[(3,5-dimethylbenzyl)sulfanyl]-4-(tetrahydro-2-furanylmethyl)-4H-1,2,4-triazol- 3-yl]-N-(4-methoxybenzyl)propananiide 3- f{4-(4-chlorophenyl)-5-[(2-methylbenzyl)sulfanyl] 41l,2,4-triazol-3-yl} phenylethyL)propanamide N-isobutyl-3- {4-(3-methoxyphenyl)-5-[(3-methylben zyl)sulfanyl]-4H-1 ,2,4-triazol-3- yllpropanamide 4- {5-[(3-chlorobenzyl)sulfanyl]-4-phenyl-4H- 1,2,4-triazol-3-yl) methoxybenzyl)butananiide 4-[5-[(3-chlorobenzyl)sulfanyl]-4-(3-chlorophenyl)-4H-1,2,4-triazol-3-yl]-N-(2- methoxybenzyl)butanannde WO 03/053437 WO 03/53437PCT/EP02/1459-l -189- 4-[5-[(3-clilorobenzyl)sulfanyl]-4-(3-methoxyphenyl)-4H-11,2,4-triazol-3-yl]-N-(2- metlioxybenzyl)butanamiide N-benzyl-4-[5-[(3-cblorobenzyl)sulfanyl]-4-(3-chlorophenyl)-4H-1 ,2,4-triazol-3- yl]butanamide N-(2-methoxybenzyl)-4- {4-(3-methoxyphenyl)-5-II(3-methylbenzyl)sulfanyl]-4H- 1,2,4-triazol-3-yllbutanamide 4-[5-[(3-chlorobenzyl)sulfanyl]-4-(3-methoxypropyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)butanamide 4-[5-[(3-chlorobenzyl)sulfanyl]-4-(3-xnethoxypropyl)-4H-1 ,2,4-triazol-3-yl]j-N-(2- phenylethyl)butanamide 4-[5-[(3-chlorobenzyl)sulfanyl]-4-(3-methoxyphenyl)-4H- 1,2,4-triazol-3-yl]-N-(4- fluorobenzyl)butananiide 4-[5-[(3,5-dimethylbenzyl)sulfanyl]-4-(3-methoxyphenyl)-4H-1I,2,4-triazol-3-yl]-N-(2- methoxybenzyl)butanamide N-(4-fluorobenzyl)-4-4-(3-methoxypheny)-5-[(4-methylbenzyl)sulfanyl]-41-1 ,2,4- triazol-3-yl}butanamide 4-[5-[(3-fluorobenzyl)sulfanyl]-4-(3-methoxyphenyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)butananiide 4- {4-(3-methoxyphenyl)-5-[(3-methylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} phenylethyl)btitananiide N-(1 ,3 -benzodioxol-5-ylmethyl)-4-(4-(3-methoxypropyl)-5- {[(2E)-3-phenyl-2- propenyl] sulfanyl}-4H-1 ,2,4-triazol-3-yl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -190- 4- {4-(3-chloropheny)-5-iI(2-fluorobel)sulfafl1-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)butanarnide N-b enzyl-4- {4-(3-methoxypheny)-5-[(2-methybelZY)sulfafl]-4H-l ,2,4-triazol-3- ylbutanamide N-ezl4[-(-horbny~ufnl -(-ehxpey)4-,2,4-triazol-3- yl]butananiide N-(4-fluorobenzyl)-4- {4-(3-methoxypheny)-5-[(2-methybel)sulfaflY1 4 H-1, 2 4 triazol-3-yllbutanamide 4-[5-[(3-chlorobenzy1)sulfany1]-4-(3-mehoxyp1eflyl)- 4 H-l ,2,4-triazol-3-yl]-N- isobutylbutanamide N-(4-fluorobenzyl) {4-(3-methoxypheny)-5-[(2,3,4,5,6-petafluorobel)sulfaflI 4H-1 ,2,4-triazol-3-yllbutananiide 4- 4(-hoohnl--(-mtybny~ufnl-H-,,-rao--l--2 rnethoxybenzyl)butanamide 4-[5-[(3-chlorobenzy1)sulfany1]-4-(3-methoxyphefl)- 4 H-l ,2,4-triazol-3-yl]-N- propylbutanamide 4-[5-[(4-fluorobenzy1)sulfany1]-4-(3-methoxyphefli)- 4 H-l ,2,4-triazol-3-yl]-N-(2- rnethoxybenzyl)butananiide 4-[5-[(3-chlorobenzyl)sulfany1]-4-(3-cb1oropheflyl)-4H-l .2,4-triazol-3-yl]-N-(4- fluorobenzyl)butanamide 4-[5-[(3-cblorobenzy1)sulfany1]-4-(3-mfethoxyphefl)-4H-l ,2,4-triazol-3-yl]-N-(4- methoxybenzyl)butanamide WO 03/053437 WO 03/53437PCT/EP02/14594 191 4-[5-[(3-chlorobenzy)sulfany]-4-(3-chlorophel)-4H-1 ,2,4-triazol-3-yl]-N- (tetrahydro-2-furanymethyl)butalalide N-benzyl-4- {4-(3-ch~orophenyl)-5-[(3,5-dimethybel)sulfanly-4H-1,2,4-rao1a- 3 yl}butanamide 4-[5-[(3-fluorobenzyl)sulfany1]-4-(3-methoxyphel)-4H-l ,2,4-triazol-3-yl]-N-(2- phenylethyl)butanam-ide 4- {4-(3-chlorophenyl)-5-[(3-cyanobenzy)sulfafl-4H-l ,2,4-triazol-3-yl} methoxybenzyl)butanan-ide 4-[5-[(3-chlorobenzy1)sulfany1]-4-(3-chlorophefl)-4H-l ,2,4-triazol-3-yl-N-(4- methoxybenzyl)butanamide 4-[5-[(3-cyanobenzy1)sulfany1]-4-(3-methoxyphefl)- 4 H-l ,2,4-triazol-3-ylI-N-(2- methoxybenzyl)butanamide N-isobutyl-4- {4-(3-methoxypheny1)-5-[(3-methybenzy)sulfal-4H- 1,2,4-triazol-3- yl~butanamide N-(4-methoxybenzyl)-4- {4-(3-methioxypheny1)-5-[(4-methybel)sulfaflyl]-4H- 1,2,4-triazol-3-yl}butanan-dde 4-[5-[(3,5-dimethylbenzy)sufany]-4-(3-mthoxyphel)-4H-l ,2,4-triazol-3-yl]-N-(2- phenylethyl)butanamide N-b enzyl-4- {4-(3-chlorophenyl)-5-[(3-methylbelzyl)sulfaflyl]-4H-l ,2,4-triazol-3- yllbutananlide 4-[5-[(2-chloro-4-fluorobenzy)sufay]-4-(3-cborophel)-4H-1 ,2,4-triazol-3-yl]-N- (2-methoxybenzyl)butananiide WO 03/053437 WO 03/53437PCT/EP02/14594 -192- N-ly--5[3clroezlslay]4(3clrpey)4-,2,4-triazol-3- yl]butanarnide 4-[I5-[(3-chorobenzy)sufany]-4(3-cbloropheny)-4H-1,2,4-triazol-3-yl]-N- isobutylbutananiide 4-[5-[(3,5-dimethylbenzyl)sulfanyl]-4-(3-methoxypheflyl)-4H-1 ,2,4-triazol-3-yl]-N-(4- fluorobenzyl)butanamide N-benzyl-4- {4-(3-chlorophenyl)-5-[(3-fluorobenzyl)sulfanyl]-4H-1 ,2,4-triazol-3- yllbutanamnide N-benzy1-4-I5-(benzylsulfany)-4-(3-clhloropheny1)-4H-1 ,2,4-triazol-3-yl]butanarnide 4- {4-(3-chlorophenyl)-5-[(2-phenylethyl)sulfanyl]-4-l 1,2,4-triazol-3-yl}-N-(2- methoxybenzyl)butananiide 4-[5-(3,5-dimethylbenzy1)sulfany1-4-(3-methoxypropy)-4H-1 ,2,4-triazol-3-yl]-N-(2- phenylethyl)butananiide N-benzyl-4- {4-(3-rnethoxyplienyl)-5-[(3-methylbenzy)sulfany1II-4H-l ,2,4-triazol-3- yllbutanainide 4-[5-[(3-olilorobenzyl)sulfanyl]-4-(3-chlorophenyl)-4H-1 ,2,4-triazol-3-yl]-N- propylbutanamide 4- {4-(3-chlorophenyl)-5-L(2-methylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl}-N-(4- fluorobenzyl)butananiide 4-[5-[(3,5-dimethylbenzyl)sulfanyl]-4-(3-rnethoxyphenyl)-4H-1 ,2,4-triazol-3-yl] -N- propylbutananide WO 03/053437 WO 03/53437PCT/EP02/14594 193 4-[5-[(cyclohexylmethyl)sulfany1]-4-(3-methoxyphel)-4H- 1,2,4-triazol-3-yl]-N-(2- mothoxybenzyl)butanan-ide 5-[5-[(3-cblorobenzy)sulfany]-4-(3-chorophel)- 4 HIl,2,4-triazol-3-yl]-N-(2- methoxybenzyl)pentanamide 5- {5-[(3-chlorobenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)pentanam-ide {4-(3-methoxypropyl)-5-[(3-methybenzy1)sulfafl]-4H-l ,2,4- triazol-3-yIlpentanamide 5-[5-[(3-cblorobenzy1)sulfany1]-4-(3-chlorophel)-4H-1 ,2,4-triazol-3-yl]-N- isobutylpentanamide {4-allyl-5-[(3-methylbenzyl)sulfanyll-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)penta-namide N-(2-methoxybenzy)-5-[5-[(3-methybenzy)sufalI-4-(2-phelethy1)-4H-1,2,4- triazol-3-yl]pentanarnide N-(2-methoxybenzyl)-5- {5-[(3-methylbenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3- yllpentanamide {4-(3-chloroplienyl)-5-[(2-fluorobenzylsulfalyll-4HT-l,2,4-triazol-3-yl} methoxybenzyl)pentananiide 5-[5-I(3-fluorobenzy)sulfany1-4-(3-methoxypropyl)-4H-l ,2,4-ffiazol-3-yl]-N-(2- methoxybcnzyl)pentanamide 5-[5-[(3-cblorobenzyl)sulfanyl-4-(3-chloropheflyl)-4H-1 ,2,4-triazol-3-yl]-N-(4- fluorobenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -194- 5-[5-I(3,5-dimethylbenzy1)siffany11-4-(2-phenylethy1)-4H-1 ,2,4-triazol-3-yl]-N- isobutylpentanamide {5-[(3-chlorobenzyl)sulfanyl]-4-phenyl-4H- 1,2,4-triazol-3-yllpentananide {5-[(3-f-Luorobenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)pentanamide 5-[5-(benzylsulfanyl)-4-(3-methoxypropyl)-4H-l ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)pentanamide {4-(3-cblorophenyl)-5-[(4-metbylbenzyl)sulfaflyl]-4H-l ,2,4-triazol-3- yllpentananiide 5- {4-allyl-5-[(3,5-dimethiylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} rnethoxybenzyl)pentananiide {4-allyl-5-[(3-chlorobenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)pentanamide 5-[5-(benzylsulfanyl)-4-phenyl-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)pentananiide 5-[4-allyl-5-(benzylsilfanyl)-41-1 ,2,4-triazol-3-yl]-N-(2-methoxybenzyl)pentanamide 5-[5-[(3,5-dimethylbenzyl)sulfanyl]-4-(2-phenylethyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- phenylethyl)pentanamnide 5-[5-[(3-chlorobenzy1)sulfany1-4-(2-phenylethyl)-4H-l ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)pentananiide -chlorophenyl)-5-[(2-mnethylbenzyl)sulfalyl]-4H- 1,2,4-triazol-3- yIlpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -195 {4-allyl-5-[(3-fluorobenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)pentananiide N-(1 ,3-benzodioxol-5-ylmethyl)-5-[5-[(2-methylbenzyl)sulfanyl]-4-(2-phenylethyl)- 4H-1 ,2,4-triazol-3-yI]pentanamide 5-[5-[(3,5-dimethylbenzyl)sulfanyl]-4-(2-phenylethyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)pentananiide {5-[(2-fluorobenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)pentananiide 5-[5-[(3-lorobenzyl)sulfanyl]-4-(2-phenylethyl)-4H--1,2,4-triazol-3-yl]-N-(4- fluorobenzyl)pentanarmide {4-(3-cblorophenyl)-5-[(2,3,4,5,6-pentafluorobenzyl)sulfaiyl]-4H- 1,2,4- triazol-3-yllpentanamide 5-[5-[(3,5-dimethylbenzyl)sulfanyl]-4-(3-rnethoxypropyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)pentanamride 5- {4-(3-chlorophenyl)-5-[(4-methylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} -N- (tetrahydro-2-furanyhnethyl)pentanamide N-benzyl-5-[5-[(3-chlorobenzyl)sulfanyl]-4-(3-chlorophenyl)-4- 1,2,4-triazol-3- yl]pentananmide {5-[(3-cblorobenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3-yl} fluorobenzyl)pentananiide {4-(3-cblorophenyl)-5-[(3-cyanobenzyl)sulfanyl]-4H-1,2,4-tiazol-3-yl} methoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 196 {4-(3-cbloropheny1)-5-IX2-methylbenzy1)sulfafl]-4H-l ,2,4-triazol-3-yl} -N- (tetrahydro-2-furanethyl)pentalalide 5-[5-(benzylsulfanyl)-4-(3-chlorophienyl)-4fl-l ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)pentanamide 5-{5-[(3,5-dimethylbenzyl)sulfanyl]-4-pheflyl-4H-l ,2,4-triazol-3-yl}-N-(2- mnethoxyethiyl)pentananiide 5-[5-[(3-methylbenzy1)sulfanyl1-4-(2-pheflethy1)-4H-1 ,2,4-triazol-3-yl]-N-(2- phenylethyl)pentanamide N-ly--5[3clroezlslay 4(3clrpey)4--,2,4-triazol-3- yl]pentanamide 5-5[2clr--looezlsufnl -3clrpey)4-,2,4-triazol-3-yl]-N- isobutylpentananiide {5-[(3,5-dimethylbenzyl)sulfanyl]-4-phellyl-4H- 1 ,2,4-triazol-3- yl}pentanamide 5- {4-(3-chloropheny1)-5-[(2,3,4,5,6-pentaflorobenzy)sulfafl]- 4 H-l ,2,4-triazol-3- yl} -N-(2-methoxybenzyl)pentanamide {5-[(3,5-dimethylbenzyl)sulfanyll-4-phenyl-4H- 1 ,2,4-triazol-3-yll -N-[3-(2-oxo-1 pyrrolidinyl)propyljpentanamide {5-[(3,5-dimnethylbenzy1)sulfany1]-4-phenyl-4H-1,2,4-triazo1-3-yl}-N-( 2 methoxybenzyl)pentananiide ,5-dimethylbenzy1)sulfany]4(3-methoxypropy)-4H-1,2,4-razo 3 yl]FN{ 4 fluorobenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594
197- 5-[5-[(3-cblorobenzy1)sulfany1]-4-(2-phenylethy)-4H-1,2,4-trazC1-3-ylI-N- propylpentanamide {4-(3-chlorophenyl)-5-[(3-fluorobenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)pentananiide 5- {4-allyl-5-[(4-methylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)pentanarnde 5-[5-[(2-fluorobenzyl)sulfanyl]-4-(2-phenylethyl)-4H-1 ,2,4-triazol-3-ylJ-N-(2- methioxybenzyl)pentanarnide {4-(3-methoxypropyl)-5-[(3-rnethylbenzyl)sulfanyl]- 4 H 1 ,2,4- triazol-3-yllpentananiide {4-(3-cbloropheny)-5-[(2-fluorobenzy1)sulfaflF4H-l ,2,4-triazol-3-yl} fluorobenzyl)pentanamide 5-{4-(3-chlorophenyl)-5-[(4-methylbenzyl)silfalyl]-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)pentanarmde N-(4-methoxybenzyl)-5- {5-[(4-methylbenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3- yllpentanamide 5-[5-[(3-chlorobenzy1)sulfany]-4-(tetrahydro-2-fi.1aflmthy)-41-1,2, 4 -tlazol 3 -ylF N-(2-phenylethyl)pentartamide 5-{4-(3-chlorophenyl)-5-[(4-methylbenzyl)sulfaflyl]-4H-l ,2,4-triazol-3-yl} -N- isobutylpentanamide 44-(3-methoxyphenyl)-5-[(3-methylbenzyl)sulfall-4H-1 ,2,4-triazol-3-yl} phenylethyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -198- 5-5[2clr--looezlslayl4(-hoohnl-H124tizl3y]N (tetrahydro-2-furanyhnethyl)pentaflamide 5-[(3-methylbenzyl)sulfanyl] -4-phenyl-4H-1 ,2,4-triazol-3- yllpentanamide N-ezl5[-(-hoo--looezlslay] -3clrpey)4-,2,4- triazol-3-yl]pentanamide N-(4-fluorobenzy)-5-[5-[(2-methybel)sulfafl]-4-(2-pheflethyl) 4 H-1,2,4- triazol-3-yljpentanamide 5-[5-I(3clorobenzy)sufany1-4-(2-phenylethyl)-4H-1 ,2,4-triazol-3-yl] -N- isobutylpentananiide {5-[(3-methylbenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3- yllpentanam-ide {4-(3-methoxyphenyl)-5-[(4-methylbenzyl)sulfalyl]-4H-1 ,2,4-triazol-3-yl}-N- propylpentanamide 5-f {5[(3,5-dimethylbenzy1)sulfany1]-4-pheny1-4H-1,2,4-triazo1-3-yl}-N-( 3 methoxypropyl)pentananide N-benzyl-5-[5-[(3,5-dimethylbenzy)sulfany1]-4-(2-phelethyl)- 4 H-l ,2,4-triazol-3- yl]pentanamide {5-I(3-methylbenzy1)sulfany1I-4-pheny1-4H-1 ,2,4-triazol-3-yl} phcnylcthyl)pentanamide {5-[(3-methylbenzyl)sulfanyll-4-plienyl-4H-1 ,2,4-triazol-3- yllpentananiide WO 03/053437 WO 03/53437PCT/EP02/14594 -199- {5-[(3,5-dimethylbenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4- triazol-3-yllpentananiide 5-{5-[(3,5-dimethylbe-nzyl)sulfanyl]-4-plienyl-4H-l ,2,4-triazol-3-yl) -N- propylpentananuide 5-[5-[(3,5-dimethylbenzy1)sulfanyl]-4-(3-methoxyphefl)-4H-l ,2,4-triazol-3-yl]-N-(2- phenylethyl)pentanamide {4-(3-chlorophenyl)-5-[(3-methylbenzyl)sulfalyl]-4H- 1,2,4-triazol-3- yllpentanamide {5-[(4-methylbenzyl)sulfanyl]-4-phenyl-4H- 1,2,4-triazol-3- yllpentanamide 5-{4(-boohnl -(-mtybny~ufnl-H-,,-rao--l--4 methoxybenzyl)pentananiide {4-(3-chloroplieny1)-5-[(3,5-dimethybel~y)sulfaflyl-4H- 1,2,4-triazol-3-yl} phenylethyl)pentananiide 5- {4-(3-cblorophenyl)-5-[(3,5-imethylbenzy)sulfafl]-4H-1 ,2,4-triazol-3-yl} (2-oxo-1 -pyrrolidinyl)propyl]pentanamide {4-(3-chlorophenyl)-5-[(3-methylbenzyl)sulfanyl]-4H-l ,2,4-triazol-3-yl} phenylethyl)pentanamide 5-[5-[(3-fluorobenzyl)sulfanyl]-4-(2-phenylethyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- mcthoxybenzyl)pentanamide {4-(3-chloropheny)-5-[(2-methybelzy)sulfal-4H-1 ,2,4-triazol-3-yl}-N-(2- methoxybenzyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/1459-l -200- 5-{4-allyl-5-[(3-methylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl}-N-(4- fluorobenzyl)pentananiide {4-(3-chlorophenyl)-5-[(2-oxo-2-phenylethyl)sulfaflyl]- 4 II 4 ,2,4-triazol-3- yllpentanarnide 5- {4-(3-chloropheny1)-5-[(3-methylbenzy)sulfafl]-4H-l,2, 4 -tlazol- 3 -yl} oxo-1 -pyrrolidinyl)propyl]pentanamide {4-(3-metlioxyphenyl)-5-[(2-methylbenzyl)sulfafll-4H- 1 ,2,4-triazol-3-yllpentanamide {5-[(3-methylbenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3-yl} -N-[3-(2-oxo-1 pyrrolidinyl)propyl]pentanamide {4-(3-chlorophenyl)-5-[(4-methylbenzyl)sulfalyl]-4H-1 ,2,4-triazol-3- yl~pentananiide N-ly--5[2clr--looezy ufnl--3clrpey)4-,2,4-tiazol- 3-yl]pentanamide 5- {4-(3-chlorophenyl)-5-[(2-methylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} -N- isobutylpentananiide {5-[(4-methylbenzyl)sulfanyl]-4-phenyl-4H-1,2,4-tiazol- 3 yllpentanam'ide 5-[5-[(3-chlorobenzyl)sulfanyl]-4-(3-methoxypropyl)-4H-l ,2,4-triazol-3-yl]-N-(2- phenylcthyl)pentananiide 5-5[2clr--lorbny~ufn (-hnlty)4-,2,4-triazol-3-yl]-N- propylpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 201 {4-(3-chlorophenyl)-5-[(3-cyanobenzy)sulfafl]-4H- 1,2,4-triazol-3- yilpentanamide 5-[5-[(3-chlorobenzy1)sulfany1]-4-(3-ch1orOphefl)-4H-l ,2,4-triazol-3-yl]-N- propylpentananide N-(2-methoxyethyl)-5- {5-[(3-rnethylbenzyl)sulfanyl]-4-phelyl-4H-1 ,2,4-triazol-3- yllpentananiide N-[3-(2-oxo-1 -pyrrolidinyl)propylll-5-(4-phenyl-5- (trifluoromethyl)benzyl]sulfanyl} -4H-1 ,2,4-triazol-3-yl)pentanamide 5-{5-I{3,5-dimethylbenzy1)sulfany1]-4-phefl-4H-1 ,2,4-triazol-3-ylI phenylethyl)pentanamide {5-[(3,5-dimehylbenzy)sulfanyl]-4-phel-4H-1 ,2,4-triazol-3- yl}pentananiide ufnl--2peyehl-H1,2,4- triazol-3-yllpentanamide 5- 4(-hoohnl-5[2oo2peyety~ufnl H1,,-rao--l-N-(4- methoxybenzyl)pentanamide N-ccorplehl--5[35dmtybny~uail--3mtoyhnl-H 1 ,2,4-triazol-3-yl]pentanarnide {5-I(3-methylbenzyl)sulfany1]-4-phefly1-4H4-l,2,4-triazol-3-yl}pentanamide 5- {4-(3-methoxypieny)-5-[(4-methybel)sufal-4H-1 ,2,4-triazol-3-yl) oxo-1-pyrrolidinyl)propyl]pentanamide 5-[5-(benzylsulfanyl)-4-phenyl-4H-1 ,2,4-triazo1-3-y1]-N-(4-fluorobenzy1)pefltaflaflde WO 03/053437 WO 03/53437PCT/EP02/14594 -202 5-[5-[(3-chlorobenzyl)sulfanyl]-4-(3-methoxyphenyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- phenylethyl)pentanamide 5-[5-[(4-fluorobenzyl)sulfanyl]-4-(2-phenylethyl)-4H-l ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)pentanam-ide N-allyl-5- {5-[(3,5-dimethylbenzyl)sulfanyl]-4-phenyl-4H-1,2,4-triazol-3- yl}pentanamide {5-[(4-methylbenzyl)sulfanyl]-4-phenyl-4H-1,2,4-triazol-3- yl}pentanamide 'N-butyl-5-[5-[(3-cblorobenzyl)sulfanyl]-4-(3-chlorophenyl)-4H-1 ,2,4-triazol-3- yl]pentananiide 5-[5-[(3-chlorobenzyl)sulfanyl]-4-(3-cblorophenyl)-4H-1 ,2,4-triazol-3-yl]-N- (cyclopropylmethyl)pentananiide N-(4-fluorobenzyl)-5-[5-[(3-methylbenzyl)sulfanyl]-4-(2-phelylethyl)-4H-1 ,2,4- triazol-3-yl]pentanamnide N-(cyclopropylme-thyl)-5-(4-phenyl-5- {[4-(trifl-uoromethyl)benzyl]sulfanyl} -4H-1 ,2,4- triazol-3-yl)pentananiide {4-allyl-5-[(3,5-dimethylbenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} fluorobenzyl)pentanamide N-isobutyl-5-[5-[(2-methylbenzyl)sulfanyl]-4-(2-phenylethyl)-41l,2,4-triazol-3- yl]pentanamnide 5-[5-[(3,5-dimethylbenazyl)sulfanyl]-4-(3-methoxyphenyl)-4H-1 ,2,4-triazol-3-yl]-N-[3- (2-oxo-1-pyrrolidinyl)propyllpentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -203- 5-[5-[(2-cbloro-4-fluorobenzyl)sulfanyl]-4-(3-chloropheflyl)-4H-1I,2,4-triazol-3-yl]-N- (2-methoxybenzyl)pentanamide {5-[(3-methylbenzyl)sulfanyl]-4-phenyl-41-1 ,2,4-triazol-3-yl}-N- propylpentanamnide 5-[5-[(3-clilorobenzyl)sulfanyl]-4-(3-methoxypheflyl)-4H-l ,2,4-triazol-3-yl] -N- (cyclopropylmethyl)pentanami dc {4-(3-chloropheny1)-5-II(4-fluorobenzy)sulfanyl]-4H-1 ,2,4-triazol-3-yl} phenylethyl)pentanamide {4-(3-methoxyphenyl)-5-[(3-iethylbenzyl)sufal-41-1 ,2,4- tiazol-3-yl~pentanam-ide {4-(3-chlorophenyl)-5-[(3-cyanobenzyl)sulfanyl]-4H-1 ,2,4-triazol-3-yl} fluorobenzyl)pentanamide f{5-[(3-clilorobenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3-yl}-N- isobutylpentanamide 5-[5-(benzylsulfanyl)-4-(3-chlorophenyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- phenylethyl)pentanamide {4-(3-clilorophenyl)-5-[(2,3,4,5,6-pentafluorobenzyl)sulfalI- 4 H-l ,2,4- triazol-3-yllpentanam-ide N-(2-methoxybenzyl)-5-[5-[(2-methybenzy)sulfafl1-4-(2-pheflethyl)- 4 H-l, 2 4 triazol-3-yl]pentananiide 5-[5-[(3,5-dimethylbenzyl)sulfanyl]-4-(2-pheflylethyl)-4H-1 ,2,4-triazol-3-yl]-N-(4- fluorobenzyl)pentananiide WO 03/053437 WO 03/53437PCT/EP02/14594 204 f{5-[(4-methylbenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3- yl~pentanamide {5-[(3-methylbenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3- yllpentanamide 5-{4-benzyl-5-[(3-methylbenzyl)sulfanyl]-4H- 1,2,4-triazol-3-yl} -N-[3-(2-oxo-1 pyrrolidinyl)propyl]pentanamide {4-(3-methoxypropyl)-5-[(3-methylbenzyl)sulfaflyl]-4H-1 ,2,4-triazol-3- yl}pentanamide {4-(3-chlorophenyl)-5-[(2,3,4,5,6-pentafluorobelzyl)sulfaflyl]- 4 H-l ,2,4-triazol-3- yl} -N-isobutylpentananfide N-4mtoyezl--5[23456pnalooezlslay]4(-hnlty) 4H-1 ,2,4-triazol-3-yl]pentananiide -3choohnl-H12,4-triazo1-3-y1]pentanarnide 5-[5-(butylsulfanyl)-4-(3-chloophenyl)-41-1 ,2,4-triazol-3-yl]-N-isobutylpentanamide N-(cyclopropylmethyl)-5- {4-(3-methoxyphenyl)-5-[(3-methylbenzyl)sulfal]l-4H- 1 ,2,4-triazol-3-yllpentanamide {4-allyl-5-[(3,5-diirnethylbenzyl)sulfanyll-4H-1 ,2,4-triazol-3-yl) phenylethyl)pentananiide 5-[5-[(3,5-dimethylbenzyl)sulfanyl]-4-(2-pheflylethyl)-4H-1 ,2,4-triazol-3-yl]-N-(4- methoxybenzyl)pentanarride {4-(3-chlorophenyl)-5-[(2-fluorobenzyl)sulfanyl]-4H-1 ,2,4-triazol-3- yllpentananiide WO 03/053437 WO 03/53437PCT/EP02/14594 205 5-[5-[(3-chilorobenzy)sulfany]-4-(3-Cb1orophel)-4H-1 ,2,4-triazol-3-yl]-N-(2- methoxyethyl)pentananiide {4-(3-methoxyphenyl)-5-[(4-methylbeflzyl)sulfafl]l-4H- 1 ,2,4-triazol-3-yllpentanarnide 5- f{4-(3-chlorophenyl)-5-[(2-met1ylbenzy1)sulfany11-4H-1 ,2,4-triazol-3-yl} fluorobenzyl)pentananiide 5-[5-II(3-chlorobenzy1)sulfany1]-4-(2-phelethy1)-4H-1 ,2,4-triazol-3-yl]-N- (tetrahydro-2-faranylmnethyl)pentananiide {4-(3-chorophenyl)-5-[R2,3,4,5,6-pentafluorobefly)sUfafylF4H-1,2,4-triazol-3- yl}I -N-(4-methoxybenzyl)pentanamide 5-[5-(butylsulfanyl)-4-(3-chlorophenyl)-4H-1 ,2,4-triazol-3-yl]-N-(2- rnethoxyethyl)pentanarnide N-benzyl-5-I[5-(benzylsulfany1)-4-phel-4H-1 ,2,4-triazol-3-yl]pentanamide {5-[(3,5-dimethylbenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3-yl} -N- isobutylpentaniamide 5-5[4furbezlslay]--hnl4-,2,4-triazol-3 -yl} methoxybenzyl)pentanamide {4-benzy1-5-[(3,5-dimethybenzy)sufal]-4H-1 ,2,4-triazol-3-yl} -N-[3-(2-oxo-1- pyrrolidinyl)propyl]pentanam-ide 5-(4-(3-chloroplienyl)-5- f{[(2E)-3-phenyl-2-propenyllsulfanylI -4H-1 ,2,4-triazol-3-yl)- N-isobutylpentanamnide WO 03/053437 WO 03/53437PCT/EP02/14594
206- {4-(3-chlorophenyl)-5-[(3-fluorobenzyl)sufalyll-4H-1 ,2,4-triazol-3-yl} phenylethyl)pentanamide 5-[5-[(2-methylbenzyl)sulfanyl]-4-(2-phenylethyl)-4H- 1,2,4-triazol-3-yl]-N- propylpentananiide N-allyl-5- {4-(3-cbloropheny1)-S-[(2-methylbenzy)sulfanyl1-4H-1 ,2,4-triazol-3- yllpentanamide N-butyl-5-(4-phenyl-5- {[4-(trifluoromethyl)benzyl]sulfanyl} -4H-1 ,2,4-triazol-3- yl)pentanamide {5-[(3-chlorobenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3-yl} -N-(tetrahydro-2- fuaranylmethyl)pentanamide 5-[5-[(4-fluorobenzy1)sulfany1I-4-(3-methoxypropyl)- 4 H-l ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)pentananmide {5-[(3-methylbenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3- yl~pentananiide N-sbtl5[-(-x--hnltylslay]4(-hnlty) -,2,4-triazol-3- yllpentanamide f{5-[(3-fluorobenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3 -ylI phenylethyl)pentananiide N-(2-methoxyethyl)-5-(4-phenyl-5- {[4-(trifluoromethyl)benzyl]sulfanyl}-4H-1 ,2,4- triazol-3-yl)pentanamide {5-[(4-methylbenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3-yl}-N-(tetrahydro-2- furanylmethyl)pentanamide WO 03/053437 WO 03/53437PCT/EP02/14594 -207 {4-(3-chlorophenyl)-5-[(3,5-dirnethylbenl~)sulfanl1-4H-1,2, 4 -tflazol- 3 -yl -N- propylpentanamide. I- I {4-(3-chloropheny1)-5-[(4-methybenzy)sulfal]- 4 H-l ,2,4-triazol-3- yllpentananiide 5-[5-[(3-chlorobenzy1)sulfany1]-4-(3-chlorophefl)-4H-l ,2,4-triazol-3-yl]-N-(3- methoxypropyl)pentanamide 5-{4-(3-chloropheny1)-5-[(2-oxo-2-pheylethy)sulfal]l-4H-l ,2,4-triazol-3-yl} -N- (tetrahydro-2-furanylmethyl)pentanamideI 5-{5-[(3,5-dmetlbenzy)sulfany1]-4-pheny1-4H-1 ,2,4-triazol-3 -yl} -N-(tetrahydro-2- furanylmnethyl)pentanamide N-(3-methoxypropyl)-5-(4-phenyl-5- {[4-(trifhioromethyl)benzyl]sulfanyl}-4H-1 ,2,4- triazol-3-yl)pentanan-ide {4-(3-chloropheny)-5-[(4-fluorobenzy)s.1fal]-4H-1,2,4-trazol- 3 -yl} rnethoxybenzyl)pentanamnide 5-(4-(3-cblorophenyl)-5- {[4-(trifluoromethyl)benzyl]sulfanyl} -41-1 ,2,4-triazol-3-yl)- N-[3-(2-oxo-1-pyrrolidinyl)propyl]pentanamnide ufnl4(-hnlty)4-,2,4-triazol- 3-yl]pentanamide 5-5[2clr--looezlslay]4-2peyehl-H124tizl3y]N (2-methoxybenzylpentanamide (-hnlty)4-,2,4-triazol-3- yl]pentananiide WO 03/053437 WO 03/53437PCT/EP02/14594 208 4 3 -cblorophenyl)-5-[(3-cyanobenzyl)sulfanyl-4H1,2,4-triazol-3yl} metlioxybenzyl)pentanamide 4 3 -chlorophenyl)-5-I(2-oxo-2-phenylethyl)sulfanyl]4H 1,2,4-triazol-3-yll -N- isobutylpentananiide 5- f{4-benzyl-5-[(3-methylbenzyl)sulfanyl]y4H-1,2,4-triazol-3-yl}-N-(2- methoxyethyl)pentanarnide N-(1 3 -benzodioxol-5-ylmethyl)-5-[5-[(3-chlorobenzyl)sulfanyly4-(2-phenylethyl). 4H-1 ,2,4-triazol-3-yl]pentananiide 5-[5-[(3-chlorobenzyl)sulfanyl]-4-(3-chlorophenyl)-4H- 1,2,4-triazol-3-yl]-N- (tetrahyclro-2-furanylmethyl)pentanarnide N-( 4 -methoxybenzy1)-5-[5-[(2-methybeny)sufany1-4-(2-phenylethyl)-4H-1,2,4 triazol-3-yl]pentananiide 4 3 -chloropheny1)-5-[(2-fluorobenzyl)sulfanyl]-4H- 1 ,2,4-triazol-3-yl} -N- isobutylpentanarnide 5-(4-phenyl-5- {[4-(trifluoromethyl)benzyl]sulfanyl} -4H-1 ,2,4-triazol-3-yl)-N- propylpentanatnide {4-a11y-5-I(4-flforobenzy)sulfany]-4H-1 ,2,4-tiazol-3-yl} methoxybenzyl)pentanami de 5-[5-(benzylsulfanyl)-4-(2-phenylethyl)Aw-1 ,2,4-triazol-3-yl]-N-(2- methoxybenzyl)pentanamide f{ 4 3 -chlorophenyl)-5-[(3-fluorobenzyl)sulfanyl]4H-1,2,4-triazol-3- yl)pentanarnide WO 03/053437 WO 03/53437PCT/EP02/14594 -209- N-(2-methoxybenzyl)-5-(4-(2-plienylethyl)-5- {[(2E)-3-phenyl-2-propenyllsulfalyl}
411-1 ,2,4-triazol-3-yl)pentanamide {4-(3-chlorophenyl)-5-[(3-methylbenzyl)sulfafl]l-4H-l ,2,4-triazol-3-yl} -N- propylpentananide 5- {4-(3-chloropheny1)-5-[k4-nethybenzy)sulfafl]-4H-1 ,2,4-triazol-3-yl} rnethoxypropyl)pentanamlide 4(-hoohey)5[35diehlez sufnl-H12,4-triazo1-3- yllpentananiide {5-[(2-methylbenzyl)sulfanyl] -4-phenyl-4H-1 ,2,4-triazol-3- yllpentanamide 5-[5-[(3,5-dimethylbenzy1)sulfany1]-4-(3-methoxypheflyl)-4H-l ,2,4-triazol-3-yl]-N-(2- methoxyethyl)pentananiide {4-(3-chloropheny1)-5-[(3,5-dimethybenzy1)sulfafl]-4H-l ,2,4-triazol-3-yl} -N- isobutylpentananide 5-[5-(butylsulfany)-4-(3-chlorophenyl)-4H-1,2,4-trazo1-3-yI]-N-( 2 methoxybenzyl)pentanamide {4-allyl-5-[(3-cblorobenzyl)sulfanyl]-4H- 1,2,4-triazol-3-yl} -N-benzylpentanamide {5-[(3-cyanobenzyl)sulfanyl]-4-phenyl-4H-1 ,2,4-triazol-3-yl} methoxybenzyl)pentananiide 5- {4-allyl-5-L(3-methylbenzyl)sulfanyl]-4H- 1,2,4-triazol-3-yl}-N-benzylpentanalide N-(1,3bnoixl5ymty) -5[2furbny~ulay]4(-hnlty) 411-1 ,2,4-triazol-3-yllpentanamide -210- {4-allyl-5-[(3-chlorobenzyl)sulfanyl] -4H- 1 ,2,4-triazol-3-yl 1,3- 5-[5-[(3-methylbenzyl)sulfanyl] -4-(2-phenylethyl)-4H- 1 ,2,4-triazol-3 -yl] -N- propylpentanamide 5-[5 -[(2-fluorobenzyl)sulfanyl]-4-(tetrahydro-2-furanylmethyl)-4H- 1,2,4- triazol-3-yl]-N-(3 -methoxypropyl)pentanamide N-(2-methoxybenzyl)-5-[5- [(4-methylbenzyl)sulfanyl] -4-(2-phenylethyl)-4H- 1 ,2,4-triazol-3 -yl]pentanamide 5-[5-[(2-chloro-4-fluorobenzyl)sulfanyl] -4-(2-phenylethyl)-4H- 1 ,2,4-triazol-3- yl] -N-(4-methoxybenzyl)pentanainide 5-[(3-chlorobenzyl)sulfanyl] -4-phenyl-4H- 1 ,2,4-triazol-3-yl -N- propylpentanamide 5-[5-[(4-methylbenzyl)sulfanyl]-4-(2-phenylethyl)-4H- 1 ,2,4-triazol-3-yl] -N- (tetrahydro-2-furanylmethyl)pentanamide 1 5 5- (4-(3-chlorophenyl)-5- [(2-phenylethyl)sulfanyl]-4H- 1 ,2,4-triazol-3-yl methoxybenzyl)pentanamide 5-[5-[(2-chloro-4-fluorobenzyl)sulfanyl]-4-(3-chlorophenyl)-4H- 1,2,4-triazol-3- yl]-N-(cyclopropylmethyl)pentanamide 7. A triazole according to any one of the preceding claims for use as a medicament. 8. Use of a triazole derivative according to any one of claims 1 to 6 as well as isomers, optically active forms as enantiomers, diastereomers and mixtures of these, as well as salts thereof for the preparation of a medicament for the treatment of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome or ocular hypertension. H:\Simwmn\Kecp\SMtC stdsU2O364291.doe 9103/06 -211 9. Use of a triazole derivative according to any one of claims 1 to 6 for the preparation of a medicament for the treatment of preterm labor, premature birth or dysmenorrhea. Use of a triazole according to any one claim 1 to 6, for the modulation of the oxytocin receptor. 11. Use according to claim 10, for the treatment or prevention of a disease associated with oxytocin receptor activity. 12. Use according to claim 10 or 11, wherein said modulation consists in the blocking of the oxytocin receptor or in antagonising the binding of oxytocin to its receptor. 13. A pharmaceutical composition containing a triazole derivative according to any one of claims I to 6 and a pharmaceutically acceptable carrier, diluent or excipient thereof. 14. A process for the preparation of a triazole derivative according to any one of claims 1 to 6 wherein B is S, comprising the reaction of a nucleophilic group of formula R 4 SH wherein R 4 is as defined in claim 1 with a triazole of formula XXXIII wherein Z is a leaving group and R 2 R 3 A and n are as defined in claim 1. R\ R R2/ H N NN XXXIII 15. A process according to claim 14 wherein the leaving group Z of formula XXXIII is Cl. 16. A process according to claim 14 wherein the leaving group Z of formula XXXIII is SO 2 Me. H:\Simcona\Keep\SMC stds\2002364291.doc 9/03/06 -212- 17. A process for the preparation of a triazole derivative according to any one of claims 1 to 6 wherein B is NR 5 comprising the reaction of a nucleophilic group of formula R 4 R'NH wherein R 4 and R 5 are as defined in claim 1 with a triazole of formula XXXIII wherein Z is a leaving group and R 2 R 3 A and n are as defined in claim 1. R R 3 R2/N A CH2 Z- N N-N XXXIII 18. A process according to claim 17 wherein the leaving group Z of formula XXXIII is Cl. 19. A process according to claim 17 wherein the leaving group Z of formula XXXIII is SO 2 Me. A process for the preparation of a triazole derivative according to any one of claims 1 to 6 wherein B is O, comprising the the reaction of a nucleophilic group of formula R 4 0 wherein R 4 is as defined in claim 1 with a triazole of formula XXXIII wherein Z is a leaving group and R 2 R 3 A and n are as defined in claim 1. R R3 R2/N A CH2 N N-N XXXIII 21. A process according to claim 20 wherein the leaving group Z of formula XXXIII is Cl. 22. A process according to claim 20 wherein the leaving group Z of formula XXXIII is SO 2 Me. HASimemm\Keep\SMC stds'2002364291.doc 9103/06 213 23. A triazole derivative of formula XXXIII: 1R 3 R2/ A CH N N-N XXXIII Wherein R 2 R 3 A and nare as defined in claim 1 and Z is Cl or S02Me. 24. A method for the treatment ofpreterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome or ocular hypertension, comprising administering a therapeutically effective amount of a triazole derivative according to any one of claims 1 to 6 to a subject in need thereof. 25. A method for the modulation of the oxytocin receptor, comprising administering a therapeutically effective amount of a triazole derivative according to any one of claims 1 to 6 to a subject in need thereof. 26. Use of a triazole derivative according to any one of claims 1 to 6 in the treatment of preterm labor, premature birth, dysmenorrhea, inappropriate secretion ofvasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome or ocular hypertension. 27. Use of a triazole derivative according to any one of claims 1 to 6 for the modulation of the oxytocin receptor. H:\Simeona\Keep\Speci\2002364291.doc 9/03/06 -214- 28. A triazole derivative, pharmaceutical compositions comprising it, uses or methods involving it or processes for its preparation, substantially as herein described with reference to the accompanying examples. Dated this 9 th day of March 2006 APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. By their Patent Attorneys GRIFFITH HACK Fellows Institute of Patent and Trade Mark Attorneys of Australia H:\Simeona\Keep\SMC stds\2002364291.doc 9/03/06
AU2002364291A 2001-12-20 2002-12-19 Triazoles as oxytocin antagonists Ceased AU2002364291B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01000778 2001-12-20
EP01000778.9 2001-12-20
PCT/EP2002/014594 WO2003053437A1 (en) 2001-12-20 2002-12-19 Triazoles as oxytocin antagonists

Publications (2)

Publication Number Publication Date
AU2002364291A1 AU2002364291A1 (en) 2003-07-09
AU2002364291B2 true AU2002364291B2 (en) 2007-08-02

Family

ID=8176114

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002364291A Ceased AU2002364291B2 (en) 2001-12-20 2002-12-19 Triazoles as oxytocin antagonists

Country Status (12)

Country Link
US (1) US7468385B2 (en)
EP (1) EP1458381B1 (en)
JP (1) JP4511184B2 (en)
AT (1) ATE311185T1 (en)
AU (1) AU2002364291B2 (en)
CA (1) CA2469042A1 (en)
DE (1) DE60207755T2 (en)
DK (1) DK1458381T3 (en)
ES (1) ES2249636T3 (en)
IL (1) IL162615A0 (en)
SI (1) SI1458381T1 (en)
WO (1) WO2003053437A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115639B2 (en) * 2001-06-18 2006-10-03 Applied Research Systems Ars Holding N.V. Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
DK1458381T3 (en) 2001-12-20 2006-03-20 Applied Research Systems Triazoles as oxytocin antagonists
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
JP2007505888A (en) * 2003-09-22 2007-03-15 ファイザー インコーポレイテッド Substituted triazole derivatives as oxytocin antagonists
ES2285554T3 (en) * 2003-12-11 2007-11-16 GALDERMA RESEARCH &amp; DEVELOPMENT NEW COMPOUNDS THAT ARE MODULATORS OF PPAR TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS.
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005082866A2 (en) * 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
GB0412874D0 (en) * 2004-06-09 2004-07-14 Pfizer Ltd Novel pharmaceuticals
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
EP1863484A1 (en) * 2005-03-21 2007-12-12 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
EP1917257A1 (en) * 2005-08-10 2008-05-07 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US8226949B2 (en) * 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
DE102010040924A1 (en) * 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituted phenylacet and phenylpropanamides and their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE570978A (en) * 1957-09-09
DE3173130D1 (en) 1980-08-27 1986-01-16 Glaxo Group Ltd Amino-1,2,4-triazole derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
FR2679903B1 (en) 1991-08-02 1993-12-03 Elf Sanofi DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
FR2665441B1 (en) 1990-07-31 1992-12-04 Sanofi Sa N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
US5187179A (en) 1991-03-22 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole
WO1996022775A1 (en) 1995-01-24 1996-08-01 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5756497A (en) * 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE69823858T2 (en) * 1997-10-17 2005-04-28 Yamanouchi Pharmaceutical Co., Ltd. AMID DERIVATIVES OR THEIR SALTS
FR2789077A1 (en) 1999-02-02 2000-08-04 Synthelabo PERAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2001058880A1 (en) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Novel triazole derivatives
DK1458381T3 (en) 2001-12-20 2006-03-20 Applied Research Systems Triazoles as oxytocin antagonists

Also Published As

Publication number Publication date
US20050187275A1 (en) 2005-08-25
JP4511184B2 (en) 2010-07-28
CA2469042A1 (en) 2003-07-03
ES2249636T3 (en) 2006-04-01
DE60207755T2 (en) 2006-07-27
US7468385B2 (en) 2008-12-23
AU2002364291A1 (en) 2003-07-09
EP1458381A1 (en) 2004-09-22
EP1458381B1 (en) 2005-11-30
DK1458381T3 (en) 2006-03-20
IL162615A0 (en) 2005-11-20
JP2005517662A (en) 2005-06-16
SI1458381T1 (en) 2006-04-30
DE60207755D1 (en) 2006-01-05
ATE311185T1 (en) 2005-12-15
WO2003053437A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
AU2002364291B2 (en) Triazoles as oxytocin antagonists
NL2000299C2 (en) Compounds that are useful in a treatment.
US10208055B2 (en) Pyrazole compounds as modulators of FSHR and uses thereof
CA2648809A1 (en) Indazole compounds and methods for inhibition of cdc7
TWI659950B (en) Pyrazolone derivatives as nitroxyl donors
US8404690B2 (en) Piperazine-2-carboxamide derivatives
UA78021C2 (en) Thiazolidine carboxamide derivatives as modulators of prostaglandine f receptors
KR20050109583A (en) Biaryl substituted triazoles as sodium channel blockers
JP2008533193A (en) Substituted triazole derivatives as oxytocin antagonists
EP1268419B1 (en) Pyrrolidine derivatives useful as bax inhibitors
TWI258478B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
EP1444225B1 (en) Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists.
CA2487532C (en) Pyrrolidine derivatives as oxytocin antagonists
AU2002256685B2 (en) Pyrrolidine ester derivatives with oxytocin modulating acitvity
AU2002331253B2 (en) Arylsulfonamide derivatives as C-JUN-N-terminal kinases (JNK&#39;S) inhibitors
US7557136B2 (en) Pyrrolidine derivatives as oxytocin antagonists
AU2003254498B2 (en) Pyrrolidine derivatives as oxytocin antagonists
TW200813007A (en) Substituted pyrrole derivatives
EP0024842B1 (en) Methyl (5-(2-thienylhydroxymethyl)-1h-benzimidazol-2-yl) carbamate, process for its preparation and compositions containing it

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: LABORATOIRES SERONO SA

Free format text: FORMER OWNER WAS: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired